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Plain language summary 
12-step programs for reducing illicit drug use are neither better nor worse than 
other interventions 
Illicit drug abuse has serious and far-reaching implications for the abuser, their family members, 
friends, and society as a whole. Preferred intervention programs are those that effectively reduce 
illicit drug use and its negative consequences, and are cost-effective as well. Current evidence 
shows that overall, 12-step programs are just as effective as alternative, psychosocial interventions. 
The costs of programs are, therefore, an important consideration. However, the strength of the 
studies is weak and further evidence regarding the effectiveness of 12-step programs is needed. 
What did the review study? 
Illicit drug abuse is a globally recognised 
problem leading to high human, social 
and economic costs.  
The 12-step program, modelled on the 
approach of Alcoholics Anonymous and 
adopted by Narcotics Anonymous and 
others, aims for complete abstinence. The 12-step approach is used both by self-help groups and 
for professional treatment called Twelve Step Facilitation (TSF). 
This review examines the effectiveness of 12-step programs in reducing the use of illicit drugs. 
Secondary outcomes considered are on criminal behaviour, prostitution, psychiatric symptoms, 
social functioning, employment status, homelessness, and treatment retention. 
What studies are included? 
Included studies assess 12-step interventions for participants with illicit drug dependence using 
randomized controlled trials and quasi-experimental studies. Study populations are participants 
who have used one or more types of illicit drugs, regardless of gender and ethnic background. 
A total of 10 studies consisting of 1,071 participants are included in the final evaluation. Nine of the 
studies were conducted in the United States, and one in the United Kingdom. The studies compare 
the 12-step program to alternative interventions. Nine studies were included in meta-analysis. 
What is the aim of this review? 
This Campbell systematic review examines the 
effectiveness of 12-step programs in reducing the 
use of illicit drugs. The review summarises findings 
from 10 studies, nine of which were conducted in 
the United States. 
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What are the main results in this review? 
There is no difference in the effectiveness of 12-step interventions compared to alternative 
psychosocial interventions in reducing drug use during treatment, post treatment, and at 6- and 
12-month follow-ups. 12-step programs combined with additional treatment did have a significant 
effect at 6-month follow-up, but this finding is based on few studies and is not found at 12-month 
follow-up. 
 
There is some evidence that 12-step programs retain fewer of their participants than other programs, 
but the evidence has shortcomings. No effect was found on other secondary outcomes. 
What do the findings in this review mean? 
The main evidence presented in this review suggests that 12-step programs for reducing illicit drug 
use are neither better nor worse than other interventions.  
 
This conclusion should be read with caution given the weakness of the evidence from the studies. 
The power to detect a difference between the 12-step interventions and alternative psychosocial 
interventions was low and the estimated effect sizes were small. Many studies failed to adjust for 
the fact that the intervention is administered to groups, and so may overestimate effects. Given all 
these shortcomings, further evidence regarding the effectiveness of this type of intervention, 
especially in self-help groups, is needed. 
How up to date is this review? 
The review authors searched for studies published until September 2016. This Campbell 
Systematic Review was published in February 2017. 
What is the Campbell Collaboration? 
The Campbell Collaboration is an international, voluntary, non-profit research network that 
publishes systematic reviews. We summarise and evaluate the quality of evidence for social and 
economic policy, programs and practice. Our aim is to help people make better choices and better 
policy decisions. 
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Executive summary 
BACKGROUND 
The effects of substance dependence have serious implications for the individual, the family and 
friends of the substance dependent individual, and society at large. Practitioners and public health 
policy makers have an interest in finding effective treatments that are also cost-effective. This 
review examined the effectiveness of 12-step programs aimed at illicit drug dependent participants 
compared to no intervention, treatment as usual, and other interventions.  
OBJECTIVES 
The main objective of this review was to systematically evaluate and synthesise effects of 12-step 
interventions for participants with illicit drug dependence against no intervention, treatment as 
usual, and alternative interventions. The primary outcome of interest was drug use. Secondary 
outcomes of interest comprised criminal behaviour, prostitution, psychiatric symptoms, social 
functioning, employment status, homelessness and treatment retention. 
SEARCH METHODS 
An extensive search strategy was used to identify studies meeting inclusion criteria. We searched 
electronic bibliographic databases in January 2010, October 2011, July 2013, August 2015, and 
September 2016. Searches for this review were performed on multiple international and Nordic 
databases. In total 11 databases were searched including PsycInfo, SocIndex, and Medline. A 
substantial range of grey literature sources were searched including governmental repositories, 
targeted web sites and trial registers. We checked the reference lists of primary studies, hand-
searched relevant key journals, and searched the Internet using Google and Google Scholar. We 
also contacted researchers who had published in the area of 12-step interventions. Neither 
language nor date restrictions were applied to the searches. The conclusions of this review are 
based on the most recent searches performed September 2016. 
SELECTION CRITERIA 
Studies had to meet the following criteria in order to qualify for inclusion in the review: 
• Intervention - only studies that considered 12-step interventions were eligible for inclusion. 
• Study Design - only studies using a RCT/QRCT design or a QES with a well-defined control 
group were eligible for inclusion. 
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• Comparison - studies that compared 12-step to either no intervention or to other 
interventions were eligible for inclusion. 
• Participants - only studies where the drug of choice of participants was an illicit drug 
(established either by self-report or via clinician) were eligible for inclusion. Where only a 
subset of study participants were illicit drug users, a study was only eligible if it reported 
outcomes separately for the subgroup of illicit drug users.  
DATA COLLECTION AND ANALYSIS 
Descriptive and numerical characteristics of included studies were coded by one review author. A 
second review author independently checked coding, and any disagreements were resolved by 
consensus. We used an extended version of the Cochrane Risk of Bias tool to assess risk of bias of 
included studies. One review author evaluated the risk of bias of all included studies. A second 
review author independently checked the assessment and disagreements were resolved by 
consensus. Random-effects meta-analysis was used to synthesise effect sizes. We compared 12-step 
to other interventions, and 12-step with add-on to other interventions with the same add-on. For 
each comparison we conducted separate meta-analyses by time: during treatment, at treatment 
end, and at 6- and 12-month follow-up. Sensitivity of the results to risk of bias was assessed. 
Publication bias was assessed by the use of funnel plots.  
MAIN RESULTS 
The total number of potentially relevant records was 21,974 (database search: 17,416, grey 
literature search: 2,639, hand search and others: 1,919), of these 428 records were screened in full 
text. Thirteen reports met the inclusion criteria, with six reports contributing data on three 
independent studies. In total 10 studies were included in the review. 
Seven of the included studies used a RCT design, two studies used a QRCT design, and one study 
used a QES design. One study, assessed as high risk of bias, was excluded from data synthesis. 
Thus, nine studies with a total of 1,071 participants contributed data to the analyses. These nine 
studies all considered outpatient settings where interventions were manual-based and delivered by 
trained therapists. In seven studies, treatment was partially or fully delivered in group therapy 
sessions. The reported statistical analyses were not corrected for this design element. 
Seven studies contributed data to the comparison of 12-step intervention to alternative 
psychosocial interventions during treatment, at treatment end, and at 6-and 12-month follow-up. 
The seven studies did not all contribute data to all time points. Analyses did not reveal any 
statistically significant differences, for the primary outcome of drug use, between 12-step and the 
alternative set of interventions.  
Three studies contributed data to the comparison of 12-step intervention with an add-on to 
alternative psychosocial interventions with an add-on. Drug use was assessed during treatment, 
post treatment, and at 6- and 12-months follow-up. All studies did not contribute data to all time 
points. We found no statistically significant effect size estimates during and post treatment. We 
found statistically significant effect size estimates at 6-month follow-up favouring 12-step with an 
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add-on compared to alternative interventions with add-on (Hedges’ g =0.48, 95% CI: 0.06 to 0.90, 
and g=0.45, 95% CI: 0.03 to 0.88). No statistically significant effect size estimates were found at 
12-months follow-up. 
There was no strong indication of heterogeneity between studies (I2 did not exceed 75%). Results 
were robust to sensitivity analysis, and there was no observed evidence of publication bias. 
AUTHORS’ CONCLUSIONS 
The results of this review suggest that 12-step interventions to support illicit drug users are as 
effective as alternative psychosocial interventions in reducing drug use. 
 
This conclusion should be seen against the weight of evidence. A total of seven studies contributed 
data to analyses comparing 12-step interventions and alternative psychosocial interventions. The 
power to detect differences was low, and estimated effect sizes were small. In addition most studies 
delivered treatment as group therapy, but did not correct the analysis for the dependence between 
participants assigned to the same group.  
 
Only one study reported results of the effects of self-help group attendance on drug use. This study 
was excluded from synthesis following the risk of bias assessment. Given the preponderance with 
which self-help 12-step interventions are delivered in practice, further evidence regarding the 
effectiveness of this type of intervention is needed. 
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1 Background 
1.1  DESCRIPTION OF THE CONDITION 
Illicit drug production and use1 remains a severe problem worldwide (United Nations Office on 
Drugs and Crime, UNODC, 2010). A central issue in reducing the worldwide drug problem is the 
demand for illicit drugs, and hence the need to identify effective methods for reducing their use. 
Prescription and recreational drugs should be differentiated from one another. In this review, we 
reserve the term ‘drug use’ to apply to the illegal, nonmedical use of drugs. Globally, the United 
Nations Office on Drugs and Crime (UNODC) estimates that between 155 and 250 million people 
(3.5 to 5.7 percent of the population aged 15-64) used illicit substances at least once in 2008 
(UNODC, 2010). Illicit substances include opium/heroin (opiates), coca/cocaine, cannabis2, and 
amphetamine-type stimulants (including MDMA/Ecstasy). Cannabis is the most commonly used 
illicit substance (with an estimated 129 – 190 million users worldwide), followed by amphetamine-
group substances, cocaine and opiates. UNODC considers some types of drug use to be more 
problematic than others, and defines problem drug use as that which involves the injection of 
drugs or the long-duration/regular use of opioids, cocaine and/or amphetamines. For 2008, 
UNODC estimates that between 16 and 38 million people worldwide are problematic drug users 
(UNODC, 2010). 
Drug use is linked to a range of health and social problems, including crime, prostitution, and 
homelessness (Office of National Drug Control Policy, ONDCP, 2000; Shelton, Taylor, Bonner, & 
van den Bree, 2009; Silbert, Pines, & Lynch, 1982). The European Monitoring Centre for Drugs 
and Drug Addiction estimates that drug-induced deaths account for approximate 4 percent of all 
deaths of Europeans aged 15-39 (European Monitoring Centre for Drugs and Drug Addiction, 
EMCDDA, 2010). A number of studies have attempted to estimate the social costs of drug use, in 
terms of both the direct cost and the indirect costs of drug use (EMCDDA, 2010). For Finland these 
costs have been estimated at between EUR 200 million and EUR 300 million in 2007, and in 
Scotland at EUR 5.1 billion in 2006.  
The high human, social and economic costs of illicit drug use motivate the strong political interest 
in treatment for illicit drug use and in identifying effective treatments. The main types of treatment 
are cognitive-behavioural therapies, motivational enhancement, contingency management, 
                                                        
1 The terms use, misuse, abuse and dependence will be used interchangeably throughout the review and refer to an 
addiction stage of drug usage.  
2 Cannabis is illegal in most, but not all countries. For example, use of cannabis in small amounts is not a criminal offence 
in the Netherlands.  
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psychoanalysis, network therapy and – the object of this review –12-step programs (Galanter & 
Kleber, 2008).  
1.2  DESCRIPTION OF THE INTERVENTION 
12-step approaches to the treatment of drug use are widespread in many countries. The oldest and 
most widely attended 12-step groups are provided by Alcoholics Anonymous (AA) that began in 
1935 and have more than 2 million members according to their own recent membership survey 
(Alcoholics Anonymous, 2012; Mäkelä et al., 1996). The principles of AA serve as a model for other 
12-step programs, of which Narcotics Anonymous (NA) is the largest focusing on drug use 
(Narcotics Anonymous, 2012). Today NA has more than 58,000 weekly meetings in 131 countries 
(Narcotics Anonymous, 2010). NA accepts all individuals with drug addiction, regardless of the 
particular drug or combination of drugs used. Other 12-step groups restrict themselves to specific 
types of abuse, such as Cocaine Anonymous, Pills Anonymous and Marijuana Anonymous (Cocaine 
Anonymous, 2012; Pills Anonymous, 2012; Marijuana Anonymous, 2012). The stated objective of 
the 12-step approaches is complete abstinence from the use of drugs, whereas other treatments 
such as psychosocial interventions or opioid substitution may focus on reducing drug use 
(EMCDDA, 2010). 12-step treatment approaches assume that, as a result of biological and/or 
psychological vulnerability, individuals have lost control over their drug use. Treatment attempts 
to bring about the individual’s acceptance of the disease model of addiction, (i.e. that addiction is a 
lifelong disease), of an “addict” identity, and of abstinence as a treatment goal. It also attempts to 
motivate involvement in 12-step activities (for example, attending meetings, obtaining a sponsor, 
working through the 12 steps) (Finney, Noyes, Coutts, & Moos, 1998). The core ideology of the 
approach is to offer individuals a new way of living that will support them in breaking the cycle of 
addiction and in maintaining abstinence (Mercer & Woody, 1999). The suggested prescription for 
abstinence, referred to as the “six pack”, is: don’t use no matter what, go to meetings, ask for help, 
get a sponsor, join a group, and get active (Laudet, 2008).  
The 12-step self-help groups work to specific principles. The meetings typically adhere to a 
prescribed format including 12-step readings (The Preamble, How and Why, The 12 Steps) at the 
start of the meeting, and a reciting of the Serenity prayer at the end for individuals who wish to do 
so (Laudet, 2008). The disease model of addiction is central to the 12-step philosophy and 
recovery, and is seen as being a significant part of the process of attaining and maintaining 
abstinence. Recovery is viewed as a lifelong process, and members thus regard themselves as 
“recovering” (Mercer & Woody, 1999). 
The basic idea is that individuals work their way into recovery by going through “12 Steps” starting 
with the recognition of being addicted to drugs, also known as “hitting the bottom” 3, and ending 
with the capability of helping others out of their own addiction (Narcotics Anonymous, 2008). A 
central element in the 12-step self-help groups is that participation is voluntary and that recovering 
individuals, and not professional staff, guide the treatment. Another important component is 
                                                        
3 The insistence on hitting bottom lies in the belief that few individuals will be sincerely motivated to commit to recovery 
unless they have “hit the bottom”. This bottom can be wherever the individual allows it to be. The central idea is that 
individuals must come to a turning point where they accept that they have reached a stage of complete defeat to drugs 
(Alcoholics Anonymous, 2005). 
 12     The Campbell Collaboration | www.campbellcollaboration.org 
sponsorship whereby a member who has made progress in the 12-step recovery program shares his 
or her experience on an individual and continuous basis with another member who is attempting to 
attain or maintain abstinence through the 12 steps (Straussner & Spiegel, 1996; Laudet, 2008). 
Sponsors share their own “experience, strength and hope” with the sponsees and accompany them 
in working the steps towards recovery. The idea is that sponsorship also helps oneself in 
maintaining abstinence, formulated as: “the cardinal virtue of sponsorship is the momentary loss 
of self-centeredness” (Jennings & Alcoholics Anonymous, 1990). Sponsorship is something that a 
member her/himself decides to become involved in. In addition, sponsors themselves have their 
own sponsors who help them in their own struggle for abstinence (Narcotics Anonymous, 2008).  
The exact wording of the 12 steps differs slightly between groups – the 12 steps of NA are presented 
in section 10.1 (Narcotics Anonymous, 2008). The steps contain a strong spiritual emphasis and 
encourage members to look outside themselves for strength (to seek a higher power) and to 
embrace spiritual values and practices that are outlined in the 12 steps. “A power greater than 
ourselves” is mentioned in step 2 and “God as we understand Him” in step 3. In addition, the steps 
emphasise the importance of reconstructing relationships with people who have been harmed by 
the drug use (e.g., family members). Inherent in the 12 steps is the realisation that addiction is a 
disease and as such is beyond personal influence. However an individual can decide to change and 
oppress disease. The strong spiritual emphasis is unique to the 12 steps and the texts that are used 
include wording that appear religious. On the other hand, the texts do not endorse a particular 
faith and the “God as we understand Him” phrase is open to interpretation. The spiritual emphasis 
may mean that some drug users are opposed to the intervention for ideological reasons, and hence 
the claim made by some that 12-step only works for individuals with the right motivation and 
outlook on life (Fiorentine, 1999). 
The “12 Steps” are accompanied by “12 Traditions” providing guidelines for the self-help groups 
(Narcotics Anonymous, 2008). The 12 traditions of Narcotics Anonymous are presented in section 
10.1. Because the individual groups are autonomous, there can be differences between them, but 
the basic concepts are the same. Each group meets at a regular time and place, and is in principle 
open to all drug users – the only requirement being the wish to become “clean”. Attendance is 
decided individually, but beginners are encouraged to attend “90 meetings in 90 days”. 
Furthermore, participation is not time-limited and the time needed to do the steps is also decided 
individually (Straussner & Spiegel, 1996). Often, drug users who have succeeded in attaining 
abstinence continue to participate in the meetings for years, and continue working the steps day 
after day. Abstinence anniversaries or birthdays are considered major accomplishments and an 
important way to mark success in attaining abstinence.  
In addition to the self-help groups, 12-step approaches are used in Twelve Step Facilitation (TSF) 
treatments (MATCH, 1997; Ries, Galanter, & Tonigan, 2008). These are typically of limited 
duration and organised around a treatment facilitation centre staffed by professionals, with 
treatment based on 12-step principles. In short, TSF is the integration of 12-step self-help groups 
with professional treatment. Usually, the individual will participate in 12-step meetings (NA or 
other) after completing TSF treatment, and a parameter of success for the TSF treatment is that the 
individual becomes motivated and ready for the self-help group. The best known TSF treatment is 
the “Minnesota model”, originating from three centres founded in Minnesota in the late 1950s 
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(Cook, 1988). The Minnesota model is characterised by the use of the 12-step philosophy as a 
foundation for therapeutic change, where the treatment goal is total abstinence. TSF treatment can 
be delivered in both inpatient and outpatient settings; the duration of the treatment can vary, but is 
typically around 12-24 weeks.  
A cardinal rule of both TSF and self-help groups is anonymity. In attempt to protect individuals 
from society’s stigmatisation, the 12-step approach gives priority to preserving members’ 
anonymity. Anonymity inevitably poses a challenge to research. 
In this review, the focus is on 12-step treatments for users of illicit drugs, and we will include both 
treatments based on self-help groups working with the 12 steps (like NA) and TSF treatments. 
Since drug users may also be alcohol dependent (Kessler et al., 1997), we will include studies where 
alcohol misuse is present provided drug abuse is the key drug of choice of participants. Thus, 
although alcohol can be part of the substance abuse we do not consider 12-step treatments 
primarily dealing with and aimed at treating alcohol dependency.  
1.3  HOW THE INTERVENTION MIGHT WORK 
The 12-step interventions included in this review are aimed at supporting the substance users to 
refrain completely from or reducing their use of illicit drugs. Abstinence is achieved by the drug 
user through working his/her way through the 12 steps. A central issue that dates back to the AA 
tradition is the acknowledgement of the addiction, and the acceptance of support by a sponsor in a 
self-help group, or by professionals in a TSF setting. One of the keys to success posed by the AA, 
and hence the NA, is “the therapeutic value of addicts working with other addicts” along with the 
cardinal idea that the 12 steps offer “a design for living”, a way of learning to live, that teaches 
skills and helps individuals to navigate and reach recovery (Alcoholics Anonymous, 2005; 
Narcotics Anonymous, 2008). The steps are carefully organised in an order, starting with the basic 
skills and continuing to the more advanced changes, that individuals should gradually seek to 
integrate into their lives. Having a sponsor and being a sponsor is an important part of 12-step self-
help groups. Sponsorship is viewed as an important tool in the process of recovery in that it helps 
to grasp the components of living, offers encouragement and support such as when relapse occurs, 
but it may also “kill” any complacency among the sponsors themselves, and thereby help them 
sustain their self-monitoring (Hornbacher, 2010). Also, central to the NA program is the statement 
that spirituality mediates 12-step involvement and later abstinence. It is suggested that, by working 
the 12 steps, one will have a spiritual awakening, and that continued practice of spiritual principles 
will lead to sustained abstinence (Narcotics Anonymous, 2008).  
The benefits associated with involvement in 12-step programs, and the mechanisms by which these 
benefits occur, have been thoroughly explored over the past two decades. Relatively little is known, 
however, about which specific behaviours catalyse the therapeutic psychological mechanisms. Self-
efficacy, or the confidence to remain abstinent, has been identified as a major component and a 
consistent predictor of subsequent improvement (Moos & Timko, 2008; MATCH, 1997). The 
importance of spirituality for later abstinence is currently unclear (Maude-Griffin et al., 1998; 
Moos & Timko, 2008; Tonigan & Connors, 2008). Regarding sponsorships, Humphreys & Noke 
(1997) point out that this social network component of treatment can be more effective in helping 
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the substance user than the support from concerned family members. The reliance on positive 
reinforcement (e.g., by recognising abstinence anniversaries) and behavioural modelling (e.g., by 
having a sponsor) have also been proposed as an underlying mechanism of change (Morgenstern, 
Bux, & Labouvie, 2002; Witkiewitz & Marlatt, 2011). Membership demographics for Narcotics 
Anonymous collected at the 2009 World Convention of NA in Barcelona, Spain reveal that more 
men than women are members (58% vs. 42%); only very few teenagers are members of NA (2%), 
whereas the most typical member is aged 41-50 years (34%); ethnicity is dominated by Caucasians 
(73%) and most members are employed (71%) (Narcotics Anonymous, 2010). Perhaps due to this 
profile, Fiorentine (1999) notes that the 12 steps have been argued to work best for Christian, 
white, middle-class males. According to Fiorentine (1999) studies fail to support this view. 
Fiorentine (1999) also accentuates that 12-step interventions may also be inappropriate for drug 
users with major psychiatric disorders, drug users in early stages of addiction, and drug users 
uncomfortable with the religious or spiritual emphasis.  
Treatment setting may also affect models of treatment and participant characteristics. In inpatient 
settings, patients stay at the treatment facility overnight and possibly for extended periods of time. 
Treatment typically includes a first period of detoxification followed by initial intensive treatment, 
including preparing patients for returning to community-based care settings. Patients participating 
in treatments in outpatient settings typically stay in their own home, while attending treatment at a 
treatment facility. Due to the nature of treatment in- and out-patient settings may differ 
substantially in participant characteristics such as e.g. substance abuse severity, clinical symptoms, 
consequences from use, motivation, and labour market attachment.  
The criminal justice system in the US is responsible for a substantial proportion of referrals to 
community-based treatment programs. Legal referral may consists of a probation officer’s 
recommendation to enter treatment, the choice in a drug court between jail time and treatment, 
the requirement of a judge to enter treatment as a precondition for probation, etc. (Farabee, 
Prendergast, & Anglin, 1998). The degree of legal pressure that the patient faces to comply with 
treatment may affect his/her motivation for change. Intrinsic motivation, understood as the 
patient’s willingness to change his/her substance use, has been linked as key to treatment success 
(e.g. Prochaska, & DiClemente, 1982). As such, court-mandated treatment may be expected to lead 
to less desirable treatment outcomes since enrolment is due to legal pressure and not intrinsic 
motivation (Farabee, Prendergast, & Anglin, 1998). Even patients who enter “voluntarily” may face 
pressure in the form of social pressure from e.g. family and friends (Perron, & Bright, 2008). 
Perhaps surprisingly, mandated treatment patients show substance abuse outcomes similar to and 
sometimes better than voluntary treatment patients (Kelly, Finney, & Moos, 2005). This may partly 
be explained by patient characteristics. Kline (1997) found that legally referred patients were 
younger, involved fewer African-Americans, less substance use, and fewer drug-related health 
problems compared to voluntary patients in residential treatment. Kelly, Finney, & Moos (2005) 
examined treatment retention and treatment outcomes at Veteran Affairs residential treatment 
facilities, where a main program component was 12-step group involvement. The justice system 
involved (JSI) patients had lower severity of substance abuse, fewer consequences of abuse, were 
younger, more likely to be white, and were less motivated for treatment than those who were not 
justice system involved in the same program. JSI patients, particularly JSI patients who were 
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mandated to treatment, showed similar or better outcomes for abstinence and remission at 1 and 5 
years post treatment, even after controlling for pre-treatment differences.  
1.4  WHY IT IS IMPORTANT TO DO THE REVIEW 
Illicit drug use has significant costs for individuals and societies in terms of social, health and 
criminal problems. 12-step programs are one of the most widespread treatments for drug use 
internationally. The general belief among clinicians is that 12-step is an effective approach 
(Forman, Bovasso, & Woody, 2001). In the US, for example, it is common procedure by courts to 
mandate 12-step treatment. Although a large number of studies have examined the use of the 
programs, no systematic knowledge of the effectiveness of the intervention is currently available. 
This is, in part, due to the strict anonymity policy and the insistence on fluid membership, 
especially in the self-help groups, which makes it difficult for researchers to track members.  
A Cochrane review evaluated the effectiveness of 12-step programs on alcohol dependence. Ferri, 
Amato, & Davoli (2006) provided a narrative synthesis of the effectiveness of 12-step approaches 
(like AA or TSF) compared with alternative psychosocial interventions (e.g. cognitive behavioural 
therapy, motivational enhancement therapy, relapse prevention). They concluded that 12-step 
approaches were as effective as alternative approaches in terms of improving drinking 
consequences, and reduction of alcohol consumption. Ferri and colleagues did not explicitly 
exclude co-dependence on illicit drugs, nor did they report whether participants, in the eight trials 
that were included in the review, had comorbid substance dependence. Treatment effectiveness for 
comorbid participants treated for alcohol disorder might inform the effectiveness for participants 
included in the present review. Even so, prevalence of alcohol disorder only in the US was 7.35 
percent, the prevalence of any drug use disorder was 2.00 percent, and the comorbidity of alcohol 
and (any) drug use disorder was 1.10 percent (2001-02 National Epidemiologic Survey on Alcohol 
and Related Conditions; Stinson, Grant, Dawson, Ruan, Huang, & Saha, 2005). This suggests that 
while comorbidity is not uncommon in the population, there is substantial non-overlap between 
populations. As such, one should be cautious in extrapolating results from Ferri, Amato, & Davoli 
(2006) to the population of interest to this review. Furthermore, individuals dependent on drugs, 
particularly illicit drugs, are often forced into a lifestyle that differs considerably from individuals 
who are dependent on alcohol, due to the criminal aspects of drug use. People who are drug 
dependent are often engaged in illegal activity when obtaining their substance of dependence 
and/or the capital needed for its procurement. Research also suggests that it may be more difficult 
for the drug user to benefit from the 12 steps compared to the individual who is dependent on 
alcohol, possibly due to the particular impact of drugs on brain neurons (Laudet, 2008).  
With its broad applicability, minimal cost, and potential benefit, the 12-step approach has great 
appeal to policy makers. Knowledge about the effectiveness of the method compared to other 
treatments, as well as knowledge about the effect of different program elements, will therefore be 
of considerable interest to policy makers and practitioners.  
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2 Objectives 
The objective of this review was to assess the effectiveness of 12-step programs to reduce illicit drug 
use. The following questions were addressed to determine the effectiveness of 12-step programs 
aimed at illicit drug users: 
1. reducing illicit drug use, during treatment, at treatment end, and at follow-up, compared 
with no intervention or a competing psychosocial intervention, and when used in 
conjunction with either a pharmaceutical add-on or another psychosocial add-on? 
2. reducing criminal behaviour and prostitution, during treatment, at treatment end, and at 
follow-up, compared with no intervention or a competing psychosocial intervention, and 
when used in conjunction with either a pharmaceutical add-on or another psychosocial 
add-on? 
3. reducing psychiatric symptoms, during treatment, at treatment end, and at follow-up, 
compared with no intervention or a competing psychosocial intervention, and when used in 
conjunction with either a pharmaceutical add-on or another psychosocial add-on? 
4. improving social functioning, during treatment, at treatment end, and at follow-up, 
compared with no intervention or a competing psychosocial intervention, and when used in 
conjunction with either a pharmaceutical add-on or another psychosocial add-on? 
5. improving employment status, during treatment, at treatment end, and at follow-up, 
compared with no intervention or a competing psychosocial intervention, and when used in 
conjunction with either a pharmaceutical add-on or another psychosocial add-on? 
6. reducing homelessness, during treatment, at treatment end, and at follow-up, compared 
with no intervention or a competing psychosocial intervention, and when used in 
conjunction with either a pharmaceutical add-on or another psychosocial add-on? 
7. improving treatment retention, during treatment, at treatment end, and at follow-up, 
compared with no intervention or a competing psychosocial intervention, and when used in 
conjunction with either a pharmaceutical add-on or another psychosocial add-on? 
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3 Methods 
3.1  TITLE REGISTRATION AND REVIEW PROTOCOL 
The title for this systematic review was approved by The Campbell Collaboration on 16 October 
2010. The review protocol was approved on 2 September 2013. The title registration and protocol 
are available at: https://www.campbellcollaboration.org/library/12-step-programmes-illicit-drug-
abuse-reduction.html 
 
3.2  CRITERIA FOR INCLUDING STUDIES IN THE REVIEW 
The purpose of this review was to synthesise the best available evidence on the effects of 12-step 
programs, broadly understood as participation in self-help programs or manual based programs 
designed to reduce illicit drug use and delivered in in- or out-patient settings. No restrictions on 
the language or the publication status of studies were applied. When we could not determine 
whether a report met the inclusion criteria we attempted to contact investigators. We applied a 
time limit of 14 days from sending our inquiry. If the study investigators notified us before this 
deadline that they would be able to provide the information in a short time, we included the 
information. If investigators did not reply to our inquiry in time, the study was listed as “Awaiting 
classification”. All inquiries and answers were stored electronically. 
 
The following criteria were used to select studies eligible for synthesis. 
3.2.1 Types of study designs 
Study designs eligible for inclusion were: 
• Randomised Controlled Trials (RCTs) – studies where individual participants, or group of 
participants were randomised to control or treatment conditions, including trials that 
randomly assigned individual participants to group treatment. 
• Quasi-randomised controlled trials (QRCTs) - where participants were allocated by, for 
example, alternation, birth date, date of the week, case number or alphabetical order, to 
treatment or control conditions. 
• Quasi-experimental studies (QESs) – studies where participants were assigned to control and 
treatment conditions in a non-random manner with a control group where pre-treatment 
group equivalence is demonstrated via matching, statistical controls, or where there is 
evidence of equivalence on key risk variables (see section 3.4.2), or where key risk variables 
are controlled for statistically.  
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We justified the inclusion of QRCTs and QESs because the open-door membership policy of 12-step 
programs generally, and for the self-help groups in particular, may pose considerable problems in 
assessing the effectiveness of treatment using a RCT design. In addition, studies that utilise quasi-
experimental designs may produce as efficient and unbiased estimates of intervention effects as 
studies utilising a RCT design (Shadish & Cook, 2009). 
3.2.2 Types of participants 
The population included participants who used illicit drugs, regardless of age, gender or ethnic 
background. We included participants who used one or more types of illicit drugs.  
Many studies included participants with both alcohol and drug use. Studies where alcohol use 
dominated drug use, either in consumption or in severity as measured by, for example, the 
Addiction Severity Index (McLellan, Luborsky, Woody, & O’Brien, 1980), were excluded. Studies 
that included participants who had both participants with illicit drugs or alcohol as their drug of 
choice were only included if they reported outcomes separately for participants with illicit drugs as 
their drug of choice. When the reported information on usage was insufficient for a judgement to 
be made, we contacted the study authors for clarification and used this information to determine 
whether the study should be included.  
We included studies of individuals who were enrolled in 12-step treatment regardless of the way in 
which their problem was labelled, and we regarded the terms ‘use’, ‘abuse’, ‘misuse’ or 
‘dependence’ of illicit drugs as equivalent.  
3.2.3 Types of settings 
The review included studies in which treatment was delivered in inpatient, outpatient, or self-help 
groups. 
3.2.4 Types of interventions 
The review included studies evaluating 12-step interventions (in either the self-help or TSF format) 
delivered with the explicit aim of stopping or reducing illicit drug use. The following core principles 
were present in the studies with 12-step intervention: 
• Addiction was viewed as an illness. 
• There was a theme of spirituality (for example, a belief in a higher power). 
• The individual discussed problems within a fellowship of peers trying to help and encourage 
one another. 
• General guidance was provided in the “12 Steps”. 
We included studies evaluating interventions that used the 12-step principles regardless of setting 
(for example, inpatient or outpatient) or the duration of treatment. 12-step interventions that 
focused solely on treating alcohol dependency, such as AA programs, were excluded even though 
the study participants may also have been addicted to illicit drugs.  
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3.2.5 Types of comparisons 
Eligible comparison conditions were no intervention, a waitlist control condition, or any other 
intervention(s).  
3.2.6 Types of outcomes 
Given that 12-step treatment accepts abstinence as the only successful treatment outcome, the 
primary outcome for this review was abstinence or reduction of drug use as measured by: 
• Biochemical tests 
• Estimates of drug use 
Secondary outcomes were as follows: 
• Criminal behaviour 
• Prostitution 
• Psychiatric symptoms 
• Social functioning 
• Employment status 
• Homelessness  
• Retention 
Primary outcome measures might be reported in the form of urine toxicology screens, as self-
reports of drug use (or reported by others such as parents, caregivers, or therapists) either as a 
prevalence measure, or a measure of use in the past month such as the Timeline Follow Back 
instrument (Sobell et al., 1996), or the relevant portion of the Addiction Severity Index (McLellan 
et al., 1980). Studies were only included if they considered one of the primary outcomes.  
Secondary outcomes, such as criminal behaviour and prostitution, may be self-reported, such as 
from the Addiction Severity Index sub-components (criminal and legal), registers or files. The 
Symptom Checklist-90-R (SCL-90-R) (Derogatis, 1983) or a similar validated scale may be used to 
report outcomes relating to psychiatric outcomes. Social functioning may be measured by the 
Social Functioning Questionnaire (SFQ) (Tyrer et al., 2005) or a similar validated scale. 
Employment and homelessness might come from self-report, or registers. Finally, retention could 
be measured in a variety of ways, such as the study authors’ own conception of treatment 
completion, number of sessions attended, or percentage of sessions attended. Types of Time Points 
Outcomes were considered at the following intervals: 
• During treatment. All studies that provided numerical effect sizes for synthesis were psycho-
social manual-based interventions delivered by professional or trained therapists. Many 
studies provided primary outcome measures while participants were being treated.  
• Post treatment/treatment end. Post treatment measures were taken directly after the end of 
intervention, or shortly thereafter. 
• Follow-up. Follow-up outcome measures were taken between 1 and 18 months after the end of 
treatment.  
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This classification of relevant time periods follows the convention frequently reported in the 
literature and differs slightly from that outlined in the published protocol (see section 8.2 for 
further details). 
3.3  SEARCH METHODS FOR IDENTIFICATION OF STUDIES 
3.3.1 Electronic searches  
Relevant studies were identified through electronic searches of bibliographic databases, 
government policy databanks and internet search engines. No date or language restrictions were 
applied to the searches. All databases where searched in the original search in January 2010. 
Access to some databases has changed throughout the four updated searches to this review. The 
date of the last search was September 19, 2016. The following bibliographic databases were 
searched: 
• ASSIA - (Searched through ProQuest) - Searched until July 2013 – no access for further years 
• Cochrane Library (including CENTRAL) - 
http://onlinelibrary.wiley.com/cochranelibrary/search?searchRow.searchOptions.searchPr
oducts=clinicalTrialsDoi - Searched until 19. September 2016 
• Embase (Searched through OVID host) - Searched until 19. September 2016 
• Medline (Searched through OVID host) - Searched until 19. September 2016 
• PsycINFO (Searched through EBSCO host) - Searched until 19. September 2016 
• CINAHL (Searched through EBSCO host) - Searched until July 2013 - no access for further 
years 
• Science Citation Index (Searched through ISI Web of Science) - Searched until 19. September 
2016 
• Social Science Citation Index (Searched through ISI Web of Science) - Searched until 19. 
September 2016 
• SocINDEX (Searched through EBSCO host) - Searched until September 2016 
• Sociological Abstracts (Searched through ProQuest) - Searched until 19. September 2016 
• Dissertation Abstracts (Searched through ProQuest) – Searched until 19. September 2016 
The following Nordic library databases were searched: 
• BIBSYS - http://www.bibsys.no/en/ - In the newest update of the review, the access to BIBSY 
(now Oria) was limited. The documented search strategy in section 9.1 reflects searches 
until August 2015 
• Bibliotek.dk - https://bibliotek.dk - Searched until 16. September 2016 
• DiVA (Digitale vetenskapeliga arkivet) - http://www.diva-
portal.org/smash/search.jsf?dswid=7660 - Searched until July 2013. 
• LIBRIS - http://libris.kb.se/ - Searched until 16. September 2016 
• SweMed+ - http://svemedplus.kib.ki.se/Default.aspx?searchform=advanced Searched until 
16. September 2016.  
• Artikelsök - http://artikelsok.se/ Searched until July 2013– no access for further years. 
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3.3.2 Search terms 
Exact search strategies for each database can be found in section 9.1.  
3.3.3 Searching other resources 
We examined the reference lists from relevant reviews identified in the electronic searches, and 
from included primary studies for studies that potentially met inclusion criteria. In addition, 
international experts were contacted to attempt to identify unpublished and on-going studies.  
3.3.4 Grey literature  
The search strategy for the grey literature search was based on the search string for the electronic 
database search. Due to the limited search capacity on grey literature information resources, web 
pages and search engines, a shortened search string was used. An example of the search strategies 
used to identify grey literature and google searches can be found in section 9.1. The most recent 
search for grey literature was performed September 6, 2016. Following websites and resources 
were searched for relevant grey literature: 
 
• Canadian Evaluation Society - http://evaluationcanada.ca/ - Searched 3. September 2016.  
• NARCIS (National Academic Research and Collaborations Information System) - 
http://www.narcis.nl/about/Language/en – Searched 3. September 2016.  
• Government of Canada - https://www.canada.ca/en/index.html - Searched 3. September 
2016. 
• USA.gov - https://www.usa.gov/ - Searched 3. September 2016. 
• Australian Government - http://www.australia.gov.au/about-government/publications - 
Searched 3. September 2016. 
• Ministry of Social Affairs and the Interior - http://sim.dk/publikationer.aspx - Searched 3. 
September 2016. 
• Government Offices of Sweden - http://www.government.se/ - Searched 4. September 
2016. 
• Government.no - https://www.regjeringen.no/en/id4/ - Searched 4. September 2016. 
• European Union - https://europa.eu/european-union/index_en - Searched 4. September 
2016. 
• Theses Canada Portal - http://www.bac-lac.gc.ca/eng/services/theses/Pages/theses-
canada.aspx - Searched 4. September 2016. 
• National Library of Germany - http://www.dnb.de/EN/Home/home_node.html - Searched 
4. September 2016. 
• Social Care Online - http://www.scie-socialcareonline.org.uk/ - Searched 4. September 
2016. 
• DART-Europe E-theses Portal - http://www.dart-europe.eu/basic-search.php - Searched 4. 
September 2016. 
• Information for Practice - http://ifp.nyu.edu/archive/ - Searched 4. September 2016. 
• Open Grey - http://www.opengrey.eu/ - Searched 5. September 2016. 
• National Institute on Drug Abuse - https://www.drugabuse.gov/ - Searched 5. September 
2016. 
• European Monitoring Centre for Drugs and Drug Addiction - 
http://www.emcdda.europa.eu/ - Searched 5. September 2016. 
• Sbustance Abuse and Mental Health Services Administration - 
http://www.samhsa.gov/data/node/20 - Searched 5. September 2016. 
• NCJRS (National Criminal Justice Reference Service) - https://www.ncjrs.gov/index.html - 
Searched 6. September 2016. 
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Additional searches were conducted using Google and Google Scholar, and the first 200 hits were 
examined in each case.  
3.3.5 Hand searching  
Searching was performed on journal editions from January 2010 to September 2013 and finally 
from August 2015 to September 2016 in attempt to identify any published studies that may not 
have been found in the electronic search. The most recent hand search was performed September 
26, 2016. The following five international journals was hand searched for relevant studies: 
• Addiction – Searched 26. September 2016.  
• Journal of Consulting and Clinical Psychology - Searched 26. September 2016. 
• Journal of Substance Abuse Treatment - Searched 26. September 2016. 
• Journal of Clinical and Adolescent Psychology - Searched 26. September 2016. 
• Research on Social Work Practice - Searched 26. September 2016. 
3.3.6 Selection of studies 
The screening process was executed in two separate phases.  
Phase 1: Two review team members independently screened each title and abstract obtained from 
the search procedures for inclusion. Each reviewer coded each citation according to the pre-
specified inclusion criteria. This information was stored in a Reference Manager database. 
Disagreements were handled by discussion and consensus agreement.  
Points of discussion included whether the design of the study met the inclusion criteria, and 
whether outcomes reported were consistent with the focus of the present review. The decisions 
available to the reviewer were: (1) ‘In’ (include for full article scan), (2) ‘Unclear’ (include for full 
scan), and (3) ‘Out’ (citation eliminated).  
Citations that met the initial inclusion criteria were retrieved for full review using available library 
resources. 
Phase 2: Two review team members independently screened the full articles for inclusion. As with 
the previous procedure, the studies were screened against the inclusion criteria, with results 
tracked in an Excel database. If the citation was excluded at this stage, the reviewer provided a 
brief description of the reason for dismissal. When there was a disagreement, two reviewers 
discussed the citation and reached an agreement. 
3.4  DATA COLLECTION AND ANALYSIS  
3.4.1 Data extraction and management 
Study level data such as author, year, and report type were extracted. In addition intervention 
characteristics, such as duration, intensity, type of delivery (e.g. group or individual), fidelity, 
outcome assessors, were coded. Most of this information was used in the risk of bias assessment of 
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each study. Outcome measurements were also extracted. If relevant effect sizes could be extracted 
directly, this information was coded. If the report did not provide effect sizes directly, reviewers 
extracted other information, such as the t-statistic and the sample size, which would allow effect 
sizes to be calculated. If sufficient information was not provided in the report, this was coded, and 
provided the basis for the detailed data requests made to the report authors. The full codebook is 
available in section 7.2 of the protocol. 
One reviewer extracted descriptive and numerical data from the included studies. A second 
reviewer checked all coded information for accuracy, and in case of discrepancies, reviewers would 
jointly agree on the final coding. The data were coded and stored electronically in Microsoft Excel. 
When descriptive or numerical data were not available in the published reports or only partly 
available we contacted the authors, requesting the required information. Eight reports comprising 
seven corresponding authors contained insufficient information for relevant effect sizes to be 
extracted. In line with the protocol for the review, we contacted the authors, requesting the 
information and allowed a two-week deadline4 from the initial attempt to contact the 
corresponding author. One author team, comprising two reports, responded positively to our 
enquiries and provided the necessary missing data. Thus for these reports data were complete; 
indeed, we were able to code outcomes that were not available in the published reports.  
3.4.2 Assessment of risk of bias in included studies 
We assessed the methodological quality of studies using a risk of bias model developed by Prof. 
Barnaby Reeves in association with the Cochrane Non-Randomised Studies Methods Group4. This 
model is an extension of the Cochrane Collaboration’s risk of bias tool; it covers risk of bias both 
for RCTs, and risk of bias for non-randomised studies with a well-defined control group. The point 
of departure for the risk of bias model is the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins & Green, 2008). The risk of bias model for non-randomised studies is an 
elaboration of the existing Cochrane risk of bias tool and incorporates particular attention to 
selection bias and risk of confounding. The extended tool includes assessment of risk of bias on a 5-
point scale for some items.  
3.4.2.1 Risk of bias judgement items 
The risk of bias model is based on nine items (see 9.4.1). For some items, risk is assessed to be 
High, Low, or Uncertain; other items are judged on a 5-point scale where 1 corresponds to No/Low 
risk of bias and 5 correspond to Yes/High risk of bias. A score of 5 indicates that the risk of bias is 
sufficiently high that the findings will not be considered in the data synthesis (because they are 
more likely to mislead than inform). 
The nine risk of bias items concern sequence generation (relevant for selection bias), 
allocation concealment (relevant for selection bias), confounders (relevant for selection bias 
in non-randomised studies), blinding (relevant for performance, detection and attrition bias), 
                                                        
4 This risk of bias model was introduced by Prof. Reeves at a workshop on risk of bias in non-randomized studies at SFI 
Campbell, February 2011. The model is a further development of work carried out in the Cochrane Non-Randomised 
Studies Method Group (NRSMG). See also Reeves, Deeks, Higgins, & Wells (2011). 
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incomplete outcome data (relevant for attrition bias), selective outcome reporting 
(relevant for reporting bias), other potential threats to validity (relevant for performance, 
detection and other sources of bias), a priori protocol, and a priori analysis plan (relevant 
for reporting bias). 
3.4.2.2 Confounders 
An important part of the risk of bias assessment for a non-randomised study is how the 
confounding factors have been dealt with (see 9.4.2.2). Selection bias is understood as systematic 
baseline differences between groups, which can compromise comparability. Baseline differences 
can be observable (e.g., age and gender) and unobservable to the researcher (e.g. motivation and 
“ability”). There is no single non-randomised study design that resolves the selection problem in all 
circumstances. Different designs attempt to solve the problem under different assumptions and 
require different types of data, particularly in relation to factors that are unobservable. The “right” 
method depends on the assumptions about the nature of the process by which participants are 
selected into a program. As there is no universally correct way to construct counterfactuals, we 
assessed the extent to which the identifying assumptions (the assumption that makes it possible to 
identify the counterfactual) were explained and discussed by the study investigators. 
In this review, the risk of bias from confounding is an additional item for each non-randomised 
study, and were assessed for each outcome. Such an assessment requires a list of pre-specified 
potential confounders. We identified the following confounding factors as the most relevant:  
• Age 
• Gender 
• Socio-economic status 
• Mental health problems 
• History of drug use 
The motivation for focusing on these confounders was that they are major risk factors related to 
drug use. Young people have a higher risk of use than older people (Labouvie, 1996), women have 
lower risk than men and have different drug use patterns (Brady & Back, 2008), and people with 
poor socio-economic status have higher risk (Spooner & Hetherington, 2004). The issue of drug 
users with mental health problems needs special attention, because the mental health problems 
can interfere with the effect of the drug treatment (Ross, 2008). Finally, the history of drug use is 
important for the likelihood of treatment success, e.g. duration of use and previous treatment 
(Greenfield & Hennessy, 2008). We also assessed how each study dealt with factors that are 
unobservable.  
The risk of bias item takes into account the following: 
• Proportion of confounders considered. 
• Whether most important confounders were considered. 
• Precision with which confounders were measured. 
• Extent of imbalance between groups at baseline. 
• Care with which adjustment was done. 
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The final judgement of this risk of bias item was made on a scale from 1 to 5 (or unclear), where a 
score of 1 reflects low risk and a score of 5 reflects a high risk of bias in relation to confounding. For 
a judgement of low risk of bias in this item, all important confounders should be balanced at 
baseline or measured “well” and “carefully” controlled for in the analysis. The final judgement of 
the confounding item is included in the overall risk of bias table. 
One review author evaluated the risk of bias of all included studies. A second review author 
independently checked the assessment and disagreements were resolved by consensus.  
3.4.3 Effect size calculations 
Effect sizes were extracted from each included study by the methods described below. Two effect 
size measures were used in the review. For continuous measures we calculated effect sizes as 
standardised mean differences (Hedges’ g). For dichotomous outcome data we calculated the odds 
ratio. Where appropriate effect sizes were recoded such that a positive effect size reflected an 
outcome that favoured the 12-step intervention (see also 4.4).  
The primary outcome for the review was drug use. Seven studies (Carroll et al. 1998; Carroll et al., 
2012; Higgins et al., 1991; McKay et al., 1997; Petry et al., 2010; Schottenfeld et at., 2011; Wells et 
al., 1994) reported drug use on a continuous scale. Six studies reported drug use on a discrete scale 
(Bisset, 2002; Caroll et al., 1998; Higgins et al., 1991; Maude-Griffin et al., 1998; Petry et al., 2010; 
Schottenfeld et al., 2011). Continuous measures were outcomes such as “days of cocaine use per 
week”, whereas the dichotomous outcomes measured constructs such as “(complete) abstinence” 
(e.g. Bisset 2002, Maude-Griffin et al., 1998). Because continuous outcome measures were 
reported in a majority of studies, and because the dichotomous outcome could be considered a 
dichotomised version of an underlying continuous construct we used the standardised mean 
difference (Hedges’ g). By transforming the relevant effect sizes we were able to include them in the 
same meta-analysis, thereby increasing power to detect possible differences. We transformed effect 
sizes from log odds ratio to standardised mean difference, for those studies that only reported drug 
use on a discrete scale. If a study reported both a continuous and a discrete scale measure for the 
same time point, we used the outcome reported on a continuous scale. Effect sizes were 
transformed for Bisset (2002) (post and follow-up measure), Maude-Griffin et al. (1998) (during, 
post and follow-up), Petry et al. (2010) (follow-up), and Schottenfeld et al. (2011) (follow-up).  
All secondary outcomes, apart from retention, were reported on a continuous scale. Therefore 
effect sizes for these outcomes were calculated as standardised mean difference (Hedges’ g). Five 
studies (Bisset et al., 2002; Carroll et al., 1998; Carroll et al., 2012; Higgins et al., 1991; 
Schottenfeld et al., 2011) reported retention as a discrete measure (“treatment completion”) and 
four studies reported retention on a continuous scale, such as “number of sessions attended” 
(Caroll et al., 2012; McKay et al., 1997; Petry et al., 2010; Wells et al., 2010). Because dichotomous 
outcome measures were in the majority and we stated “treatment completion” as the outcome 
measure of interest in the protocol (section 3.1.4) a log odds ratio effect size was chosen. We 
transformed effect sizes to log odds ratio, for those studies where only a continuous scale effect size 
for retention was available (McKay et al., 1997; Petry et al. 2010; Wells et al., 1994).  
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Where appropriate outcomes were recoded such that a more positive score reflected an 
improvement of the outcome in question. For example Caroll et al. (2012) used self-reports in the 
Timeline Followback to measure drug use as “number of days per month using cocaine”. In this 
case, using raw outcomes, a superior outcome of 12-step over the alternative intervention would 
imply a negative effect size. Accordingly these estimated effect sizes were multiplied by -1. 
The table in section 11.2 presents outcome measures by study and time of measurement. 
3.4.3.1 Discrete data 
For discrete measures, the effect size was calculated as the log odds ratio (LOR). The LOR and its 
approximate standard deviation were calculated as (Lipsey & Wilson, 2001:53-54): 
𝐿𝐿𝐿𝐿𝐿𝐿 = 𝑙𝑙𝑙𝑙𝑙𝑙 �𝑎𝑎𝑎𝑎
𝑏𝑏𝑏𝑏
� , 𝑆𝑆𝐸𝐸𝐿𝐿𝐿𝐿𝐿𝐿 = �1𝑎𝑎 + 1𝑏𝑏 + 1𝑏𝑏 + 1𝑎𝑎 
where a is the frequency of “good” outcomes in the treatment group (e.g. the number retained), b is 
the frequency of “bad” outcomes in the treatment group (the number of participants who were not 
retained), and c and d are the number of good and bad outcomes in the control group, respectively.  
When appropriate (for studies that only reported a discrete measure for drug use at a given time 
point) we transformed the LOR to Hedges’ g using the Cox-transformation (see section 3.4.3.4). 
3.4.3.2 Continuous data 
For continuous measures, we calculated the effect size as the standardised mean difference 
(Hedges’ g), and applied the small N correction. Hedges’ (adjusted) g and its standard error are 
calculated as (Lipsey & Wilson, 2001:47-49) 
𝑙𝑙 = �1 − 34𝑁𝑁 − 9� × �𝑋𝑋�1 − 𝑋𝑋�2𝑠𝑠𝑝𝑝 � , 𝑆𝑆𝐸𝐸𝑔𝑔 = � 𝑁𝑁𝑛𝑛1𝑛𝑛2 + 𝑙𝑙22𝑁𝑁 
where 𝑁𝑁 = 𝑛𝑛1 + 𝑛𝑛2 is the total sample size, 𝑋𝑋� denotes the (adjusted) mean of a group, and 𝑠𝑠𝑝𝑝 is the 
pooled standard deviation defined as  
𝑠𝑠𝑝𝑝 = �(𝑛𝑛1 − 1)𝑠𝑠12 + (𝑛𝑛2 − 1)𝑠𝑠22(𝑛𝑛1 − 1) + (𝑛𝑛2 − 1)  
Here, 𝑠𝑠1 and 𝑠𝑠2 denotes the standard deviation of the two groups. 
When data were not available we extracted the effect size from auxiliary statistics. For example 
Wells, Peterson, Gainey, Hawkins, & Catalano (1994) reported means and the t-statistic for 
retention, but no standard deviation. By using standard techniques (Lipsey & Wilson, 2001) we 
were able to construct an effect size.  
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When appropriate (for studies that only reported a continuous measure for retention) we 
transformed Hedges’ g to LOR using the Cox-transformation (see section 3.4.3.4). 
3.4.3.3 Data from graphs and figures 
When data in the reports were insufficient to construct an effect size, we attempted to contact study 
authors directly. We only successfully established contact with one group of authors who had 
retained primary data or summary statistics. Three studies (Higgins et al., 1991; Schottenfeld et al., 
2011; Maude-Griffin et al., 1998) provided graphs or figures that permitted the construction of 
relevant effect sizes, either directly or with additional assumptions. In these instances, and in order 
to base the meta-analysis on as much data material as possible, we attempted to recover effect sizes 
from graphs and figures provided. For each of these three studies, two members of the review team 
(MB and TF) independently took measurements, results were compared, and a consensus 
measurement agreed upon.  
From Figure 1 (p. 1222, top panel) in Higgins, Delaney, Budney, & Bickel, (1991) we constructed a 
measure of drug use during the intervention based on number of weeks abstinent. Since we knew 
the total number of participants assigned to each condition, we were able to reconstruct individual 
durations of abstinence. We used a ruler to convert the percentages reported in the figure to 
number of participants. From this data, means and standard deviations by condition were 
constructed and formed the basis for calculating effect sizes.  
Schottenfeld, Moore, & Pantalon (2011) did not provide any numerical data that were directly 
amenable to meta-analysis. Instead, data were constructed from Figures 3 and 4 (drug use during 
and at 3 months follow-up, respectively). We were able to read precise individual participant 
measurements from Figure 3. From these measurements, means and standard deviations by 
condition were constructed. In order to construct measurements of the 3 months follow-up, we 
used the information provided in Figure 1 about how many participants were followed up, and we 
used a ruler in order to get an accurate measure of the point prevalence of percent abstinent by 
condition. We then constructed a 2 x 2 frequency table. 
We constructed effect sizes for Maude-Griffin et al. (1998) post treatment and at 14-week follow-up 
in a similar fashion. Maude-Griffin et al. (1998) did not provide the sample size at each 
measurement point by condition, but did report overall follow-up rates. Under the assumption that 
follow-up rates were independent of assignment, we were able get a measure of the “percent of 
subjects abstinent from cocaine” by taking measurements with a ruler. We constructed the 2 x 2 
frequency table from these measurements.  
3.4.3.4 Effect size transformations 
We used the Cox-transformation to transform continuous scale effect sizes (Hedges’ g) to log odds 
ratio and vice versa. The Cox-transformation for the effect size and the associated standard error is 
(Sánchez-Meca, Marín-Martínez, & Chacón-Moscoso, 2003): 
𝐿𝐿𝐿𝐿𝐿𝐿 = 1.65 × 𝑙𝑙, 𝑆𝑆𝐸𝐸𝐿𝐿𝐿𝐿𝐿𝐿 = 1.65 × 𝑆𝑆𝐸𝐸𝑔𝑔 
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We applied the transformation from LOR to g for drug use, and from g to LOR for retention, where 
appropriate. 
3.4.3.5 Dependent effect sizes 
Dependencies between effect sizes may occur for a multitude of reasons, including when studies 
are multi-arm trials. For example, Carroll, Nich, Ball, McCance, & Rounsavile (1998) conducted a 5 
arm trial. In 3 of these, disulfiram was given as an add-on to the psychosocial interventions: TSF, 
CBT, and CM. Since the comparisons relevant to this review involve TSF against an alternative, the 
comparisons between TSF/CBT and TSF/CM are dependent.  
A study may also report several effect sizes for the same theoretical construct. For example, Petry, 
Weinstock, Alessi, Lewis, & Dieckhaus (2010) measured “drug use” during treatment both as 
longest consecutive number of weeks of negative samples submitted and also as the proportion of 
negative samples submitted.  
Effect sizes may also be serially correlated, such as when a study contributes effect sizes at several 
time points. Where this occurred, only one outcome measure per construct was retained for meta-
analysis. 
Data from multi-arm trials were synthesised in different meta-analyses. We also split analyses by 
time points to avoid dependencies between effect sizes. 
3.4.3.6 Unit of analysis issues 
If designs other than individually randomised, parallel-group randomised trials were included, we 
described any methods used to address clustering, matching or other design features.  
12-step interventions may be delivered in groups or individually, and often take place with some 
sessions delivered individually, and some delivered as group sessions. For example, Maude-Griffin 
et al. (1998) individually randomised participants to receive either CBT or 12-step facilitation 
delivered as three group therapy sessions and one individual counselling session each week for 12 
weeks.  
A study design where participants are individually randomised to treatment, but that treatment is 
delivered in a group setting, are known as individually randomised group treatment (IRGT) trials 
(Pals et al., 2008). The analysis in such a study design must correct for the fact that dependencies 
may arise between individuals that happen to receive the intervention in the same group. The 
analogy is the cluster randomised trial where clusters of participants are randomised to treatment. 
The analysis of cluster randomised trials must correct standard errors for the dependencies among 
individual participants in clusters. The correction involves knowledge of the intra-cluster 
correlation coefficient (ICC) and the (mean) group size. With this in hand, the estimated standard 
errors can be corrected with a design effect. Unfortunately none of studies report the ICC, and only 
2 studies report group size. In the two studies that reported group size, Wells et al., 1994 delivered 
to groups with a mean size of 12, while Petry et al. (2010) reported a mean group size of 4 (for TSF 
intervention) and 4.5 (for the comparison condition). Pals et al. (2008) reviewed 34 IRGT trials in 
public health and noted that reporting of ICCs were very rare. The data that are available produced 
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ICC estimates ranging between 0.04 and 0.44 depending on participants, interventions, and 
outcomes.  
Since we had no relevant information on either ICC or group size, we decided that we could not 
reliably correct estimates for this unit of analysis error. Instead, studies that employed an IRGT 
design and did not correct the analysis for this design choice were scored on the “Other Bias” item. 
We then carried out a sensitivity analysis on this item. 
3.5  DATA SYNTHESIS 
Studies that scored 5 on a risk of bias item were excluded from the meta-analysis.  
3.5.1 Effect size synthesis 
Separate meta-analyses were carried out by outcome, and by time point (see section 3.2.7). In 
addition, analyses were organised based upon whether the comparison was 12-step versus other 
psychosocial intervention, or 12-step + add-on vs other psychosocial intervention + add-on. Only 
one included study (Bisset, 2002) contributed data to the comparison of 12-step vs no intervention. 
Accordingly meta-analysis could not be performed. We report the study level effect size for this 
comparison.  
We retained only one effect size measure per comparison for each outcome construct for meta-
analysis. When a study contributed dependent effect sizes, these were synthesised in separate 
meta-analyses. For example, as mentioned in section 3.4.3.5, the study by Carroll et al. (1998) 
contributed two relevant effect sizes: TSF versus CBT and TSF versus CM; these were synthesised 
in separate meta-analyses. 
All analyses were carried out using inverse variance weighted random effects statistical models that 
incorporated both the sampling variance and between-study variance components into study level 
weights. We decided to use a random effects model to represent the overall effect as we expected 
included studies to deal with diverse populations of participants and intervention types.  
Results of meta-analyses were presented by outcome and time of measurement. For each analysis 
we reported the number of studies, the average effect size with 95% confidence intervals, and 
where appropriate measures of heterogeneity, and in the case of I2 with an uncertainty interval (see 
section 3.5.2). 
3.5.2 Assessment of heterogeneity 
Heterogeneity was assessed through the use of the χ2-test. A p-value smaller than 0.1 was taken as 
indication of significant heterogeneity of treatment effects (protocol, sec. 3.3.7). Since the test has 
low power to detect differences in typical meta-analysis context (few studies) p is sometimes set to 
0.1 (Higgins, & Green, 2008, sec. 9.5.2) rather than the standard 0.05. The test statistic was used to 
represent the degree of variability in the treatment effect estimates due to heterogeneity:  
𝐼𝐼2 = (𝑄𝑄 − 𝑎𝑎𝑑𝑑) 𝑄𝑄�    x 100% 
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where Q is the χ2 test-statistic and df is its degrees of freedom (Higgins & Green, 2008). The value 
of I2 lies between 0% and 100%, with a value of 0% indicating no observed heterogeneity and larger 
values show increasing heterogeneity (Higgins, Thompson, Deeks, & Altman, 2003). When there 
was a sufficient number of studies per meta-analysis we calculated and reported uncertainty 
intervals for I2 (Higgins & Thompson, 2002). We found a moderate degree of heterogeneity 
between studies in some of the meta-analyses, and investigated further when a threshold of 75% 
was exceeded. In addition we reported the between-studies variance component (τ2).  
3.5.3 Assessment of publication bias 
Publication bias may occur because studies that report statistically significant treatment results are 
more likely to be published. We used two strategies to assess whether publication bias was present. 
First, our search strategy was designed to uncover any unpublished studies that met inclusion 
criteria, by searching dissertation databases and grey literature. Second, we examined funnel plots 
for asymmetry. The funnel plot is constructed by plotting a study’s effect size against the standard 
error of the estimate. In the absence of publication bias one would expect a symmetric graph where 
the variation in effect size estimates increase with the standard error of the estimate. Although an 
asymmetric funnel plot does not necessarily imply that publication bias is present, it is an 
indication that the published research literature may suffer from this type of bias.  
3.5.4 Handling of missing data 
Not all studies reported sufficient details to allow the calculation of an effect size. When a study 
reported insufficient data for the calculation of a numeric effect size, we contacted the study 
authors requesting data. In some cases this allowed us to extract the information needed, but in the 
majority of cases our attempt to contact authors was unsuccessful5. For example, McKay et al. 
(1999) reported means and standard deviations for drug use but did not report sample size by 
treatment assignment; only the overall follow-up rate. In this and similar cases we assumed that 
follow-up attrition was independent of treatment assignment, allowing us to impute the missing 
data6. In addition, as detailed in section 3.4.3.3, when summary statistics were not available, 
effects sizes were extracted from figures and graphs where possible.  
3.5.5 Sensitivity analysis 
Sensitivity analysis was carried out with respect to risk of bias items. Meta-analysis was performed 
excluding studies where the ‘sequence generation’ item was scored either as High or Unclear, 
where the ‘incomplete data’ item was scored at 4, and where the ‘other bias’ item was scored at 4.  
3.5.6 Software used for synthesis 
We used Version 5.3 of Review Manager (2014) and Version 13 of Stata (StataCorp, 2013) for data 
synthesis.  
                                                        
5 Authors were contacted in September, 2014. Four corresponding authors did not reply to our enquiries, two replied that 
data had been discarded, and one replied positively and supplied the requested study level information in full detail.  
6 Pigott (2009) describes a number of statistical techniques for dealing with missing data.  
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4 Results 
4.1  RESULTS OF THE SEARCH 
We ran the searches in January 2010, October 2011, July 2013, and August 2015, and September 
2016. 
We searched 15 international and Nordic bibliographic databases, searched for grey literature and 
hand searched five core journals in September 2016 (see section 3.3 for more information). 
The total number of potentially relevant records was 21,974 after excluding duplicates (database 
search: 17,416; grey literature search: 2,639; hand search and others: 1919). 
All 21,974 records were screened based on title and abstract. 428 of these records were retrieved 
and screened in full text. Thirty-six of the full texts were initially deemed to meet inclusion criteria. 
Upon closer inspection 23 full texts did not meet inclusion criteria. The primary reason for 
exclusion of these full texts is listed in section 9.3.  
Thirteen reports met the inclusion criteria and data were extracted from these reports.  
A total of 10 unique studies, reported in 13 reports, were included in the review. See ‘Flow of 
studies’ figure in section 10.2. See section 4.2 for further details on included studies. References to 
included reports can be found in section 7.1. 
 
4.2  DESCRIPTION OF INCLUDED STUDIES 
4.2.1  Study designs  
Seven of the included studies were randomised controlled trials (Bisset, 2002; Carroll, Nich, Ball, 
McCance, & Rounsavile; 1998 Carroll, Nich, Shi, Eagan, & Ball, 2012; Maude-Griffin, Hohenstein, 
Humfleet, Reilly, Tusel, & Hall, 1998; McKay, Alterman, Cacciola, Rutherford, O'Brien, & 
Koppenhaver, 1997; Petry, Weinstock, Alessi, Lewis, & Dieckhaus, 2010; Schottenfeld, Moore, & 
Pantalon, 2011). Two studies had quasi-random allocation of participants to treatment (Higgins, 
Delaney, Budney, & Bickel, 1991; Wells, Peterson, Gainey, Hawkins, & Catalano, 1994). One quasi-
experimental study was included (Gossop, Stewart, & Marsden, 2007).  
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4.2.2 Location of the studies 
All but one of the ten included studies were conducted in the US (Bisset, 2002; Carroll et al., 1998; 
Carroll et al., 2012; Higgins et al., 1991; Maude-Griffin et al., 1998; McKay et al., 1997; Petry et al., 
2010; Schottenfeld et al., 2011; Wells et al., 1994). Gossop et al. (2007) was conducted in the 
United Kingdom.  
All studies were facilitated in outpatient settings. 
4.2.3 Participants 
As displayed in tables in section 9.2, the number of males and females were approximately equal in 
three studies (Bisset, 2002; Carroll et al., 2012; Petry et al., 2010). Five studies included a majority 
of male participants (Carroll et al., 1998; Gossop et al., 2007; Higgins et al., 1991; Maude griffin et 
al., 1998; Wells et al., 1994). One study included only men (McKay et al., 1997), and another 
involved only women due to the inclusion criteria of the study that required participants to be 
female and either pregnant or have custody of a young child (Schottenfeld et al., 2011).  
The mean age of the participants varied between 29 and 43 years.  
The ten included studies reported the participants’ socioeconomic group in five different ways. In 
two studies, 81% and 62.7% had 12 or more years of education (Bisset, 2002; Higgins et al., 1991). 
Two studies reported a mean of around 12 years of education (McKay et al., 1997; Petry et al., 
2010). Carroll et al. (1998) reported that 23% of participants had some college education, 47% had 
finished their high school education and 17% had not completed high school. A similar 
classification was used in Carroll et al. (2012), where the percentages were 34%, 43% and 17%. In 
two studies, 84% and 95% were either unemployed or did not have a fulltime job (Maude-Griffin et 
al., 1998; Schottenfeld et al., 2011). In Schottenfeld et al. (2011) it was also reported that 57 % of 
the participants had at least finished high school or its equivalent. In one study, 68% of the 
participants had had a full time job the previous 3 years and more than half had worked at least 20 
days in the past month (Wells et al., 1994).   
Eight studies (Bisset, 2002; Carroll et al., 1998; Carroll et al., 2012; Higgins et al., 1991; Maude-
Griffin et al., 1998; McKay et al., 1997; Petry et al., 2010; Schottenfeld et al., 2011) reported 
participants’ mental health conditions either before or when entering treatment. Five studies 
reported that minimum a third of the participants had some kind of mental disorder (Bisset, 2002; 
Carroll et al., 1998; Carroll et al., 2012; Maude-Griffin et al., 1998; McKay et al., 1997), including 
depression, personality disorder, and antisocial personality disorder. One study reported that 24% 
of the participants met the criteria for current major depression disorder (Schottenfeld et al., 2011). 
Two studies reported psychiatric problem severity using the Addiction Severity Index Composite 
Score (ASI) (Higgins et al., 1991; Petry et al., 2010). Two studies did not report the mental health 
status of participants (Gossop et al., 2007; Wells et al., 1994).   
Participants in the included studies had overall a long history of drug use, ranging from 5 to 19 
years of drug addiction (Carroll et al., 1998; Gossop et al., 2007; Higgins et al., 1991; McKay et al., 
1997; Wells et al., 1994). A number of studies reported drug use among the majority of the 
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participants within the last 30 days before entering the trial (Bisset, 2002; Carroll et al., 2012; 
Gossop et al., 2007; Schottenfeld et al., 2011; Wells et al., 1994).  
In five studies the participants were predominantly white Caucasian (Bisset, 2002; Carroll et al., 
2012; Gossop et al., 2007; Higgins et al., 1991; Wells et al., 1994), in three studies most participants 
were African American, and two studies reported a combination of ethnic groups (Carroll et al., 
1998; Maude-Griffin et al., 1998; McKay et al., 1997; Petry et al., 2010; Schottenfeld et al., 2011).   
4.2.4 Interventions 
12-step therapy was delivered in a variety of ways across the studies. In four studies, ordinary TSF 
was delivered (Carroll et al., 1998; Carroll et al., 2012; Maude Griffin et al., 1998; Schottenfeld et 
al., 2011). The content of the TSF is intended to be consistent with the 12 Steps, but with an 
importance of steps 1-5 and a disease model of addiction added to the original program. In Bisset 
(2002), the therapy was delivered as Intensive Twelve Step Facilitation (ITSF). ITSF differs from 
the ordinary Twelve Step Facilitation (TSF) by offering the participants 48 sessions rather than the 
12 session in TSF. 12-step drug counselling was delivered in one study (Higgins et al., 1991). Two 
studies delivered the therapy as a mix of addiction counselling and 12-step recovery practices 
(McKay et al., 1997; Petry et al., 2010). In one of these studies, the therapy was delivered as an 
aftercare program (McKay et al., 1997). In one study the 12-step program was delivered as a self-
help group attendance (Gossop et al., 2007). 
The duration of the interventions varied between 12 weeks and 6 months. Treatment sessions took 
place once or twice weekly in all studies.  
4.2.5 Control conditions 
The control conditions in the included studies was categorised as follows: 12-step therapy was 
compared to the treatment as usual, another psychosocial intervention or an intervention where 
12-step with an add-on was compared to another intervention with an add-on. 
In Bisset (2002) participants in one of the two comparison conditions received only methadone 
and no psychosocial therapy. In one study, one comparison condition was defined as being 
participants who did not attend any 12-step self-help group meetings (Gossop et al., 2007). The 
second comparison group in this study consisted of participants who attended self-help sessions 
less than once a week. 
In six of the included studies the comparison conditions were psychosocial interventions without 
any supplement (Bisset, 2002; Higgins et al., 1991; Maude-Griffin et al., 1998; McKay et al., 1997; 
Petry et al., 2010; Wells et al., 1994). In one study the comparison condition was Behavioural 
Therapy (Higgins et al., 1991). Two studies delivered Cognitive Behavioural Therapy to the 
comparison group (Maude-Griffin et al., 1998; Wells et al., 1994). Acceptance and Commitment 
Therapy, Contingency Management, and Relapse Prevention interventions were delivered to the 
comparison group in Bisset (2002), Petry et al. (2010) and McKay et al. (1997), respectively.    
In Carroll et al. (1998) participants were divided into five groups. Two groups received CBT and 12-
step without add-ons. The remaining three groups all received disulfiram in addition to their 
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weekly therapy sessions in 12-step, Cognitive Behavioural Therapy and Clinical management. In 
Carroll et al. (2012) one comparison condition received disulfiram and no psychosocial therapy and 
the second comparison condition received 12-step and disulfiram. Community reinforcement was 
delivered to the comparison group, and as add-on the study included contingency and non-
contingent yoked voucher control (Schottenfeld et al., 2011).  
4.2.6 Treatment fidelity 
Therapists with masters or doctoral level training in psychology or with an equivalent degree 
delivered the treatments in the included studies. One study did not report who delivered the 
treatment (Gossop et al., 2007).  
Seven studies utilised supervision to assess the fidelity of treatment (Bisset, 2002; Carroll et al., 
1998; Maude griffin et al., 1998; McKay et al., 1997; Petry et al., 2010; Schottenfeld et al., 2011; 
Wells et al., 1994). 
4.2.7 Measurement of outcomes  
An overview of outcomes and how they were measured in each included study can be found in 
section 11.1. 
4.2.7.1 Drug use 
The primary outcome for this review was abstinence or reduction in drug use measured by 
biochemical tests, estimates of drug use, and/or psychometric scales. Eight studies used 
biochemical tests to verify abstinence (Bisset, 2002; Carroll et al., 2012; Higgins et al., 1991; 
Maude-Griffin et al., 1998; McKay et al., 1997; Petry et al., 2010; Schottenfeld et al., 2011; Wells et 
al., 1994).  
Six studies used other means of assessing drug use, typically self-report (Carroll et al., 2012; Carroll 
et al., 1998; Gossop et al., 2007; Maude-Griffin et al., 1 998; McKay et al., 1997; Schottenfeld et al., 
2011). In addition, in three studies the ASI-drug subscale was administered (Bisset, 2002; McKay 
et al., 1997; Schottenfeld et al., 2011).  
Continuous outcomes were measured in seven studies (Carroll et al., 1998; Carroll et al., 2012; 
Gossop et al., 2007; McKay et al., 1997; Petry et al., 2010; Schottenfeld et al., 2011; Wells et al., 
1994), whereas dichotomous outcomes were measured in six of the studies (Bisset, 2002; Carroll et 
al., 1998; Higgins et al., 1991; Maude-Griffin et al., 1998; McKay et al., 1997; Schottenfeld et al., 
2011).  
4.2.7.2 Secondary outcomes 
Two studies measured outcomes in the criminal behaviour domain with the ASI-legal subscale 
(Bisset, 2002; Carroll et al., 1998). The ASI-legal interview also covers issues related to 
prostitution. 
Three studies used the ASI to assess psychiatric symptoms, social functioning and employment 
status of the participants (Bisset, 2002; Carroll et al., 1998; McKay et al., 1997). Bisset (2002) also 
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utilised The Beck Depression Index, and the Symptom Checklist-90-R questionnaires to assess 
psychological problems and symptoms of psychopathology. 
None of the studies measured or reported outcomes related to homelessness.  
4.2.8 Time points 
Table 1 provides an overview of when measurements were taken in the included studies. The 
majority of studies took outcome measurements at one or more time points during treatment, 
except Gossop et al. (2007), Higgins et al. (1991), Petry et al. (2010), and Wells et al. (1994). All 
studies except Gossop et al. (2007) took outcome measurements at the end of treatment. All 
studies except Higgins et al. (1991) also took outcome measurements at one or more follow-up 
points.  
 
Table 1: Time points in included studies 
Study Time points in study post enrolment Treatment duration 
Bisset (2002) 
8 weeks 
16 weeks 
6 months 
16 weeks 
Carroll et al. (1998) 
1 month 
2 months 
12 weeks 
16 weeks 
24 weeks 
36 weeks 
1 year and 12 weeks 
12 weeks 
Carroll et al. (2012) 
1 month 
2 months 
12 weeks 
16 weeks 
24 weeks 
36 weeks 
1 year 
1 year and 12 weeks 
12 weeks  
Gossop et al. (2007) 
1 year 
2 years 
4-5 years 
self-help groups 
Higgins et al. (1991) 12 weeks 12 weeks 
Maude-Griffin et al. 
(1998) 
4 weeks 
8 weeks 
12 weeks 
26 weeks 
12 weeks 
McKay et al. (1997)  
1-6 months 
7-12 months 
13-18 months 
19-24 months 
24 weeks 
Petry et al. (2010)  24 weeks 6 months 24 weeks 
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Study Time points in study post enrolment Treatment duration 
Schottenfeld et al. 
(2011) 
3 months 
1-24 weeks 
6 months 
9 months 
12 months 
24 weeks  
Wells et al. (1994) 12 weeks 36 weeks 12 weeks 
 
4.3  RISK OF BIAS IN INCLUDED STUDIES 
All included studies were assessed for risk of bias. Each study was rated independently by two 
reviewers in the following 6 domains.  
• Selection bias 
o Adequate sequence generation 
o Allocation concealment 
• Blinding 
• Incomplete outcome data addressed  
• Free of selective reporting 
• Free of other bias 
Some items such as sequence generation were rated on a High risk/Low risk/Unclear risk scale. 
Other items such as incomplete outcome data were assessed on a scale from 1 to 5, where a score of 
5 indicates an unacceptable high risk of bias. Risks of bias tables for each study are presented in 
section 9.4.1. In all included studies the outcomes were organised into primary outcomes, 
secondary outcomes and retention within the domains blinding, incomplete outcome data 
addressed and free of selective reporting. Outcomes within a study received a separate rating if the 
risk of bias differed between them.  
As displayed in Figure 2, four of the included studies received a low risk of bias score for Adequate 
sequence generation. The remaining six studies were either classified as high risk (3) or as unclear 
risk (3) for sequence generation. Randomisation was performed via a computerised urn-algorithm 
in studies that were classified with low risk in the adequate sequence generation item. For 
allocation concealment, three studies were rated as low risk of bias, whereas the remaining studies 
were rated with either high risk (3) or unclear risk (4). The assessment within these two domains 
indicates that several of the studies are at high risk of some form of selection bias.  
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For blinding, none of the included studies received a low risk rating. Six studies were considered as 
high risk of bias, mainly because of the natural difficulties in blinding therapists and participants.  
Eight studies received a medium risk of bias classification (score of 2 or 3) in the incomplete 
outcome data addressed domain. For the domain free of selective reporting 6 studies were 
classified with low risk of bias. The remaining studies were classified with some risk of bias in this 
domain. One study was judged to be free of other forms of bias. Eight studies were given a score of 
3 or 4. This was due the lack of correction of the statistical analysis for the group therapy element 
of the intervention.  
The study by Gossop, Stewart, & Marsden (2007) was excluded from meta-analysis following risk 
of bias assessment. Gossop et al. (2007) used a quasi-experimental design, and accordingly the 
study was in addition assessed on the confounding item of the risk of bias tool. The study was 
judged at high risk of bias on the confounding item, leading to its exclusion from quantitative 
synthesis. Further details on the risk of bias assessment can be found in section 9.5. 
4.3.1 Example of risk of bias assessment 
Here we present an example of the risk of bias assessment that we conducted for the Higgins et al. 
(1991) study. Non-random sequence generation was used to assign participants to treatment; 13 
participants were allocated to Behavioural therapy and the next 15 participants were allocated to 
the 12-step group. Because of this allocation, the study was rated with high risk for adequate 
sequence generation. There was no information in the report regarding allocation concealment. 
Because the decision to allocate exactly 13 participants to behavioural therapy was not pre-
specified, it is likely that this decision was not concealed to study investigators. The study was 
scored with a high risk rating in allocation concealment. 
Neither participants, therapists, nor assessors were blind to treatment allocation, something which 
is difficult to achieve with these interventions. Because the Behavioural Therapy intervention 
includes an incentive pay mechanism it is unlikely that staff was blind to the allocation.  
Figure 1: Risk of Bias summary for drug use 
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For incomplete outcome data/attrition bias, the study was rated with high risk for the primary 
outcome and with low risk for the outcome of treatment retention. The reason for judging primary 
outcome at high risk, is due to the rather large, and differential attrition between treatments.  
For selective reporting/reporting bias, the study was received a score of 2, indicating a small risk of 
bias. The reason for the judgement 2 was that reporting on the missing outcome data item was not 
adequate.  
The 12-step intervention was delivered in groups. The statistical analysis in the report did not 
correct for this design feature. This is assessed in the other risk of bias domain.  
4.4  EFFECTS OF INTERVENTION  
Effect sizes for each study are reported in the online appendix (see section 12) and forest plots for 
all meta-analyses are reported in Section 11.4.  
Prior to calculating effect sizes, outcome measures were recoded such that a higher score was 
indicative of an improvement in the relevant domain. For example, the ASI is measured on a scale 
from 0 to 1 where a higher score indicates higher degree of severity. This measure was therefore 
recoded. Subsequently, effect sizes were constructed such that a positive effect size favoured the 12-
step intervention rather than the comparison/control.  
Studies used several different scales to measure the same outcome construct. For example, Bisset 
(2002) measured the primary outcome “drug use” with a urine analysis screen and "relevant 
portions of ASI" (Hayes et al., 2004, p 673). McKay et al. (1999) used the Timeline Follow Back to 
construct a measure of percentage of days using cocaine. All effect sizes for drug use were 
expressed in or transformed to the SMD-family of effect sizes (standardised mean difference). 
When studies reported multiple effect sizes for drug use, we chose the effect size that relied on a 
continuous outcome measure. 
Treatment retention was also measured in a variety of ways. Some studies measured retention as 
number of completed sessions (e.g. McKay et al., 1997), others measured retention as treatment 
completion (e.g. Carroll et al., 1998). Since the majority of studies reported dichotomous outcomes, 
effect sizes were expressed in or converted to the odds ratio. Studies only contributed one effect 
size on this outcome construct. 
The remaining secondary outcomes were all measured with the relevant subcomponent of the ASI 
(Addiction Severity Index). Since the ASI is a continuous measure, effect sizes were expressed in 
the SMD-family of effect sizes. None of the studies contributed multiple effect sizes on these 
outcome constructs. 
A complete list of outcome measures is available in the appendix (section 11.1) 
Below we report the results of effect size synthesis. Meta-analysis was conducted separately for two 
comparisons: 12-step vs. other psychosocial treatment, and 12-step with an add-on (either 
pharmaceutical add-on such as disulfiram, or another psychosocial add-on such as contingency 
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management) vs other psychosocial treatment with an identical add-on. Only one study (Bisset, 
2002) contributed data to the comparison 12 step vs. no intervention at post treatment and at 
follow-up. Meta-analysis was therefore not performed, but we report the effect sizes for this study 
for completeness.  
When studies contributed to more than one relevant comparison, these were analysed in separate 
meta-analyses. Separate meta-analyses were also conducted for each of the outcomes relevant to 
the review. Finally meta-analysis was conducted separately by time: during intervention, post 
intervention, and follow-up. The time point division differed from that specified in the protocol. In 
our protocol we stated that we expected that the included studies would contain interventions of a 
self-help nature and we anticipated synthesising outcomes in the short-term (less than 6 months 
after enrolment into treatment), medium-term (6-12 months after enrolment), and long-term (12 
months or more after enrolment). However, all studies included in our synthesis were either 
randomised or quasi-randomised trials. Since most studies reported on the primary outcome 
during the intervention and at post-intervention, we found it appropriate to follow the research 
literature in choosing appropriate time intervals7.  
In several studies all or part of the intervention was implemented as group therapy. None corrected 
for the correlation inherent in these interventions between participants (randomly) assigned to the 
same group. Since we lacked both plausible information on intra-cluster correlation and on 
(average) group size, we decided that we could not reliably correct effect sizes; instead the risk of 
bias assessment for these studies reflected the risk of bias present in the effect estimates for this 
group of studies.  
4.4.1 Comparison: 12-step vs no intervention 
4.4.1.1 Primary outcome: drug use 
4.4.1.1.1 During treatment 
No studies contributed effect sizes for drug use to the comparison of 12-step versus no intervention 
during treatment. 
4.4.1.1.2 Post treatment 
One study (Bisset, 2002) contributed effect sizes to the comparison of 12-step versus no 
intervention at post-treatment. Meta-analysis was therefore not possible. The effect size from 
Bisset (2002) for drug use is presented in Table 2 below. 
  
                                                        
7 Kiluk, Nich, Witkiewitz, Babuscio, & Carroll (2014) show that greater cocaine abstinence during treatment is associated 
with fewer problems on follow up. 
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Table 2: Effect size (SMD) for 12-step vs no intervention, outcome: drug use measured post treatment 
Outcome Effect Size (95% CI) 
Drug use 0.45 (-0.25:1.14) 
Notes: Positive effect size favours 12-step intervention. Effect size for retention: odds ratio.  
* p < .05, ** p < .01 
4.4.1.1.3 Follow-up 
Only one study contributed a comparison of 12-step versus no intervention (Bisset, 2002), at 
follow-up, therefore no meta-analysis was possible. Table 3 presents the study level effect size for 
drug use. 
Table 3: Effect size (Hedges’ g) for 12-step vs no intervention, outcome: drug use at follow-up (6 months) 
Outcome Effect Size (95% CI) 
Drug use 0.91* (0.03:1.78) 
Notes. Positive effect size favours 12-step intervention. 
* p < .05, ** p < .01 
4.4.1.2 Secondary outcomes 
4.4.1.2.1 During treatment 
No secondary outcomes were available during treatment for the comparison between 12-step and 
no intervention. 
4.4.1.2.2 Post treatment 
Only one study contributed a comparison of 12-step versus no intervention (Bisset, 2002), 
therefore no meta-analysis was possible. Table 4 presents the study level effect size for the 
secondary outcomes: retention, criminal behaviour, psychiatric symptoms, social functioning and 
employment, measured post treatment. 
Table 4: Effect sizes (Hedges’ g) for 12-step vs no intervention, secondary outcomes measured post 
treatment 
Outcome Effect Size (95% CI) 
Criminal Behaviour -0.45 (-0.97:0.06) 
Psychiatric Symptoms -0.47 (-0.98:0.04) 
Social Functioning -0.55* (-1.06:-0.03) 
Employment 0.20 (-0.31:0.71) 
Retention 0.37 (0.14:0.97) 
Notes: Positive effect size favours 12-step intervention. Effect size for retention: odds ratio.  
* p < .05, ** p < .01 
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4.4.1.2.3 Follow-up 
Only one study contributed a comparison of 12-step versus no intervention (Bisset, 2002), 
therefore meta-analysis was not possible. Table 5 presents the study level effect size for the 
secondary outcomes: retention, criminal behaviour, psychiatric symptoms, social functioning and 
employment, measured at 6-months follow-up 
 
Table 5: Effect sizes (Hedges’ g) for 12-step vs no intervention, secondary outcomes at follow-up (6 
months) 
Outcome Effect Size (95% CI) 
Criminal Behaviour -0.11 (-0.65:0.44) 
Psychiatric Symptoms -0.34 (-0.89:0.21) 
Social Functioning 0.15 (-0.40:0.69) 
Employment -0.30 (-0.85:0.25) 
Notes. Positive effect size favours 12-step intervention. 
* p < .05, ** p < .01 
 
4.4.2 Comparison: 12-step vs other psychosocial interventions 
4.4.2.1 Primary outcome: drug use 
4.4.2.1.1 During treatment 
Five of the seven studies included compared 12-step to a psychosocial intervention contained 
sufficient information for us to construct an effect size for drug use during treatment (Carroll et al., 
1998; Higgins et al., 1991; Maude-Griffin et al., 1998; McKay et al., 1997; Petry et al., 2010). Bisset 
(2002) and Wells et al. (1994) did not report measures of drug use during treatment.  
Table 6 displays the results of meta-analysis for the comparison of 12-step versus other 
psychosocial intervention for drug use. See Figure 11.4.1.1.1 in Appendix 11.4 for the forest plot. 
Outcomes were measured during treatment. 
Table 6: Meta-analysis, 12-step vs psychosocial intervention, drug use measured during treatment 
Outcome Studies 
Participants 
Effect Size 
(95% CI) 
Heterogeneity 
Assigned In analysis 
sample 
τ2 
I2 
(95% UI) 
Drug use 5 
502 482 -0.29  
(-0.62:0.05) 
0,07 
57% 
(0%, 84%) 
Notes: Positive effect size favours 12-step intervention. Effect size measure is Hedges’ g. * p < .05, ** p < .01 indicates 
statistical significance of effect size. Uncertainty intervals reported for I2 where applicable (Higgins & Thompson 2002). 
 
Effect sizes varied between -1.42 (Higgins et al., 1991) and 0.33 (Carroll et al., 1998). All studies 
except Carroll et al. (1998) included a group element in the intervention, and the estimated 
standard errors of the effect sizes are therefore likely biased. In the meta-analysis of five studies 
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(Table 6), there was no statistically significant difference between 12-step and another psychosocial 
intervention during treatment for the outcome of drug use (Hedges’ g = -0.29; 95% CI -0.62 to 
0.05). This indicates that 12-step treatment is neither worse nor better than the other psychosocial 
interventions in reducing drug use. Outcome data were available for 482 out of 502 assigned 
participants (96%). The I2 statistic (57%) indicated that there was a moderate degree of 
heterogeneity present. 
4.4.2.1.2 Post treatment 
Five of the seven studies that considered the comparison between 12-step and other psychosocial 
interventions contributed data to the meta-analysis for the outcome of drug use measured post 
treatment (Bisset, 2002; Carroll et al., 1998; Maude-Griffin et al., 1998; McKay et al., 1997; Wells 
et al., 1994). Higgins et al. (1991) and Petry et al. (2010) did not measure drug use post treatment.  
Table 7 presents results from meta-analysis of the comparison of 12-step intervention versus 
psychosocial intervention, for drug use, measured post treatment. See Figure 11.4.1.1.2 in Appendix 
11.4 for the forest plot. 
Table 7: Meta-analysis, 12-step vs psychosocial intervention, drug use measure post treatment 
Outcome Studies 
Participants 
Effect Size 
(95% CI) 
Heterogeneity 
Assigned In analysis 
sample 
τ2 
I2 
(95% UI) 
Drug use 5 
500 412 -0.03  
(-0.24:0.18) 
0.00 
0% 
(0%, 73%) 
Notes. Positive effect size favours 12-step intervention.  
* p < .05, ** p < .01 indicates statistical significance of effect size. Effect size measure is Hedges’ g. Uncertainty 
intervals reported for I2 where applicable (Higgins & Thompson 2002).  
 
Effect sizes ranged between -0.28 (Maude-Griffin et al., 1998) to 0.25 (Wells et al., 1994). In the 
meta-analysis of 5 studies (Table 7), there was no statistically significant difference between 12-
step and another psychosocial intervention post treatment for the outcome of drug use (Hedges’ g 
= -0.03; 95% CI -0.24 to 0.18). Four of the studies involved group based interventions and data 
were not corrected for clustering. Data completion rate was 82% on average that is outcome data 
were available for 82% of participants assigned to treatment. There was no indication of 
heterogeneity between studies on drug use, but note that the uncertainty interval for I2 is wide. 
4.4.2.1.3 Follow-up 
Table 8 presents the results of meta-analyses for the comparison of 12-step treatment versus other 
psychosocial treatment. Six studies contributed data (Bisset, 2002; Carroll et al., 1998; Maude-
Griffin et al., 1998; McKay et al., 1997; Petry et al., 2010; Wells et al., 1994). Outcomes measured 6 
months post treatment and 12 months post treatment were synthesised in meta-analysis. Some 
studies provided follow-up measures at additional time points. For example McKay et al. (1999) 
provide measures at 18 months follow-up. However 6 and 12 months follow-up times were the time 
points covered by the most studies, and were chosen for meta-analysis. See Figure 11.4.1.1.3 in 
Appendix 11.4 for the forest plot. All effect sizes are available in our Online Supplement 1.  
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Table 8: Meta-analysis, 12-step vs psychosocial intervention, drug use at follow-up 
Outcome 
Time point 
(months 
post 
treatment) 
Studies 
Participants 
Effect Size  
(95% CI) 
Heterogeneity 
Assigned In 
analysis 
sample 
τ2 I
2 
(95% UI) 
Drug use 
6  6 
670 527 -0.12  
(-0.31:0.08) 
0.00 
0% 
(0%, 0%) 
12  2 
176 146 -0.02  
(-0.35:0.3) 
0.00 0% 
Notes: * p < .05, ** p < .01 indicates statistical significance of effect size. Uncertainty intervals reported for I2 where 
applicable (Higgins & Thompson 2002). Effect size measure is Hedges’ g. Positive effect size favours 12-step 
intervention. 
 
Six studies contributed data to the meta-analysis for drug use at 6 months post treatment (Bisset, 
2002; Carroll et al., 1998; Maude-Griffin et al., 1998; McKay et al., 1997; Petry et al., 2010; Wells et 
al., 1994). Individual effect sizes ranged between -0.29 (Maude-Griffin et al., 1998) and 0.05 
(Carroll et al., 1998). In the meta-analysis of 6 studies (Table 8), there was no statistically 
significant difference between 12-step and another psychosocial intervention at 6 months follow-up 
for the outcome of drug use (Hedges’ g = -0.12; 95% CI -0.31 to 0.08). The average follow-up rate 
was 79%. In one study (Carroll et al., 1998) treatment was delivered individually. In the remaining 
studies, treatment was either group therapy alone or a combination of individual and group 
therapy. Since failing to correct for clustering typically leads to a downward bias in estimated 
standard errors of the study level effect sizes (leading to too high weights in meta-analysis) the 
conclusion that there is no statistical difference between 12-step and other psychosocial treatments 
for the outcome of drug use at 6 months follow-up is likely to be robust to this bias. There was no 
indication of heterogeneity (I2 = 0%). 
Two studies contributed data to the meta-analysis for the outcome drug use 12 months after 
treatment end (Carroll et al., 1998; McKay et al., 1997). Study level effect sizes ranged between -
0.08 (McKay et al., 1997) and 0.30 (Carroll et al., 1998). In the meta-analysis of these 2 studies 
(Table 8), there was no statistically significant difference between 12-step and another psychosocial 
intervention at 12 months follow-up for the outcome of drug use (Hedges’ g = -0.02; 95% CI -0.35 
to 0.30). The average follow-up rate at 12 months after treatment end was 83%.  
4.4.2.2 Secondary outcomes 
4.4.2.2.1 During treatment 
No studies contributed data for secondary outcomes during treatment. 
4.4.2.2.2 Post treatment 
Table 9 presents results from the meta-analysis of 12-step vs psychosocial interventions for 
secondary outcomes measured post treatment. Forest plots for all secondary outcomes can be 
found in 11.4.1.2 in the Appendix. 
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Table 9: Meta-analysis, 12-step vs psychosocial intervention, secondary outcomes measured post 
treatment 
Outcome Studies 
Participants 
Effect Size 
(95% CI) 
Heterogeneity 
Assigned In analysis 
sample 
τ2 
I2 
(95% UI) 
Criminal 
behaviour  
2 130 81 -0.31  
(-0.76:0.13) 
0.00 0% 
 
Psychiatric 
symptoms 
3 262 211 0.08  
(-0.19:0.35) 
0.00 0% 
(0%, 84%) 
Social 
functioning 
3 262 211 -0.15  
(-0.42:0.12) 
0.00 0% 
(0%, 79%) 
Employment 3 262 211 0.03  
(-0.24:0.3) 
0.00 0% 
(0%, 66%) 
Retention¤ 6 
570 567 0.75* 
(0.56:1.00) 
0.00 
1% 
(0%, 75%) 
Notes. ¤ Effect size: odds ratio; Positive effect size favours 12-step intervention (effect size > 1 for retention).  
* p < .05, ** p < .01 indicates statistical significance of effect size. Uncertainty intervals reported for I2 where 
applicable (Higgins & Thompson 2002). Effect size measure is Hedges’ g. 
 
Two studies contributed data on criminal behaviour (Bisset, 2002; Carroll et al., 1998). Study level 
effect size estimates were between -0.33 and -0.28. In the meta-analysis of these 2 studies (Table 
9), there was no statistically significant difference between 12-step and another psychosocial 
intervention post-treatment for the outcome of criminal behaviour (Hedges’ g = -0.31; 95% CI -
0.76 to 0.13). The I2 statistic indicated a low degree of heterogeneity (0%). An uncertainty interval 
for I2 could not be computed due to the small number of studies. 
 
Three studies (Bisset, 2002; Carroll et al., 1998; McKay et al., 1997) contributed data on psychiatric 
symptoms, employment and social functioning. The data completion rate for these three outcomes 
was 81%. Two of the studies used individual randomisation to group therapy.  
Effect size estimates for psychiatric symptoms ranged between -0.13 and 0.20. In the meta-analysis 
of 3 studies (Table 9), there was no statistically significant difference between 12-step and another 
psychological intervention post-treatment for the outcome of psychiatric symptoms (Hedges’ g = 
0.08; 95% CI -0.19 to 0.35). The I2 statistic indicated a low degree of heterogeneity (0%), but note 
that the uncertainty interval for I2 is wide. 
Study level effect sizes for social functioning ranged between -0.2 and 0.22. In the meta-analysis of 
3 studies (table 9), there was no statistically significant difference between 12-step and another 
psychosocial intervention post-treatment for the outcome of social functioning (Hedges’ g = -0.15; 
95% CI -0.42 to 0.12). The I2 statistic indicated a low degree of heterogeneity (0%), but note that 
the uncertainty interval for I2 is wide. 
Employment effect size estimates ranged between -0.03 and 0.32. In the meta-analysis of 3 studies 
(table 9), there was no statistically significant difference between 12-step and another psychosocial 
intervention post-treatment for the outcome of employment (Hedges’ g = 0.03; 95% CI -0.24 to 
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0.3). The I2 statistic indicated a low degree of heterogeneity (0%), but note that the uncertainty 
interval for I2 is wide. 
Six studies (Bisset, 2002; Carroll et al., 1998; Higgins et al., 1991; McKay et al., 1997; Petry et al., 
2010; Wells et al., 1994) contributed data to the meta-analysis for the outcome treatment retention. 
Since most studies reported retention as a binary variable, the odds ratio effect size was used for 
synthesis. The data completion rates were above 99%. Five out of the six studies involved group 
based treatments. The summary effect size was statistically significant at the 5% level (OR = 0.75; 
95% CI 0.56 to 1.00). 12-step interventions thus appear to do worse at retaining participants in 
treatment than the other psychosocial interventions. Five of the studies did not correct for the fact 
that outcome analysis was conducted at the individual level, but allocation involved individual 
randomisation to group therapy. As such there is a risk that the estimated standard error of the 
effect size is too small. Therefore the conclusion that 12-step interventions appear worse at 
retaining participants in treatment than other psychosocial interventions should be drawn 
cautiously. The I2 statistic indicated a low degree of heterogeneity between studies (I2 = 1%), but 
note that the uncertainty interval for I2 is wide. 
4.4.2.2.3 Follow-up 
For the secondary outcomes (psychiatric symptoms, employment, social functioning) a total of 
three studies contributed data at 6 months follow-up (Bisset 2002; Carroll et al., 1998; McKay et 
al., 1997); only two of the three (Carroll et al., 1997; McKay et al. 1997) contributed data at 12 
months follow-up. Average follow-up rate was 73% at 6 months follow-up, and 80% at 12 months 
follow-up. Carroll et al. (1998) and Bisset (2002) contributed data for the outcome of criminal 
behaviour at 6 months follow-up (55% follow-up rate). Only Carroll et al. (1998) provided follow-
up data for this outcome measure at 12 months follow-up. Accordingly meta-analysis was not 
possible for this time point but we have reported the study level effect size in Table 10. Forest plots 
for secondary outcomes at follow-up can be found 11.4.1.2.2 in the Appendix. 
 
  
 46     The Campbell Collaboration | www.campbellcollaboration.org 
Table 10: Meta-analysis, 12-step vs psychosocial intervention, secondary outcomes at follow-up 
Outcome 
Time point 
(months 
post 
treatment) 
Studies 
Participants 
Effect Size  
(95% CI) 
Heterogeneity 
Assigned In 
analysis 
sample 
τ2 I
2 
(95% UI) 
Criminal 
behaviour 
6 2 
130 71 -0.17  
(-0.78:0.45) 
0.07 35% 
12 1 
34 19 -0.32 
(-1.29:0.66) 
NA NA 
Psychiatric 
symptoms 
6 3 
262 192 -0.06 
 (-0.38:0.25) 
0.01 
10% 
(0%, 91%) 
12 2 
176 140 0.02  
(-0.32:0.35) 
0.00 
0% 
 
Social 
functioning 
6 3 
262 192 0.02  
(-0.26:0.31) 
0.00 
0% 
(0%, 0%) 
12 2 
176 141 -0.06  
(-0.4:0.27) 
0.00 0% 
Employment 
6 3 
262 191 -0.07  
(-0.36:0.22) 
0.00 
0% 
(0%, 90%) 
12 2 
176 140 -0.18  
(-0.52:0.15) 
0.00 0% 
Notes: * p < .05, ** p < .01 indicates statistical significance of effect size. Uncertainty intervals reported for I2 where 
applicable (Higgins & Thompson 2002). Positive effect size favours 12-step intervention. Effect size measure is 
Hedges’ g. 
 
For all outcomes and time points the estimated summary effect sizes were not statistically 
significant (range: -0.18 to 0.02). Between study heterogeneity ranged from low to moderate (I2 
between 0% and 35%). 
4.4.3 Comparison: 12-step with add-on vs other psychosocial interventions with 
add-on 
4.4.3.1 Primary outcome: drug use 
4.4.3.1.1 During treatment 
Table 11 presents meta-analytical results for the comparison of 12-step intervention with an add-on 
treatment (either pharmaceutical or psychosocial) against a psychosocial intervention with the 
same add-on for drug use. Outcome measurements were taken during treatment. Three studies 
contributed effect sizes to the meta-analysis (Carroll et al., 1998; Carroll et al., 2012; Schottenfeld 
et al., 2011). The comparison in Carroll et al. (1998) was between 12-step and either cognitive 
behavioural therapy (CBT) or clinical management (ClM). Disulfiram (Dis) was used as an add-on. 
In Carroll et al. (2012) the comparison was between 12-step and clinical treatment-as-usual (TAU). 
Either disulfiram (Dis) or placebo (Pla) was used as an add-on, which gave rise to two relevant 
comparisons: 12+Dis v TAU+Dis and 12+Pla v TAU+Pla. Schottenfeld et al. (2011) examined the 
comparison between 12-step and community reinforcement approach (CRA) interacted with either 
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contingency management (CM) or voucher control (VC). Forest plots are presented in 11.4.2.1 in 
the Appendix. 
Table 11: Meta-analysis, 12-step with add-on vs psychosocial intervention with add-on, drug use 
measured during treatment 
Outco
me 
Comparison 
Stud
ies 
Participants 
Effect Size 
(95% CI) 
Heterogeneity 
Main 
Comparison: 
12- step vs.  
Add-on Assigned In 
analysis 
sample 
τ2 
I2 
(95% UI) 
Drug 
use 
CBT, CRA, 
TAU 
Dis, CM 
3a 
183 154 0.15  
(-0.17:0.46) 
0.00 
0% 
(0%, 47%) 
Dis, CM, Pla 
3b 
177 152 0.3  
(-0.15:0.75) 
0.07 
45% 
(0%, 83%) 
Dis, VC 
3c 
182 152 0.11  
(-0.21:0.42) 
0.00 
0% 
(0%, 67%) 
Dis, VC, Pla 
3d 
176 150 0.26  
(-0.23:0.76) 
0.10 
54% 
(0%, 86%) 
ClM, CRA, 
TAU  
Dis, CM 
3e 
184 152 0.18  
(-0.14:0.50) 
0.00 
0% 
(0%, 39%) 
Dis, CM, Pla 
3f 
178 150 0.35  
(-0.07:0.77) 
0.05 
37% 
(0, 80%) 
Dis, VC 
3g 
183 150 0.14  
(-0.18:0.46) 
0.00 
0% 
(0%, 70%) 
Dis, VC, Pla 
3h 
177 148 0.32  
(-0.16:0.80) 
0.09 
50% 
(0%, 85%) 
 Notes. Main comparison: CBT = Cognitive Behavioural Therapy, CRA = Community Reinforcement Approach, TAU = 
Treatment as Usual (Standard Counseling), ClM =Clinical Management. Add-ons: Dis = Disulfiram, CM = Contingency 
Management, Pla = Placebo, VC = Voucher Control. Positive effect size favours 12-step intervention. Effect size measure 
is Hedges’ g.  
* p < .05, ** p < .01 indicates statistical significance of effect size. Uncertainty intervals reported for I2 where applicable 
(Higgins & Thompson 2002). 
 a Carroll 1998: 12+Dis v CBT+Dis, Schottenfeld 2011: 12+CM v CRA+CM, Carroll 2012: 12+Dis v TAU+Dis; b Carroll 
1998: 12+Dis v CBT+Dis, Schottenfeld 2011: 12+CM v CRA+CM, Carroll 2012: 12+Pla v TAU+Pla; c Schottenfeld 2011: 
12+VC v CRA+VC, Carroll 1998: 12+Dis v CBT+Dis, Carroll 2012: 12+Dis v TAU+Dis; d Schottenfeld 2011: 12+VC v 
CRA+VC, Carroll 1998: 12+Dis v CBT+Dis, Carroll 2012: 12+Pla v TAU+Pla; e Schottenfeld 2011: 12+CM v CRA+CM, 
Carroll 1998: 12+Dis v ClM+Dis, Carroll 2012: 12+Dis v TAU+Dis; f Schottenfeld 2011: 12+CM v CRA+CM, Carroll 1998: 
12+Dis v ClM+Dis, Carroll 2012: 12+Pla v TAU+Pla; g Schottenfeld 2011: 12+VC v CRA+VC, Carroll 1998: 12+Dis v 
ClM+Dis, Carroll 2012: 12+Dis v TAU+Dis; h Schottenfeld 2011: 12+VC v CRA+VC, Carroll 1998: 12+Dis v ClM+Dis, 
Carroll 2012: 12+Pla v TAU+Pla. 
 
Average effect sizes estimates ranged from 0.11 to 0.35. None of the summary effect size estimates 
for the outcome of drug use were statistically significant at the 5% level. Data completion rates 
varied between 82-86%. All of the studies were randomised trials where treatment was delivered 
individually. Across the different analyses, the degree of heterogeneity between studies (I2) varied 
from low to moderate (0-54%). 
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4.4.3.1.2 Post treatment 
In Table 12 we report meta-analytical results for the comparison 12-step with an add-on versus 
other psychosocial treatment with an identical add-on for the primary outcome of drug use. Forest 
plots are presented in 11.4.2.1.2 in the Appendix. 
Table 12: Meta-analysis, 12-step with add-on vs psychosocial intervention with add-on, drug use 
measured post treatment 
Outcome 
Comparison 
Studi
es 
Participants 
Effect Size  
(95% CI) 
Heterogeneity 
Main 
compariso
n: 12 step 
vs. 
Add-on Allocated In 
analysis 
sample 
τ2 
I2 
(95% UI) 
Drug use 
CBT, 
TAU 
 
Dis 
2a 
108 94 0.07  
(-0.64:0.78) 
0.18 66% 
Dis, Pla 
2b 
104 89 -0.01 
 (-0.56:0.54) 
0.07 41%  
ClM, 
TAU 
 
Dis 
2c 
111 96 0.29 
 (-0.11:0.70) 
0.00 0% 
Dis, Pla 
2d 
105 91 0.20  
(-0.22:0.61) 
0.00 0% 
 Notes. Main comparison: CBT = Cognitive Behavioural Therapy, CRA = Community Reinforcement 
Approach, TAU = Treatment as Usual (Standard Counseling), ClM =Clinical Management. Add-ons: Dis = 
Disulfiram, CM = Contingency Management, Pla = Placebo, VC = Voucher Control.  
* p < .05, ** p < .01 indicates statistical significance of effect size. Effect size measure is Hedges’ g. 
Uncertainty intervals reported for I2 where applicable (Higgins & Thompson 2002).; Positive effect size 
(odds ratio above 1) favours 12-step intervention; ¤ odds ratio;  
 a Carroll 1998: 12+Dis v CBT+Dis, Carroll 2012: 12+Dis v TAU+Dis; b Carroll 1998: 12+Dis v CBT+Dis, 
Carroll 2012: 12+Pla v TAU+Pla; c Carroll 1998: 12+Dis v ClM+Dis. Carroll 2012: 12+Dis v TAU+Dis; d 
Carroll 1998: 12+Dis v ClM+Dis, Carroll 2012: 12+Pla v TAU+Pla 
Two studies contributed data to the meta-analysis on drug use (Carroll et al., 1998; Carroll et al., 
2012). 12-step was compared to either cognitive behavioural therapy (CBT), clinical management 
(ClM) or treatment-as-usual (TAU). Disulfiram (Dis) and placebo (Pla) were add-ons. The main 
treatments were delivered individually. Individual effect sizes ranged between -0.32 (Carroll et., 
1998; 12-step and disulfiram versus CBT and disulfiram) to 0.41 (Carroll et al., 2012; 12-step and 
disulfiram in addition to treatment-as-usual versus treatment-as-usual and disulfiram). None of 
the estimated summary effect sizes (range: -0.01 to 0.29) for drug use at post-treatment were 
statistically significant. Data completion rates were 86-87%. Heterogeneity was moderate (I2 
ranging from 0 to 66%). An uncertainty interval could not be computed due to the low number of 
studies. 
4.4.3.1.3 Follow-up 
Table 13 below presents results from meta-analyses where 12-step with an add-on was compared 
against other psychosocial intervention with the same add-on for drug use. Only two studies 
(Carroll et al., 1998; Carroll et al., 2012) contributed to the meta-analysis at 6 and 12 months post 
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treatment8. 12-step was compared to either cognitive behavioural therapy (CBT), clinical 
management (ClM), or treatment-as-usual (TAU). Disulfiram (Dis) and placebo (Pla) were add-
ons. Forest plots are presented in 11.4.2.1.3 in the Appendix. 
Table 13: Meta-analysis, 12-step with add-on vs psychosocial intervention with add-on, drug use at 
follow-up 
Outcome 
Comparison 
Studies 
Time 
point 
(months 
post treat-
ment) 
Participants 
Effect Size 
(95% CI) 
Heterogeneit
y 
Main 
comparis
on: 12 
step vs. 
Add 
on 
Assigned In analysis 
sample τ2 I2 
Drug use 
CBT, 
TAU  
Dis 
2a 
6  
 
110 
87 0.17  
(-0.52:0.86) 
0.15 60% 
12  
84 0.08  
(-0.56:0.71) 
0.11 50% 
Dis, 
Pla 
2b 
6 
104 84 0.14  
(-0.50:0.79) 
0.12 53% 
12 
82 0.03  
(-0.49:0.54) 
0.04 26% 
ClM, 
TAU 
Dis 
2c 
6 
111 90 0.48* 
(0.06:0.90) 
0,00 0% 
12 
84 0.27  
(-0.16:0.71) 
0.00 0% 
Dis, 
Pla 
2d 
6 
105 87 0.45* 
(0.03:0.88) 
0,00 0% 
12 
82 0.20  
(-0.23:0.64) 
0,00 0% 
 Notes: Main comparison: CBT = Cognitive Behavioural Therapy, TAU = Treatment as Usual (Standard 
Counseling), ClM = Clinical Management. Add-ons: Dis = Disulfiram, Pla = Placebo. ; Positive effect size 
favours 12-step intervention;  
* p < .05, ** p < .01 indicates statistical significance of effect size. Effect size measure is Hedges’ g. 
a Carroll 1998: 12+Dis v CBT+Dis, Carroll 2012: 12+Dis v TAU+Dis; b Carroll 1998: 12+Dis v CBT+Dis, 
Carroll 2012: 12+Pla v TAU+Pla; c Carroll 1998: 12+Dis v ClM+Dis, Carroll 2012: 12+Dis v TAU+Dis; d 
Carroll 1998: 12+Dis v ClM+Dis, Carroll 2012: 12+Pla v TAU+Pla.  
Follow-up rates were between 76% and 83%. Two of the summary effect sizes for drug use at 6 
months follow-up were statistically significant at the 5% level. Both summary effect sizes favoured 
the 12-step intervention. The estimated summary effect size for drug use at 6 months for 12-step 
versus TAU or Clinical Management with disulfiram add-on was statistically significant (Hedges’ g 
= 0.48; 95% CI 0.06 to 0.90). The meta-analysis was based on an analysis sample of 90 
participants from 2 studies (Caroll et al., 1998; Caroll et al., 2012). The estimated summary effect 
size for drug use at 6 months for 12-step versus TAU (with placebo add-on) or Clinical 
Management (with disulfiram add-on) was statistically significant (Hedges’ g = 0.45; 95% CI 0.03 
to 0.88). The meta-analysis was based on an analysis sample of 87 participants from 2 studies 
(Caroll et al., 1998; Caroll et al., 2012). The results of the remaining two analyses for drug use at 6 
months follow-up were not statistically significant. These meta-analyses were based on 2 studies 
                                                        
8 Since only two studies were available for synthesis calculating uncertainty intervals for I2 was not possible. 
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(Caroll et al., 1998; Caroll et al., 2012). In one analysis 87 participants contributed data where 12-
step was compared to CBT and TAU (with disulfiram as add-on). In the other analysis, 84 
participants contributed data to analysis where 12-step was compared to CBT (with disulfiram as 
add-on) and TAU (with placebo as add-on).  
Analyses of the outcome of drugs use conducted 12 months after end of treatment did not reveal 
statistically significant differences between 12-step with an add-on treatment and the alternative 
intervention(s) with add-on treatment.  
Conclusions must be drawn cautiously. Both studies contributing data were from the same team of 
investigators and dependencies between study level effect sizes may contribute to exaggerated p-
values.  
Across all the meta-analyses reported in Table 13, there was indication of a low to medium degree 
of study heterogeneity (I2 statistic ranged from 0% to 60%). 
4.4.3.2 Secondary outcomes 
4.4.3.2.1 During treatment 
No studies contributed data on secondary outcomes during treatment. 
4.4.3.2.2 Post treatment 
Three studies (Carroll et al., 1998; Carroll et al., 2012; Schottenfeld et al., 2011) contributed data on 
treatment retention (Table 14). Forest plots are presented in 11.4.2.2.1 in the Appendix. 
 
  
 51     The Campbell Collaboration | www.campbellcollaboration.org 
Table 14: Meta-analysis, 12-step with add-on vs psychosocial intervention with add-on, treatment 
retention measured post treatment 
Outcome 
Comparison 
Studi
es 
Participants 
Effect Size  
(95% CI) 
Heterogeneity 
Main 
compariso
n: 12 step 
vs. 
Add-on Allocated In 
analysis 
sample 
τ2 
I2 
(95% UI) 
Reten-
tion¤  
CBT, 
CRA, 
TAU 
Dis, 
CM 
3e 
183 183 0.70 
(0.38:1.29) 
0.00 
0% 
(0%, 64%) 
Dis, 
CM, Pla 
3f 
177 177 0.74 
(0.39:1:39) 
0.00 
0% 
(0%, 31%) 
Dis, VC 
3g 
182 182 0.73 
(0.40:1.33) 
0.00 
0% 
(0%, 67%) 
Dis, 
VC, Pla 
3h 
176 176 0.77 
(0.41:1.44) 
0.00 
0% 
(0%, 35%) 
CRA, 
ClM, 
TAU 
Dis, 
CM 
3i 
184 184 0.78 
(0.42:1.44) 
0.00 
0% 
(0%, 86%) 
Dis, 
CM, Pla 
3j 
178 178 0.83 
(0.44:1.56) 
0.00 
0% 
(0%, 81%) 
Dis, VC 
3k 
183 183 0.81 
(0.44:1.49) 
0.00 
0% 
(0%, 86%) 
Dis, 
VC, Pla 
3l 
177 177 0.87 
(0.46:1.62) 
0.00 
0% 
(0%, 79%) 
 Notes. ¤ odds ratio; Main comparison: CBT = Cognitive Behavioural Therapy, CRA = Community 
Reinforcement Approach, TAU = Treatment as Usual (Standard Counseling), ClM =Clinical Management. 
Add-ons: Dis = Disulfiram, CM = Contingency Management, Pla = Placebo, VC = Voucher Control.  
* p < .05, ** p < .01 indicates statistical significance of effect size. Effect size measure is Hedges’ g. 
Uncertainty intervals reported for I2 where applicable (Higgins & Thompson 2002).; Positive effect size 
(odds ratio above 1) favours 12-step intervention;  
 e Carroll 1998: 12+Dis v CBT+Dis, Schottenfeld 2011: 12+CM v CRA+CM, Carroll 2012: 12+Dis v TAU+Dis; f 
Carroll 1998: 12+Dis v CBT+Dis, Schottenfeld 2011: 12+CM v CRA+CM, Carroll 2012: 12+Pla v TAU+Pla; g 
Schottenfeld 2011: 12+VC v CRA+VC, Carroll 1998: 12+Dis v CBT+Dis, Carroll 2012: 12+Dis v TAU+Dis; h 
Schottenfeld 2011: 12+VC v CRA+VC, Carroll 1998: 12+Dis v CBT+Dis, Carroll 2012: 12+Pla v TAU+Pla; i 
Schottenfeld 2011: 12+CM v CRA+CM, Carroll 1998: 12+Dis v ClM+Dis, Carroll 2012: 12+Dis v TAU+Dis; j 
Schottenfeld 2011: 12+CM v CRA+CM, Carroll 1998: 12+Dis v ClM+Dis, Carroll 2012: 12+Pla v TAU+Pla; k 
Schottenfeld 2011: 12+VC v CRA+VC, Carroll 1998: 12+Dis v ClM+Dis, Carroll 2012: 12+Dis v TAU+Dis; l 
Schottenfeld 2011: 12+VC v CRA+VC, Carroll 1998: 12+Dis v ClM+Dis, Carroll 2012: 12+Pla v TAU+Pla. 
 
Study effect sizes (odds ratios) ranged between 0.50 (Carroll et al., 2012; 12-step and disulfiram in 
addition to treatment-as-usual versus disulfiram and treatment-as-usual) and 1.33 (Carroll et al, 
1998; 12-step and disulfiram versus clinical management and disulfiram). Estimated summary 
effect sizes ranged between 0.73 and 0.87. None of the estimated summary effect sizes for 
treatment retention were statistically significant. The I2 statistic indicated a low degree of 
heterogeneity (0%). 
4.4.3.2.3 Follow-up 
No studies contributed data to secondary outcomes at follow-up. 
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4.5  SENSITIVITY ANALYSIS 
We conducted sensitivity analysis for drug use and treatment retention for the comparison 12-step 
against other psychosocial intervention. Separate sensitivity analyses were conducted (when 
possible) for drug use during treatment, post treatment, and six months after end of treatment. 
These were the only outcomes where the number of studies contributing data was sufficient for 
sensitivity analysis to be meaningful. We examined the sensitivity of the results to the risk of bias 
items: sequence generation, incomplete data, and other bias. These analyses did not uncover any 
significant changes in the point estimates of the summary effect size. Given the small number of 
studies available, the power to detect such changes was also low (see section 11.5).  
4.6  PUBLICATION BIAS 
In attempt to investigate whether the available data might indicate publication bias, we constructed 
funnel plots for two outcomes: drug use (during treatment, post treatment, and at 6 months follow-
up), and treatment retention. Inspection of the funnel plots did not indicate the presence of 
publication bias (see section 11.6). However, the power to detect the presence of publication bias is 
limited by the small number of available studies (Higgins, & Green, 2008, chapter 10.4.3.1). 
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5 Discussion 
5.1  SUMMARY OF MAIN RESULTS 
The main objective of this review was to synthesise the effects of 12-step programs aimed at 
reducing drug use of individuals who use illicit drugs. After an extensive systematic search we 
found a total of ten studies that met the inclusion criteria for the review. In total we found ten 
studies meeting our inclusion criteria. Seven of the included studies used a RCT design, two studies 
used a QRCT design, and one study used a QES design. In seven studies, treatment was partially or 
fully delivered in group therapy sessions. One study, assessed at high risk of bias, was excluded 
from meta-analysis. Thus nine studies with a total of 1,071 participants contributed data to the 
analyses.  
 
In the meta-analyses we compared a) 12-step intervention to other psychosocial intervention(s), 
and b) 12-step with an add-on treatment versus other psychosocial intervention(s) with an 
(identical) add-on treatment. Seven studies contributed data to the comparison of 12-step 
intervention to alternative psychosocial interventions during treatment, at treatment end, and at 
follow-up (Bisset, 2002; Carroll et al., 1998; Higgins et. al, 1991; Maude-Griffin et al., 1998; McKay 
et al., 1997; Petry et al. 2010; Wells et al., 1994). The seven studies did not all contribute data to all 
time points. Three studies contributed data to the comparison between 12-step with an add-on and 
other psychosocial interventions with the same add-on during treatment, at treatment end, and at 
follow-up (Carroll et al., 1998; Carroll et al., 2012; Schottenfeld et al., 2011). The primary outcome 
of interest was reduction in drug use or abstinence from drugs. The secondary outcomes 
considered were criminal behaviour, prostitution, psychiatric symptoms, social functioning, 
employment status, homelessness, and retention in treatment. We used random-effects meta-
analysis to synthesise effects for each comparison, outcome, and time point (during treatment, post 
treatment, and at follow-up). 
  
The main bulk of evidence refers to the comparison of 12-step interventions versus other 
psychosocial interventions. At each time point where a separate meta-analysis was conducted, the 
estimated summary effect size for drug use was not statistically significant, and therefore did not 
favour either 12-step or the alternative set of interventions. An additional note of caution stems 
from the fact that six out of seven studies (Bisset, 2002; Higgins et. al, 1991; Maude-Griffin et al., 
1998; McKay et al., 1997; Petry et al. 2010; Wells et al., 1994) did not correct for the design-effect 
that resulted from individual participants being randomised to group therapy (IRGT-design).  
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The evidence from comparing 12-step with an add-on treatment against psychosocial intervention 
with an (identical) add-on treatment for the outcome of drug use were cautiously in favour of 12-
step at 6 months follow-up. The evidence builds on data contributed from at most three studies 
(Carroll et al., 1998; Caroll et al., 2012; Schottenfeld et al., 2011), two of which have the same 
principal investigator. Summary effect sizes favouring 12-step reached statistical significance at 6 
months follow-up, but not at 12 months follow-up. Because multiple testing is involved the tests 
are unlikely to have nominal size. One of the three studies utilised an IRGT-design (Carroll et al., 
2012). We found no statistically significant differences for other outcomes or time points. 
 
All included studies measured and reported on treatment retention. Six studies contributed data 
for retention to the meta-analysis of the comparison between 12-step and other psychosocial 
interventions. The summary effect size (OR) was estimated as 0.75 (CI 95%: 0.56 to 1.00) and this 
effect was significant at the 5% level. This suggests that the alternative set of interventions had 
more success retaining participants. However five of the studies employed an IRGT-design, which 
likely exaggerates the precision of the estimated effect sizes. Other comparisons revealed no 
statistically significant summary effect sizes.  
 
Three studies (Bisset, 2002; Carroll et al., 1998, McKay et al., 1997) reported on a secondary 
outcome: criminal behaviour, psychiatric symptoms, social function and employment. Meta-
analysis for these outcomes did not reveal any statistically significant summary effect sizes. Our 
secondary outcomes included prostitution and homelessness. None of the studies reported directly 
on these outcomes, therefore we were not able to present any evidence about the effectiveness of 
the intervention of these two secondary outcomes, although the legal subcomponent of the ASI, 
administered in three studies (Bisset, 2002; Carroll et al., 1998; McKay et al., 1997), contains 
indirect information on prostitution. 
 
5.2  OVERALL COMPLETENESS AND APPLICABILITY OF EVIDENCE 
We performed a comprehensive electronic database search, combined with grey literature 
searching, and hand searching of key journals. In addition, experts in the field were consulted 
regarding potentially missing studies from our list of included studies. No studies are awaiting 
classification, nor have we been made aware of any on-going studies. All citations were screened by 
two independent screeners.  
 
Contrary to our expectations, our search uncovered only one quasi-experimental study meeting the 
inclusion criteria (Gossop et al., 2007). Gossop et al. (2007) was not included in any meta-analysis 
because it was deemed to entail too high of a risk of bias. In the context of 12-step, it is surprising 
that we only located one quasi-experimental study report in our search. Narcotics Anonymous has 
over 58,000 weekly meetings worldwide (Narcotics Anonymous, 2012). This is indicative of a 
discrepancy between practice and evidence. In this sense the results of this review regarding effects 
of 12-step in other settings must be viewed cautiously. This lack of evidence is an important caveat 
in terms of understanding how and whether the results are applicable to 12-step interventions in 
self-help settings. 
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Our main result is that 12-step interventions are, given the available evidence, neither better nor 
worse than competing interventions. In this situation the cost of the intervention is an important 
parameter for a decision maker. With a fixed budget and two equally effective interventions, an 
agency is able to treat more patients if the budget is spent on the less expensive intervention. From 
a cost perspective, self-help groups with their emphasis on peers, role modelling and social 
support, appear particularly attractive. We did not study this issue systematically, and included 
studies did not report on the cost of implementation.  
 
5.3  QUALITY OF THE EVIDENCE 
The results of this review should be seen in the context of the weight of evidence. Ten unique 
studies met inclusion criteria, and not all of these studies contributed data to the same 
comparisons. 
The target population for studies included in this review is notoriously difficult to treat, retain, and 
follow-up. This results in attrition despite the best efforts of primary researchers to follow-up the 
complete study sample. As a result, none of the studies were able to perform a true intention-to-
treat analysis. For the outcome of drug use for the comparison of 12-step to other psychosocial 
interventions during treatment the average data completion rate (percent of participants assigned 
where outcome data was available for analysis) was 96%. The data completion rate for drug use 
measured post-treatment and at follow-up was lower, in both cases around 80%. Most studies 
imputed missing values by, for example, assuming that missing urine samples were positive. Other 
studies limited attention to the part of the sample they were able to follow-up with. Some of the 
more recent studies used more advanced statistical techniques such as regression analysis that 
allow for missing data.  
Perhaps the biggest concern is the level of analysis. Only two of the included studies carried out 
statistical analysis at the same level that randomisation was done. The remaining studies employed 
an IRGT-design (Pals et al., 2008), where participants were individually allocated to treatment, but 
the treatment itself was administered either fully or partially as group therapy. In these studies, the 
level of statistical analysis was not conducted at the group level, but rather at the individual level, 
ignoring the dependency between participants assigned to the same group. If estimates of within-
cluster variance and group size are available, a design effect (Kish, 1965) can be calculated and 
used to correct study level standard errors of effect size estimates. Because studies neither reported 
intra-cluster correlations, nor group sizes, and no credible auxiliary evidence could be brought to 
bear, we did not correct effect sizes for this design feature. Instead, studies were scored in the 
Other Bias item in the risk of bias assessment. Regardless, this feature of the evidence warrants 
caution. When the statistical analysis does not account for clustering there is a risk that the 
estimated standard errors of effect sizes are too small. 
We did not find any clear indication of reporting bias. Authors generally reported all results 
relevant to the review when they had stated that outcomes were measured. On the other hand, this 
does not imply that reporting bias is not present. For example, only two of the seven RCT studies 
reported having registered a protocol (Carroll et al., 2012; Schottenfeld et al., 2011). In the cases 
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where investigators reported having measured additional outcomes relevant to the review, and 
when these outcomes were not available in the published report, we were able to contact study 
investigators and obtain the data.  
The meta-analyses did not suggest a high degree of statistical heterogeneity. We performed a 
sensitivity analysis on the basis of the study level risk of bias assessments. These analyses 
suggested that conclusions were robust with respect to excluding studies with a high risk of bias on, 
respectively, sequence generation, incomplete data, and other bias. We did not find evidence of 
publication bias, but the number of studies examined was also small, implying low statistical power 
to detect bias. 
 
5.4 LIMITATIONS AND POTENTIAL BIASES IN THE REVIEW PROCESS 
Our search strategy did not include any language restrictions. Even so it is noteworthy that all but 
one of the included studies were conducted in the US. Our literature search was also conducted on 
non-English electronic databases, and the grey literature search was directed toward non-English 
sources. Thus we have no particular reason to believe that any language bias has been introduced. 
In our protocol we did not state that we would assess adverse events. This is a potential limitation, in 
as far as 12-step interventions might have more or fewer adverse events compared to other 
interventions. Adverse events were not systematically reported in study reports, and 12-step 
programs were not reported as leading to additional adverse events compared to other interventions.  
The majority of studies employed a study design where participants were individually randomised 
to group treatment. Such procedures introduce issues with the unit of analysis, because studies 
conducted analysis at the individual level. This was coded in the “Other bias” item of the risk of 
bias tool. 
We did not include cost as an outcome of interest and none of the included studies supplied data 
on the cost of implementation. 
5.5 AGREEMENTS AND DISAGREEMENTS WITH OTHER STUDIES OR REVIEWS 
To the best of our knowledge there is no review that compares 12-step interventions to no 
intervention or to other interventions for illicit drug users. There are reviews that compare specific 
drug treatment programs to a condition such as methadone maintenance (Marsch, 1998) and 
contingency management (Griffith, Rowan-Szal, Roark, & Simpson, 2000) that could be viewed as 
‘no intervention’. They found that the specific drug treatment programs were effective compared to 
no intervention. Prendergast, Podus, Chang, and Urada (2002) compared drug abuse treatments to 
a no/minimal treatment and to treatment as usual and found a statistically significant summary 
effect size around 0.30.  
 
Ferri, Amato, and Davoli (2006) reviewed AA and other 12-step programs (TSF) for alcohol 
dependence and included eight trials. They tentatively concluded that AA/TSF is not more effective 
than competing interventions; a finding this review echoes, on a different population. 
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6 Authors’ conclusions 
 
6.1  IMPLICATIONS FOR PRACTICE AND POLICY 
This review set out to compare 12-step programs (TSF and self-help) for illicit drug dependence to 
no/minimal intervention and to competing interventions.  
 
The review located only one study that compared 12-step to minimal intervention (Bisset, 2002). 
In this context it is important to emphasise that other reviews have demonstrated that drug abuse 
treatment is effective in reducing drug use compared to no/minimal intervention (see for example, 
Prendergast et al. 2002 and the references cited therein).  
 
The main bulk of evidence of this review compares 12-step approaches to other competing 
psychosocial approaches to drug treatment, such as contingency management, CBT, BT, and 
relapse prevention. We also found a smaller evidence base that compared 12-step with an add-on 
to other psychosocial interventions with an add-on.  
 
The primary outcome of drug use was assessed during treatment, post treatment, and at 6 and 12 
months follow-up. We found no statistically significant summary effect size estimates for drug use 
during treatment and post treatment. At 6 months follow-up we found that 12-step with an add-on 
compared to other interventions with an identical add-on led to lower drug use (Hedges’ g =0.48, 
95% CI: 0.06 to 0.90, and g=0.45, 95% CI: 0.03 to 0.88). Other comparisons at 6 months follow-
up for drug use were not statistically significant. No statistically significant differences between 
treatments for drug use were found at 12-months follow-up. 
  
There are a number of reasons to interpret results cautiously. First, the population is hard to retain 
in treatment and even harder to follow-up. This increases the uncertainty with which effects of 
interventions are measured. For example very few studies report intention-to-treat (ITT) estimates. 
In the context of voluntary participation in programs an ITT estimate of effectiveness is most 
relevant when selecting between competing programs. Second, most drug abuse treatments are 
implemented in group therapy settings. None of the studies who delivered treatment in group 
therapy settings adequately dealt with this design feature in their statistical analysis. The 
implication is that the precision of effect size estimates from individual studies will tend to be 
exaggerated.  
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Based on these results our interpretation of the evidence is that 12-step programs appear to be as 
effective as competing drug abuse treatments. The evidence is inconclusive about whether one 
alternative program is better than another. This implies that local context and experience should 
take precedence when choosing between competing treatments.  
 
The participants in the included studies were both males and females. Across studies the average 
age of participants ranged from 28 to 43 years on average. Participants were predominantly 
cocaine dependent, and in two studies participants were also on methadone maintenance (Bisset, 
2002; Carroll et al., 2012). Two studies considered participants that were particularly vulnerable 
who in addition to drug dependence were either: HIV positive (Petry et al., 2010) or pregnant/had 
young dependants (Schottenfeld et al., 2011). This review offers limited evidence about the effects 
of treatment for other types of illicit drug dependencies than cocaine dependence, and for 
treatment effects for older adolescents.  
 
The types of interventions included in this review were overwhelmingly manual-based 
interventions delivered by experienced therapists. Only one of the included studies studied 12-step 
programs in the self-help domain (Gossop et al., 2007), and this study was excluded from meta-
analysis following risk of bias assessment. This review offers little evidence about the effectiveness 
of 12-step programs as delivered in self-help groups. There appears to be a discrepancy between 
how 12-step interventions are typically implemented in practice, in self-help groups, and the type 
of study designs and research evidence available for meta-analysis. All studies that were 
synthesised in meta-analysis were conducted in the US. In as far as population, setting, and 
delivery differs in other countries, the results should be interpreted in this light. 
 
Economic considerations such as cost of treatment were not included in this review. None of the 
included studies supplied data on the cost of implementation. Because we cannot say that one 
treatment is better than another, based on the results of this review, considerations of cost may be 
particularly relevant. 
 
6.2  IMPLICATIONS FOR RESEARCH 
Although the main evidence presented in this review must be interpreted with caution, there are 
some important implications for research.  
 
Compared to 12-step approaches, other psychosocial treatments appear to be neither worse nor 
better at reducing drug use. This conclusion has implications for research in this area. First, 
detecting small differences in the effectiveness of treatments will require large trials, or increased 
use of meta-analytical techniques to pool results across different trials. Second, a complementary 
approach is to more thoroughly establish a theory of change. This will be a first step allowing 
researchers to go beyond program names and towards understanding not only the active 
ingredients of treatments, but also understanding the importance of these ingredients for primary 
outcomes of interest. One approach to this challenge would be to develop intermediate treatment 
specific measures through which treatment is hypothesised to work. For example, 12-step 
programs are built up around a series of steps through which the patient gradually learns a set of 
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skills that allow them to deal with their addiction and achieve abstinence. Providing evidence on 
the gradual attainment of such skills and their influence on final or intermediate outcomes will be 
of great interest. Likewise, other psychosocial interventions specify competing mechanisms 
through which the patients will learn to master their addiction. Establishing whether such links 
exist will help us understand the commonalities between different programs and identify active 
ingredients. In addition, such a research program may involve complementary research 
methodologies of a more qualitative nature.  
 
As our knowledge in this field gradually accumulates it will also be important for investigators to 
document and report potential prognostic factors e.g. social background, referral type (e.g. court-
mandated, voluntary, etc.) and treatment motivation of participants. Meta-regression could then 
be applied to explore and generate hypotheses regarding positive and negative factors influencing 
treatment success. It will be of increasing importance that investigators report implementation 
costs in addition to the effects of intervention such that a cost-effectiveness analysis can be 
performed. This is particularly important in the context of drug abuse treatment because (a) 
treatment is typically very expensive, and (b) the negative impacts of drug abuse on friends, family 
and society may be great. 
 
Many drug abuse treatments are delivered in a group therapy setting. It will be important for 
future research to adequately control for this design feature. Investigators should report or make 
available estimates of intra-cluster correlations and document group sizes. If such a practice was 
adopted, it would be possible to revisit reviews like this one and credibly correct the precision of 
effect size estimates for this design feature. 
 
We need more evidence about the effects of 12-step programs for other populations. Increasing our 
knowledge of the effect of treatment for younger participants with drug dependence is an 
important area. Also increased knowledge of effects of 12-step programs for populations who are 
dependent on other drugs than cocaine is needed.  
 
Finally, 12-step interventions to treat drug dependency are also offered in the form of self-help 
groups. It is plausible that this form of treatment attracts different populations than those studied 
in this review. For example participation in self-help groups, is often based more loosely on 
voluntary participation. Such 12-step services may be the next step after initial inpatient 
detoxification. This review found only one study which considered this setting. Future research 
may explore the effect of 12-step interventions in self-help groups. Identifying credible causal 
effects in these settings appears to be more challenging. Treatment intensity will be lower than in 
more institutionalised settings, and sample attrition may be a bigger threat to identification. 
Nevertheless, given the widespread practice and the lack of solid evidence on its effectiveness, this 
is an important area for future research. 
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8.2  DIFFERENCES BETWEEN PROTOCOL AND REVIEW 
In the protocol we stated that we would synthesise outcomes by calendar time as follows:  
• Short-term effects (less than 6 months after enrolment into treatment). 
• Medium-term effects (6 months to less than 12 months after enrolment into treatment). 
• Long-term effects (12 months or more after enrolment into treatment). 
This decision was made because we expect that the majority of included studies would be based on 
treatments in self-help groups. Only one included study had treatments of this nature (Gossop et 
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at follow-up, we decided to follow the included literature in synthesising the available evidence, 
during, post-treatment, and at follow-up. 
We had planned to do moderator analyses of effect sizes. Because of the small number of studies 
uncovered during the search process, we did not perform meta-regression. 
In the protocol we had planned to do regression based tests for publication bias. However we did 
not find a sufficient number of studies to perform these tests.  
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9 Tables 
9.1  SEARCH TERM BY DATABASE 
Bibliotek.dk  
Searched January 2011. 
Update July 2013, August 2015, and final update September 2016. 
 
Search  Term Totals 
s1 
(narcotics anonymous) eller (cocaine anonymous?) eller (crystal meth 
anonymous?) eller (pills anonymous?) eller (marijuana anonymous? ) 
eller ( heroin anonymous?) eller (12 step ) eller (selvhjælpsgrupper) 
eller (selfhelp group?) eller (minnesota model?) eller (minnesota 
program? ) eller (minnesota behandling?) 
51 
 
s2 
(narcotics anonymous) eller (cocaine anonymous?) eller (crystal meth 
anonymous?) eller (pills anonymous?) eller (marijuana anonymous? ) 
eller ( heroin anonymous?) eller (12 step ) eller (selvhjælpsgrupper) 
eller (selfhelp group?) eller (minnesota model?) eller (minnesota 
program? ) eller (minnesota behandling?) – Limited to 2015-current 
 
2 
 
Bibsys (Bibliotekbasen, ForskDok publikasjoner, ForskDok prosjekter) 
Searched January 2011.  
 
Updates in September 2011, July 2013, August 2015. In the newest update of the review 
(September 2016), the access to BIBSY (now Oria) was limited. The documented search strategy 
reflects searches until August 2015. 
 
Search 
number 
Term Totals 
s1 Anonyme narkomane eller narcotics anonymous 13 
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s2 Cocaine Anonymous 4 
s3 marijuana Anonymous eller anonyme og hasj og avhengig? 2 
s4 Heroin Anonymous 1 
s5 Anonyme narkomane eller narcotics anonymous eller Cocaine 
Anonymous eller marijuana Anonymous eller anonyme og hasj og 
avhengig? eller Heroin Anonymous 
15 
s6 Selvhjelpsgruppe 7 
s7 støttegruppe 12 
s8 Twelve-step? eller tolv trinn? eller tolv tradisjoner 31 
s9 12-step? eller 12 trinn? 44 
s10 emne = selvhjelpsgruppe? 160 
s11 model? eller program? eller behandling? eller rehabilit? eller kur eller 
terapi eller detox eller avrus eller recovery eller intervensjon? Eller 
metode? og minnesota 
140 
s12 TSF 15 
s13 Selvhjelpsgruppe eller støttegruppe eller Twelve-step? eller tolv trinn? 
eller tolv tradisjoner eller 12-step? eller 12 trinn? eller emne 
=selvhjelpsgruppe? eller model? eller program? eller behandling? Eller 
rehabilit? eller kur eller terapi eller detox eller avrus eller recovery eller 
intervensjon? eller metode? og minnesota eller TSF 
398 
s14 emne = Amphetamine Related Disorders 48 
s15 emne = cocaine related disorders 181 
s16 emne = marijuana abuse 107 
s17 emne = opioid related disorders 713 
s18 emne = substance abuse intravenous 94 
s19 emne = Substance Withdrawal Syndrome eller abstinenser 31 
s20 emne = heroin abuse 55 
s21 emne = Amphetamine Related Disorders eller emne = cocaine related 
disorders eller emne = marijuana abuse eller emne = opioid related 
disorders eller emne = substance abuse intravenous eller emne = 
Substance Withdrawal Syndrome eller abstinenser eller emne = heroin 
1025 
s22 emne = opium 116 
s23 emne = heroin 277 
s24 emne = cannabinoid? eller emne = cannabis 372 
s25 emne = Marijuana Smoking 88 
s26 emne = cocaine 322 
s27 emne = methamphetamine 27 
s28 emne = Amphetamine 73 
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s29 emne = Designer Drugs 71 
s30 emne = opium eller emne = heroin eller emne = cannabinoid? eller emne 
= cannabis eller emne = Marijuana Smoking eller emne = cocaine eller 
emne = methamphetamine eller emne = Amphetamine eller emne = 
Designer Drugs 
1059 
s31 stimulan? 238 
s32 Opium 310 
s33 Heroin 388 
s34 Crack 607 
s35 Cocaine eller kokain 536 
s36 Methamphetamine eller metamfetamin? eller amphetamin? eller 
amfetamin? 
267 
s37 Ecstasy 314 
s38 stimulan? eller Opium eller Heroin eller Crack eller Cocaine eller kokain 
eller Methamphetamine eller metamfetamin? eller amphetamin? Eller 
amfetamin? eller Ecstasy 
2272 
s39 Cannabis eller marijuana eller marihuana eller hash eller hasj eller 
hashish 
842 
s40 drug? eller stof? og designer 72 
s41 Narko? 4363 
s42 Drug? eller stof? 22604 
s43 stof? eller drug? eller stimulan? eller narko? og misbruk? eller brug? Eller 
avheng? 
697 
s44 Anonyme narkomane eller narcotics anonymous eller Cocaine 
Anonymous eller marijuana Anonymous eller anonyme og hasj og 
avhengig? eller Heroin Anonymous eller Selvhjelpsgruppe eller 
støttegruppe eller Twelve-step? eller tolv trinn? eller tolv tradisjoner eller 
12-step? eller 12 trinn? eller emne = selvhjelpsgruppe? eller model? Eller 
program? eller behandling? eller rehabilit? eller kur eller terapi eller detox 
eller avrus eller recovery eller intervensjon? eller metode? Og minnesota 
eller TSF 
411 
s45 emne = Amphetamine Related Disorders eller emne = cocaine related 
disorders eller emne = marijuana abuse eller emne = opioid related 
disorders eller emne = substance abuse intravenous eller emne = 
Substance Withdrawal Syndrome eller abstinenser eller emne = heroin 
abuse og Anonyme narkomane eller narcotics anonymous eller Cocaine 
Anonymous eller marijuana Anonymous eller anonyme og hasj og 
avhengig? eller Heroin Anonymous eller Selvhjelpsgruppe eller 
7 
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støttegruppe eller Twelve-step? eller tolv trinn? eller tolv tradisjoner eller 
12-step? eller 12 trinn? eller emne = selvhjelpsgruppe? eller model? Eller 
program? eller behandling? eller rehabilit? eller kur eller terapi eller detox 
eller avrus eller recovery eller intervensjon? eller metode? Og minnesota 
eller TSF 
s46 emne = opium eller emne = heroin eller emne = cannabinoid? eller emne 
= cannabis eller emne = Marijuana Smoking eller emne = cocaine eller 
emne = methamphetamine eller emne = Amphetamine eller emne = 
Designer Drugs og Anonyme narkomane eller narcotics anonymous eller 
Cocaine Anonymous eller marijuana Anonymous eller anonyme og hasj og 
avhengig? eller Heroin Anonymous eller Selvhjelpsgruppe eller 
støttegruppe eller Twelve-step? eller tolv trinn? eller tolv tradisjoner eller 
12-step? eller 12 trinn? eller emne = selvhjelpsgruppe? eller model? Eller 
program? eller behandling? eller rehabilit? eller kur eller terapi eller detox 
eller avrus eller recovery eller intervensjon? eller metode? Og minnesota 
eller TSF 
3 
s47 stimulan? eller Opium eller Heroin eller Crack eller Cocaine eller kokain 
eller Methamphetamine eller metamfetamin? eller amphetamin? Eller 
amfetamin? eller Ecstasy og Anonyme narkomane eller narcotics 
anonymous eller Cocaine Anonymous eller marijuana Anonymous eller 
anonyme og hasj og avhengig? eller Heroin Anonymous eller 
Selvhjelpsgruppe eller støttegruppe eller Twelve-step? eller tolv trinn? 
eller tolv tradisjoner eller 12-step? eller 12 trinn? eller emne = 
selvhjelpsgruppe? eller model? eller program? eller behandling? Eller 
rehabilit? eller kur eller terapi eller detox eller avrus eller recovery eller 
intervensjon? eller metode? og minnesota eller TSF 
6 
s48 Cannabis eller marijuana eller marihuana eller hash eller hasj eller 
hashish og Anonyme narkomane eller narcotics anonymous eller 
Cocaine Anonymous eller marijuana Anonymous eller anonyme og hasj og 
avhengig? eller Heroin Anonymous eller Selvhjelpsgruppe eller 
støttegruppe eller Twelve-step? eller tolv trinn? eller tolv tradisjoner eller 
12-step? eller 12 trinn? eller emne = selvhjelpsgruppe? eller model? Eller 
program? eller behandling? eller rehabilit? eller kur eller terapi eller detox 
eller avrus eller recovery eller intervensjon? eller metode? Og minnesota 
eller TSF 
5 
s49 drug? eller stof? og designer og Anonyme narkomane eller narcotics 
anonymous eller Cocaine Anonymous eller marijuana Anonymous eller 
anonyme og hasj og avhengig? eller Heroin Anonymous eller 
0 
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Selvhjelpsgruppe eller støttegruppe eller Twelve-step? eller tolv trinn? 
eller tolv tradisjoner eller 12-step? eller 12 trinn? eller emne = 
selvhjelpsgruppe? eller model? eller program? eller behandling? eller 
rehabilit? eller kur eller terapi eller detox eller avrus eller recovery eller 
intervensjon? eller metode? og minnesota eller TSF 
s50 Narko? og Anonyme narkomane eller narcotics anonymous eller 
Cocaine Anonymous eller marijuana Anonymous eller anonyme og hasj og 
avhengig? eller Heroin Anonymous eller Selvhjelpsgruppe eller 
støttegruppe eller Twelve-step? eller tolv trinn? eller tolv tradisjoner eller 
12-step? eller 12 trinn? eller emne = selvhjelpsgruppe? eller model? Eller 
program? eller behandling? eller rehabilit? eller kur eller terapi eller detox 
eller avrus eller recovery eller intervensjon? eller metode? Og minnesota 
eller TSF 
14 
s51 Drug? eller stof? og Anonyme narkomane eller narcotics anonymous 
eller Cocaine Anonymous eller marijuana Anonymous eller anonyme og 
hasj og avhengig? eller Heroin Anonymous eller Selvhjelpsgruppe eller 
støttegruppe eller Twelve-step? eller tolv trinn? eller tolv tradisjoner eller 
12-step? eller 12 trinn? eller emne = selvhjelpsgruppe? eller model? Eller 
program? eller behandling? eller rehabilit? eller kur eller terapi eller detox 
eller avrus eller recovery eller intervensjon? eller metode? Og minnesota 
eller TSF 
28 
s52 stof? eller drug? eller stimulan? eller narko? og misbruk? eller brug? Eller 
avheng? og Anonyme narkomane eller narcotics anonymous eller Cocaine 
Anonymous eller marijuana Anonymous eller anonyme og hasj og 
avhengig? eller Heroin Anonymous eller Selvhjelpsgruppe eller 
støttegruppe eller Twelve-step? eller tolv trinn? eller tolv tradisjoner eller 
12-step? eller 12 trinn? eller emne = selvhjelpsgruppe? eller model? Eller 
program? eller behandling? eller rehabilit? eller kur eller terapi eller detox 
eller avrus eller recovery eller intervensjon? eller metode? Og minnesota 
eller TSF 
5 
S53   stof? eller drug? eller stimulan? eller narko? og misbruk?       0 
  eller brug?   Eller avheng? og Anonyme narkomane eller narcotics anonymous 
eller Cocaine Anonymous eller marijuana Anonymous eller anonyme og hasj og 
avhengig? eller Heroin Anonymous eller Selvhjelpsgruppe eller støttegruppe 
eller Twelve-step? eller tolv trinn? eller tolv tradisjoner eller 12-step? eller 12 
trinn? eller emne = selvhjelpsgruppe? eller model? Eller program? eller 
behandling? eller rehabilit? eller kur eller terapi eller detox eller avrus eller 
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recovery eller intervensjon? eller metode? Og minnesota eller TSF – Limited to 
2015-current. 
 
CINAHL 
Searched January 2010  
Update September 2011, July 2013, August 2015, no access in final update September 2016.  
 
Search 
number 
Term Totals 
s1 TI ( narcotics anonymous or Cocaine Anonymous or Crystal Meth 
Anonymous or Pills Anonymous or Marijuana Anonymous or Heroin 
Anonymous ) or AB (narcotics anonymous or Cocaine Anonymous or 
Crystal Meth Anonymous or Pills Anonymous or Marijuana Anonymous 
or Heroin Anonymous ) Search modes   
29 
s2 TI Self-Help N1 group* or AB Self-Help N1 group*  491 
s3 TI Support* n1 group* or AB Support* n1 group*  
 
3605 
s4 TI ( 12-step* or 12 n1 step* ) or AB ( 12-step* or 12 n1 step* )  
 
259 
s5 TI ( twelve-step* or twelve n1 step* ) or AB ( twelve-step* or twelve n1 
step* )  
89 
s6 (MM "Support Groups")  
 
3053 
s7 TI (Recover* n1 group*) and AB (Recover* n1 group*)  
 
5 
s8 TI Minnesota n3 model* or AB Minnesota n3 model*  
 
18 
s9 TI Minnesota n3 program* or AB Minnesota n3 program*   Search Screen 
- Advanced Search  
77 
s10 TI Minnesota n3 treatment* or AB Minnesota n3 treatment* Search 
modes  
   Boolean/Phrase Interface - EBSCOhost  
   Search Screen - Advanced Search  
20 
s11 TI Minnesota n3 rehab* or AB Minnesota n3 rehab* Search modes -  
   Boolean/Phrase Interface - EBSCOhost  
   Search Screen - Advanced Search  
7 
s12 TI Minnesota n3 cure* or AB Minnesota n3 cure* Search modes -  
     
0 
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   Search Screen - Advanced Search  
s13 TI Minnesota n3 therap* or AB Minnesota n3 therap*  
 
8 
s14 TI Minnesota n3 detox* or AB Minnesota n3 detox*  
 
0 
s15 TI Minnesota n3 recover* or AB Minnesota n3 recover*  
 
0 
s16 TI Minnesota n3 intervent* or AB Minnesota n3 intervent*  
 
14 
s17 TI Minnesota n3 method* or AB Minnesota n3 method*  
 
46 
s18    S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17  
    
171 
s19  S1 or S2 or S3 or S4 or S5 or S6 or S7 or S18  
 
1641 
s20 TI Drug* or AB Drug*  
 
80573 
s21 TI Substance* or AB Substance*  
 
15339 
s22 TI Stimulan* or AB Stimulan*  
 
1186 
s23 TI Narcotic* or AB Narcotic*  
 
1160 
s24 TI ( Opium or Heroin or Crack or Cocaine* or Methamphetamine* or  
   Amphetamin*or Ecstasy or Fantasy or Cannabis or Marijuana or 
Hashish ) or AB ( Opium or Heroin or Crack or Cocaine* or 
Methamphetamine* or Amphetamin*or Ecstasy or Fantasy or Cannabis 
or Marijuana or Hashish )  
    
7495 
s25 TI Designer n1 drug* or AB Designer n1 drug*  
 
54 
s26 S20 or S21 or S22 or S23 or S24 or S25  
 
96576 
s27 TI substance* n3 abus* or AB substance* n3 abus*  
 
6328 
s28 TI substance* n3 us* or AB substance* n3 us*  
 
5696 
s29 TI substance* n3 addict* or AB substance* n3 addict 253 
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s30 TI substance* n3 depend* or AB substance* n3 depend*  
 
701 
s31 TI substance* n3 misus* or AB substance* n3 misus*  
 
669 
s32 S27 or S28 or S29 or S30 or S31  
 
11454 
s33 TI drug* n3 abus* or AB drug* n3 abus*  
 
3252 
s34 TI drug* n3 misus* or AB drug* n3 misus*  
 
502 
s35 TI drug* n3 addict* or AB drug* n3 addict*  
 
919 
s36 TI drug* n3 depend* or AB drug* n3 depend*  
 
1151 
s37 TI drug* n3 us* or AB drug* n3 us*  
 
17322 
s38 S33 or S34 or S35 or S36 or S37  
 
21091 
s39 TI stimulan* n3 abus* or AB stimulan* n3 abus*  
 
58 
s40 TI stimulan* n3 us* or AB stimulan* n3 us*  
 
322 
s41 TI stimulan* n3 misus* or AB stimulan* n3 misus*  
 
11 
s42 TI stimulan* n3 addict* or AB stimulan* n3 addict* Search modes -    
     
16 
s43 TI stimulan* n3 depend* or AB stimulan* n3 depend*       
     
28 
s44 S39 or S40 or S41 or S42 or S43      
     
394 
s45 TI Narcotic* n3 abus* or AB Narcotic* n3 abus*      
     
22 
s46 TI Narcotic* n3 us* or AB Narcotic* n3 us*   
     
     
266 
s47 TI Narcotic* n3 misus* or AB Narcotic* n3 misus*   
     
2 
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s48 TI Narcotic* n3 addict* or AB Narcotic* n3 addict*   
     
     
35 
s49 TI Narcotic* n3 depend* or AB Narcotic* n3 depend*   
     
     
15 
s50 S45 or S46 or S47 or S48 or S49  Boolean/Phrase  
   Interface - EBSCOhost  
     
331 
s51 S32 or S38 or S44 or S50  Boolean/Phrase Interface -  
   EBSCOhost  
   Search Screen - Advanced Search 
30289 
s52 TI TSF or AB tsf    
     
66 
s53 (S19 or S52)    
     
6189 
s54 S26 and S53    
     
429 
s55 S51 and S53    
     
340 
s56 (S54 or S55)    
     
429 
s57 (S54 or S55) Limiters - Published Date from: 20100901-20110931  
      
   Search Screen - Advanced Search 
21 
 
Cochrane 
Search February 2011. Update September 2011, July 2013, August 2015, and final update 
September 2016.  
 
Search 
number 
Terms Totals 
s1 (narcotics anonymous):ti,ab,kw 9 
s2 (Cocaine Anonymous):ti,ab,kw 7 
s3 (Crystal Meth Anonymous):ti,ab,kw 0 
s4 (Pills Anonymous):ti,ab,kw 1 
s5 (Marijuana Anonymous):ti,ab,kw 2 
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S6 (Heroin Anonymous):ti,ab,kw 1 
s7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6) 16 
s8 (Self-Help adj1 group*):ti,ab,kw 0 
s9 (Support* adj1 group*).:ti,ab,kw 0 
s10 (twelve-step* or twelve near/1 step*):ti,ab,kw 45 
s11 (12-step* or 12 near/1 step*):ti,ab,kw 67 
s12 Self-Help Groups/ 1420 
s13 (Recover* near/1 group*):ti,ab,kw 204 
s14 (Minnesota near/3 (model* or program* or treatment*or Rehab* or 
cure* or therap* or detox* or recover* or intervent* or 
method*)):ti,ab,kw 
149 
s15 (TSF):ti,ab,kw 42 
s16 (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15) 1858 
s17 Amphetamine-Related Disorders/ 100 
s18 Cocaine-Related Disorders/ 473 
s19 Marijuana Abuse/ 311 
s20 Opioid-Related Disorders/ 584 
s21 Substance Withdrawal Syndrome/ 1838 
s22 Heroin Dependence/ 709 
s23 (#17 OR #18 OR #19 OR #20 OR #21 OR #22) 3428 
s24 Opium/ 156 
s25 Heroin/ 1057 
s26 exp Cannabinoids/ or Cannabis/ 686 
s27 Marijuana Smoking/ 317 
s28 exp cocaine/ 55 
s29 Methamphetamine/ 281 
s30 Amphetamine/ 1027 
s31 Designer Drugs/ 29 
s32 (Drug*):ti,ab,kw 276295 
s33 (Substance*):ti,ab,kw 9439 
s34 (Stimulan*):ti,ab,kw 2477 
s35 (Narcotic*):ti,ab,kw 3812 
s36 (Opium.):ti,ab,kw 127 
s37 (Heroin):ti,ab,kw 989 
s38 (Crack):ti,ab,kw 225 
s39 (Cocaine*):ti,ab,kw 1749 
s40 (Methamphetamine* or Amphetamin*).:ti,ab,kw 0 
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s41 (Ecstasy):ti,ab,kw 76 
s42 (Fantasy):ti,ab,kw 104 
s43 (Cannabis or Marijuana or Hashish).:ti,ab,kw 0 
s44 (Designerdrug* or (designer near/1 drug*)):ti,ab,kw 7 
s45 (#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 
OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR 
#41 OR #42 OR #43 OR #44) 
281719 
s46 (substance* or drug* or stimulan* or Narcotic*) near/3 (abus* or us* or 
misus* or addict* or depend*):ti,ab,kw 
61546 
s47 MeSH descriptor Substance Abuse, Intravenous explode all trees 310 
s48 (#23 OR #47) 3660 
s49 (#7 OR #16) 1869 
s50 (#48 AND #49) 67 
s51 (#45 AND #49) 393 
s52 (#46 AND #49) 181 
S53 (#50 OR #51 OR #52) 399 
S54 (#50 OR #51 OR #52) - Limited to 2015-current 4 
   
Embase 
Searched January 2011.  
Update September 2011, July 2013, August 2015 and final update September 2016. 
 
Search 
number 
Term totals 
s1 (narcotics anonymous or Cocaine Anonymous or Crystal Meth 
Anonymous or Pills Anonymous or Marijuana Anonymous or Heroin 
Anonymous).ab,kw,ti. 
117  
s2 ((Self-Help adj1 group*) or (Support* adj1 group*)).ab,ti. 9266  
s3 (twelve-step* or 12-step*).ab,ti. 1334  
s4 Self-Help Groups/ 10817  
s5 (Recover* adj1 group*).ab,ti. 1821  
s6 (Minnesota adj3 (model* or program* or treatment*or Rehab* or 
cure* or therap* or detox* or recover* or intervent* or 
method*)).ab,ti. 
576  
s7 TSF.ab,ti. 1044  
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s8 1 or 2 or 3 or 4 or 5 or 6 or 7 22601  
s9 Amphetamine-Related Disorders/ or Cocaine-Related Disorders/ or 
Marijuana Abuse/ or opioid-Related Disorders/ or Substance Abuse, 
Intravenous/ or Substance Withdrawal Syndrome/ or heroin 
Dependence/ 
116800  
s10 Opium/ or Heroin/ or exp Cannabinoids/ or Cannabis/ or Marijuana 
Smoking/ or exp cocaine/ or methamphetamine/ or Amphetamine/ or 
Designer Drugs/ 
158507  
s11 (Drug* or Substance* or Stimulan* or Narcotic* or Opium or Heroin 
or Crack or Cocaine* or (Methamphetamine* or Amphetamin*) or 
Ecstasy or Fantasy or (Cannabis or Marijuana or Hashish) or 
(Designer adj1 drug*)).ab,ti. 
1691746  
s12 ((substance* or drug* or stimulan* or Narcotic*) adj3 (abus* or us* or 
misus* or addict* or depend*)).ab,ti. 
268568  
s13 9 or 10 or 11 1781908  
s14 8 and 13 2293  
s15 limit 14 to humans 1978  
s16 (narcotics anonymous or Cocaine Anonymous or Crystal Meth 
Anonymous or Pills Anonymous or Marijuana Anonymous or Heroin 
Anonymous).ab,kw,ti. 
117  
s17 ((Self-Help adj1 group*) or (Support* adj1 group*)).ab,ti. 9266  
s18 (twelve-step* or 12-step*).ab,ti. 1334  
s19 Self-Help Groups/ 10817  
s20 (Recover* adj1 group*).ab,ti. 1821  
s21 (Minnesota adj3 (model* or program* or treatment*or Rehab* or 
cure* or therap* or detox* or recover* or intervent* or 
method*)).ab,ti. 
576  
s22 TSF.ab,ti. 1044  
s23 16 or 17 or 18 or 19 or 20 or 21 or 22 22601  
s24 Amphetamine-Related Disorders/ or Cocaine-Related Disorders/ or 
Marijuana Abuse/ or opioid-Related Disorders/ or Substance Abuse, 
116800  
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Intravenous/ or Substance Withdrawal Syndrome/ or heroin 
Dependence/ 
s25 Opium/ or Heroin/ or exp Cannabinoids/ or Cannabis/ or Marijuana 
Smoking/ or exp cocaine/ or methamphetamine/ or Amphetamine/ or 
Designer Drugs/ 
158507  
s26 (Drug* or Substance* or Stimulan* or Narcotic* or Opium or Heroin 
or Crack or Cocaine* or (Methamphetamine* or Amphetamin*) or 
Ecstasy or Fantasy or (Cannabis or Marijuana or Hashish) or 
(Designer adj1 drug*)).ab,ti. 
1691746  
s27 ((substance* or drug* or stimulan* or Narcotic*) adj3 (abus* or us* or 
misus* or addict* or depend*)).ab,ti. 
268568  
s28 24 or 25 or 26 1781908  
s29 23 and 28 2293  
s30 limit 29 to humans 1978  
s31 limit 30 to yr="2015 -Current" 214  
s32 opiate*.ti,ab. 29806 
s33 8 and 32 68 
s34 limit 33 to human 66  
s35 31 or 34  277  
 
LIBRIS 
Searched July 2013, August 2015 and final update September 2016.  
 
Search  Term Totals 
s1 (narcotics anonymous) or (cocaine anonymous*) 
or (crystal meth anonymous*) or (pills 
anonymous*) or (marijuana anonymous* ) eller ( 
heroin anonymous*) or (12 step ) or (hjälpgrupp*) 
eller (selfhelp group?) or (minnesota model*) or 
(minnesota program*) or (minnesota 
behandling?) or (tolvstegsbehandling*) 
 
11 
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s2 (narcotics anonymous) or (cocaine anonymous*) 
or (crystal meth anonymous*) or (pills 
anonymous*) or (marijuana anonymous* ) eller ( 
heroin anonymous*) or (12 step ) or (hjälpgrupp*) 
eller (selfhelp group?) or (minnesota model*) or 
(minnesota program*) or (minnesota 
behandling?) or (tolvstegsbehandling*) - Limited 
to 2015-current 
0 
 
Medline 
Searched January 2010.  
Update September 2011, July 2013, August 2015 and final update September 2016.  
 
Search 
Number 
Term Totals 
1 narcotics anonymous.ab,kw,ti. 63  
2 Cocaine Anonymous.ab,kw,ti. 3  
3 Crystal Meth Anonymous.ab,kw,ti. 2  
4 Pills Anonymous.ab,kw,ti. 1  
5 Marijuana Anonymous.ab,kw,ti. 0  
6 Heroin Anonymous.ab,kw,ti. 0  
7 1 or 2 or 3 or 4 or 5 or 6 66  
8 (Self-Help adj1 group*).ab,ti. 1175  
9 (Support* adj1 group*).ab,ti. 4699  
10 twelve-step*.ab,ti. 159  
11 12-step*.ab,ti. 613  
12 Self-Help Groups/ 6943  
13 (Recover* adj1 group*).ab,ti. 1151  
14 (Minnesota and (model* or program* or treatment*or 
Rehab* or cure* or therap* or detox* or recover*)).ab,ti. 
3024  
15 TSF.ab,ti. 715  
16 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 16194  
17 Amphetamine-Related Disorders/ 1547  
18 Cocaine-Related Disorders/ 5105  
19 Marijuana Abuse/ 3417  
20 Opioid-Related Disorders/ 6644  
21 Substance Abuse, Intravenous/ 10829  
22 Substance Withdrawal Syndrome/ 17575  
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23 Heroin Dependence/ 7294  
24 17 or 18 or 19 or 20 or 21 or 22 or 23 47243  
25 Opium/ 1678  
26 Heroin/ 4497  
27 exp Cannabinoids/ or Cannabis/ 12874  
28 Marijuana Smoking/ 1848  
29 exp cocaine/ 20516  
30 Methamphetamine/ 5733  
31 Amphetamine/ 10679  
32 Designer Drugs/ 539  
33 Drug*.ab,ti. 863790  
34 Substance*.ab,ti. 180252  
35 Stimulan*.ab,ti. 16686  
36 Narcotic*.ab,ti. 10913  
37 Opium.ab,ti. 1285  
38 Heroin.ab,ti. 8879  
39 Crack.ab,ti. 3436  
40 Cocaine*.ab,ti. 25231  
41 (Methamphetamine* or Amphetamin*).ab,ti. 22897  
42 Ecstasy.ab,ti. 2317  
43 Fantasy.ab,ti. 1895  
44 (Cannabis or Marijuana or Hashish).ab,ti. 11762  
45 (Designer adj1 drug*).ab,ti. 425  
46 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 
35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 
45 
108152
5  
47 (substance adj1 abus*).ab,ti. 15078  
48 (substance adj1 us*).ab,ti. 12077  
49 (substance adj1 addict*).ab,ti. 184  
50 (drug adj1 us*).ab,ti. 37875  
51 (drug adj1 usage).ab,ti. 870  
52 (drug adj1 abus*).ab,ti. 14242  
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53 (drug adj1 addict*).ab,ti. 7340  
54 (drug adj1 depend*).ab,ti. 5031  
55 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 79271  
56 7 or 16 16211  
57 24 and 56 224  
58 46 and 56 1532  
59 55 and 56 811  
60 57 or 58 or 59 1579  
61 limit 60 to humans 1474  
62 limit 61 to yr="2015 -Current" 78 
63 opiate*.ti,ab 21965 
64 56 and 63 48 
65 limit 64 to humans 46 
66 62 or 65 124 
 
PsycINFO 
Searched December 2010.  
Update September 2011, July 2013, August 2015 and final update September 2016.  
Search Terms Limiters Total 
S57 S54 OR S55  Limiters - Date of Publication: 
20150901-Current 
Search modes - Boolean/Phrase 
 (312) 
 
 
S56 S54 OR S55  Search modes - Boolean/Phrase  (278,755) 
 
S55 S51 AND S53  Search modes - Boolean/Phrase  (1,892) 
 
S54 S26 OR S53  Search modes - Boolean/Phrase  (278,755) 
 
S53 S19 OR S52  Search modes - Boolean/Phrase  (16,660) 
 
S52 TI "TSF" OR AB TSF  Search modes - Boolean/Phrase  (130) 
S51 S32 OR S38 OR S44 OR S50  Search modes - Boolean/Phrase  (119,611) 
S50 S45 OR S46 OR S47 OR S48 OR S49  Search modes - Boolean/Phrase  (1,290) 
S49 TI Narcotic* n3 depend* OR AB 
Narcotic* n3 depend*  
Search modes - Boolean/Phrase  (117) 
 
S48 TI Narcotic* n3 addict* OR AB 
Narcotic* n3 addict*  
Search modes - Boolean/Phrase  (701) 
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S47 TI Narcotic* n3 misus* OR AB 
Narcotic* n3 misus*  
Search modes - Boolean/Phrase  (14) 
 
S46 TI Narcotic* n3 us* OR AB Narcotic* 
n3 us*  
Search modes - Boolean/Phrase  (495) 
 
S45 TI Narcotic* n3 abus* OR AB 
Narcotic* n3 abus*  
Search modes - Boolean/Phrase  (125) 
 
S44 S39 OR S40 OR S41 OR S42 OR S43  Search modes - Boolean/Phrase  (2,612) 
S43 TI stimulan* n3 depend* OR AB 
stimulan* n3 depend*  
Search modes - Boolean/Phrase  (322) 
 
S42 TI stimulan* n3 addict* OR AB 
stimulan* n3 addict*  
Search modes - Boolean/Phrase  (163) 
 
S41 TI stimulan* n3 misus* OR AB 
stimulan* n3 misus*  
Search modes - Boolean/Phrase  (96) 
 
S40 TI stimulan* n3 us* OR AB stimulan* 
n3 us*  
Search modes - Boolean/Phrase  (1,895) 
 
S39 TI stimulan* n3 abus* OR AB 
stimulan* n3 abus*  
Search modes - Boolean/Phrase  (537) 
 
S38 S33 OR S34 OR S35 OR S36 OR S37  Search modes - Boolean/Phrase  (73,777) 
 
S37 TI drug* n3 depend* OR AB drug* n3 
depend*  
Search modes - Boolean/Phrase  (7,183) 
 
S36 TI drug* n3 addict* OR AB drug* n3 
addict*  
Search modes - Boolean/Phrase  (9,069) 
 
S35 TI drug* n3 misus* OR AB drug* n3 
misus*  
Search modes - Boolean/Phrase  (1,703) 
 
S34 TI drug* n3 us* OR AB drug* n3 us*  Search modes - Boolean/Phrase  (50,706) 
S33 TI drug* n3 abus* OR AB drug* n3 
abus*  
Search modes - Boolean/Phrase  (19,282) 
 
S32 S27 OR S28 OR S29 OR S30 OR S31  Search modes - Boolean/Phrase  (59,214) 
 
S31 TI substance* n3 misus* OR AB 
substance* n3 misus*  
Search modes - Boolean/Phrase  (2,790) 
 
S30 TI substance* n3 depend* OR AB 
substance* n3 depend*  
Search modes - Boolean/Phrase  (4,561) 
 
S29 TI substance* n3 addict* OR AB 
substance* n3 addict*  
Search modes - Boolean/Phrase  (1,981) 
 
S28 TI substance* n3 us* OR AB 
substance* n3 us*  
Search modes - Boolean/Phrase  (32,012) 
 
S27 TI substance* n3 abus* OR AB 
substance* n3 abus*  
Search modes - Boolean/Phrase  (31,439) 
 
S26 S20 OR S21 OR S22 OR S23 OR S24 
OR S25  
Search modes - Boolean/Phrase  (264,505) 
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S25 TI Designer n1 drug* OR AB Designer 
n1 drug*  
Search modes - Boolean/Phrase  (213) 
 
S24 TI ( ( Opium or Heroin or Crack or 
Cocaine* or Methamphetamine* or 
Amphetamin*or Ecstasy or Fantasy or 
Cannabis or Marijuana or Hashish ) ) 
OR AB ( ( Opium or Heroin or Crack 
or Cocaine* or Methamphetamine* or 
Amphetamin*or Ecstasy or Fantasy or 
Cannabis or Marijuana or Hashish ) )  
Search modes - Boolean/Phrase  (54,540) 
 
 
S23 TI Narcotic* OR AB Narcotic*  Search modes - Boolean/Phrase  (3,060) 
 
S22 TI Stimulan* OR AB Stimulan*  Search modes - Boolean/Phrase  (9,366) 
 
S21 TI Substance* OR AB Substance*  Search modes - Boolean/Phrase  (75,860) 
 
S20 TI Drug* OR AB Drug*  Search modes - Boolean/Phrase  (179,397) 
S19 S1 OR S2 OR S3 OR S4 OR S5 OR S6 
OR S7 OR S18  
Search modes - Boolean/Phrase  (16,614) 
 
S18 S8 OR S9 OR S10 OR S11 OR S12 OR 
S13 OR S14 OR S15 OR S16 OR S17  
Search modes - Boolean/Phrase  (459) 
 
S17 TI Minnesota n3 method* OR AB 
Minnesota n3 method*  
Search modes - Boolean/Phrase  (83) 
 
S16 TI Minnesota n3 intervent* OR AB 
Minnesota n3 intervent*  
Search modes - Boolean/Phrase  (22) 
 
S15 TI Minnesota n3 recover* OR AB 
Minnesota n3 recover*  
Search modes - Boolean/Phrase  (2) 
 
S14 TI Minnesota n3 detox* OR AB 
Minnesota n3 detox*  
Search modes - Boolean/Phrase  (0) 
 
S13 TI Minnesota n3 therap* OR AB 
Minnesota n3 therap*  
Search modes - Boolean/Phrase  (22) 
 
S12 TI Minnesota n3 cure* OR AB 
Minnesota n3 cure*  
Search modes - Boolean/Phrase  (0) 
 
S11 TI Minnesota n3 rehab* OR AB 
Minnesota n3 rehab*  
Search modes - Boolean/Phrase  (19) 
 
S10 TI Minnesota n3 treatment* OR AB 
Minnesota n3 treatment*  
Search modes - Boolean/Phrase  (79) 
 
S9 TI Minnesota n3 program* OR AB 
Minnesota n3 program*  
Search modes - Boolean/Phrase  (216) 
 
S8 TI Minnesota n3 model* OR AB 
Minnesota n3 model*  
Search modes - Boolean/Phrase  (95) 
 
S7 TI (Recover* n1 group*) OR AB 
(Recover* n1 group*)  
Search modes - Boolean/Phrase  (698) 
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S6 SU "SELF-help groups" OR SU 
"SELF-help groups for substance 
abusers"  
Search modes - Boolean/Phrase  (3,025) 
 
S5 TI ( twelve-step* or twelve n1 step* ) 
OR AB ( twelve-step* or twelve n1 
step* )  
Search modes - Boolean/Phrase  (1,952) 
 
S4 TI ( 12-step* OR 12 n1 step* ) OR AB ( 
12-step* OR 12 n1 step* )  
Search modes - Boolean/Phrase  (1,952) 
 
S3 TI Support* n1 group* OR AB 
Support* n1 group*  
Search modes - Boolean/Phrase  (10,561) 
 
S2 TI Self-Help N1 group* OR AB Self-
Help N1 group*  
Search modes - Boolean/Phrase  (1,905) 
 
 
S1 TI ( ( narcotics anonymous or Cocaine 
Anonymous or Crystal Meth 
Anonymous or Pills Anonymous or 
Marijuana Anonymous or Heroin 
Anonymous ) ) OR AB ((narcotics 
anonymous or Cocaine Anonymous or 
Crystal Meth Anonymous or Pills 
Anonymous or Marijuana Anonymous 
or Heroin Anonymous))  
Search modes - Boolean/Phrase  (237) 
 
 
 
Science Citation Index  
Searched December 2010.  
Update September 2011, July 2013, and final update September 2016. 
In the 2016 update, Science Citation Index and Social Science Citation Index were searched 
together. Search #47 is the total result from both Science Citation Index and Social Science Citation 
Index in the 2016 update.  
 
Search 
number 
Term Totals 
s1 
TS=("narcotics anonymous") OR TI=("narcotics anonymous") 
Databases=SCI-EXPANDED Timespan=All Years 
32 
s2 
TS=("cocaine anonymous") OR TI=("cocaine anonymous") 
Databases=SCI-EXPANDED Timespan=All Years 
3 
s3 
TS=("Crystal Meth Anonymous") OR TI=("Crystal Meth 
Anonymous") Databases=SCI-EXPANDED Timespan=All 
Years 
2 
s4 
TS=("Pills Anonymous") OR TI=("Pills Anonymous") 
Databases=SCI-EXPANDED Timespan=All Years 
1 
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s5 
TS=("marijuana anonymous") OR TI=("marijuana 
anonymous") Databases=SCI-EXPANDED Timespan=All 
Years 
0 
s6 
TS="heroin anonymous" OR TI="heroin anonymous" 
Databases=SCI-EXPANDED Timespan=All Years 
0 
s7 
#6 OR #5 OR #4 OR #3 OR #2 OR #1 Databases=SCI-
EXPANDED Timespan=All Years 
34 
s8 
TS=(self-help SAME group*) OR TI=(self-help SAME group*) 
Databases=SCI-EXPANDED Timespan=All Years 
777 
s9 
TS=(support* SAME group*) OR TI=(support* SAME group*) 
Databases=SCI-EXPANDED Timespan=All Years 
26,736 
s10 
TS=twelve-step* OR TI=twelve-step* Databases=SCI-
EXPANDED Timespan=All Years 
131 
s11 
TS=12-step* OR TI=12-step* Databases=SCI-EXPANDED 
Timespan=All Years 
547 
s12 
TS=("self-help group*") OR TI=("self-help group*") 
Databases=SCI-EXPANDED Timespan=All Years 
598 
s13 
TS=(recover* SAME group*) OR TI=(recover* SAME group*) 
Databases=SCI-EXPANDED Timespan=All Years 
15,293 
s14 
TS=(Minnesota SAME (model* or program* or treatment*or 
Rehab* or cure* or therap* or detox* or recover* or intervent* 
or method*)) OR TI=(Minnesota SAME (model* or program* 
or treatment*or Rehab* or cure* or therap* or detox* or 
recover* or intervent* or method*)) Databases=SCI-
EXPANDED Timespan=All Years 
1,768 
s15 
TS=TSF OR TI=TSF Databases=SCI-EXPANDED 
Timespan=All Years 
657 
s16 
#15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 
Databases=SCI-EXPANDED Timespan=All Years 
45,216 
s17 
TS=(amphetamine-related SAME disorder*) OR 
TI=(amphetamine-related SAME disorder*)Databases=SCI-
EXPANDED Timespan=All Years 
7 
s18 
TS=(Cocaine-Related SAME Disorder*) OR TI=(Cocaine-
Related SAME Disorder*) Databases=SCI-EXPANDED 
Timespan=All Years 
30 
s19 
TS=(Marijuana SAME Abuse) OR TI=(Marijuana SAME 
Abuse) Databases=SCI-EXPANDED Timespan=All Years 
258 
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s20 
TS=(opioid-related SAME disorder*) OR TI=(opioid-related 
SAME disorders) Databases=SCI-EXPANDED Timespan=All 
Years 
52 
s21 
TS=((substance SAME abuse) AND Intravenous) OR 
TI=((substance SAME abuse) AND Intravenous) 
Databases=SCI-EXPANDED Timespan=All Years 
342 
s22 
TS=(substance SAME withdrawal SAME syndrome) OR 
TI=(substance SAME withdrawal SAME syndrome) 
Databases=SCI-EXPANDED Timespan=All Years 
74 
s23 
TS=(heroin SAME dependence) OR TI=(heroin SAME 
dependence) Databases=SCI-EXPANDED Timespan=All 
Years 
541 
s24 
#23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 
Databases=SCI-EXPANDED Timespan=All Years 
1,273 
s25 
TS=opium OR TI=opium Databases=SCI-EXPANDED 
Timespan=All Years 
1,652 
s26 
TS=heroin OR TI=heroin Databases=SCI-EXPANDED 
Timespan=All Years 
8,746 
s27 
TS=cannabi* OR TI=cannabi* Databases=SCI-EXPANDED 
Timespan=All Years 
18,094 
s28 
TS=(marijuana SAME smoking) OR TI=(marijuana SAME 
smoking) Databases=SCI-EXPANDED Timespan=All Years 
524 
s29 
TS=cocaine* OR TI=cocaine* Databases=SCI-EXPANDED 
Timespan=All Years 
30,927 
s30 
TS=methamphetamine* OR TI=methamphetamine* 
Databases=SCI-EXPANDED Timespan=All Years 
7,149 
s31 
TS= amphetamine* OR TI= amphetamine* Databases=SCI-
EXPANDED Timespan=All Years 
22,692 
s32 
TS=(designer SAME drug*) OR TI=(designer SAME drug*) 
Databases=SCI-EXPANDED Timespan=All Years 
656 
s33 
TS=drug* OR TI=drug* Databases=SCI-EXPANDED 
Timespan=All Years 
>100,0
00  
s34 
TS=substance* OR TI=substance* Databases=SCI-
EXPANDED Timespan=All Years 
>100,0
00  
s35 
TS=stimulan* OR TI=stimulan* Databases=SCI-EXPANDED 
Timespan=All Years 
14,591 
s36 
TS=narcotic* OR TI=narcotic*Databases=SCI-EXPANDED 
Timespan=All Years 
8,407 
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s37 
TS=crack OR TI=crack Databases=SCI-EXPANDED 
Timespan=All Years 
72,462 
s38 
TS=ectasy OR TI=ectasy Databases=SCI-EXPANDED 
Timespan=All Years 
24 
s39 
TS=fantasy OR TI=fantasy Databases=SCI-EXPANDED 
Timespan=All Years 
1,159 
s40 
TS=(marijuana OR hashish) OR TI=(marijuana OR hashish) 
Databases=SCI-EXPANDED Timespan=All Years 
5,524 
s41 
#40 OR #39 OR #38 OR #37 OR #36 OR #35 OR #34 OR #33 
OR #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR #26 OR 
#25 Databases=SCI-EXPANDED Timespan=All Years 
>100,0
00  
s42 
TS=((substance* or drug* or stimulan* or Narcotic*) SAME 
(abus* or use* or misus* or addict* or depend*)) OR 
TI=((substance* or drug* or stimulan* or Narcotic*) SAME 
(abus* or use* or misus* or addict* or depend*)) 
Databases=SCI-EXPANDED Timespan=All Years 
>100,0
00  
s43 #16 OR #7 Databases=SCI-EXPANDED Timespan=All Years 45,23 
s44 
#43 AND #24 Databases=SCI-EXPANDED Timespan=All 
Years 
12 
s45 
#43 AND #41 Databases=SCI-EXPANDED Timespan=All 
Years 
3,192 
s46 
#43 AND #42 Databases=SCI-EXPANDED Timespan=All 
Years 
1,049 
s47 
#46 OR #45 OR #44 Databases=SCI-EXPANDED, SSCI 
Timespan=2015-2016 
1.176 
 
Social Science Citation Index 
Searched January 2011 
Update September 2011, July 2013, September 2015 and final update September 2016.  
In the 2016 update, Science Citation Index and Social Science Citation Index were searched 
together. See the searches for Science Citation Index for 2016 results.  
 
Search 
number 
Term Totals 
1 
Topic=(("narcotics anonymous")) OR Title=(("narcotics 
anonymous")) Databases=SSCI Timespan=All years 
16 
2 
Topic=(("narcotics anonymous")) OR Title=(("narcotics 
anonymous")) Databases=SSCI Timespan=All years 
16 
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3 
Topic=(("cocaine anonymous")) OR Title=(("cocaine 
anonymous")) Databases=SSCI Timespan=All years 
0 
4 
Topic=(("Crystal Meth Anonymous")) OR Title=(("Crystal Meth 
Anonymous")) Databases=SSCI Timespan=All years 
0 
5 
Topic=("marijuana anonymous") OR Title=("marijuana 
anonymous") Databases=SSCI Timespan=All years 
0 
6 
Topic=("heroin anonymous") OR Title=("heroin anonymous") 
Databases=SSCI Timespan=All years 
0 
7 
#6 OR #5 OR #4 OR #3 OR #2 OR #1 Databases=SSCI 
Timespan=All years Databases=SSCI Timespan=All years 
16 
8 
Topic=((self-help SAME group*)) OR Title=((self-help SAME 
group*)) Databases=SSCI Timespan=All years 
341 
9 
Topic=((support* SAME group*)) OR Title=((support* SAME 
group*)) Databases=SSCI Timespan=All years  
11,754 
10 
Topic=(twelve-step*) OR Title=(twelve-step*) Databases=SSCI 
Timespan=All years 
24 
11 
Topic=(12-step*) OR Title=(12-step*) Databases=SSCI 
Timespan=All years 
89 
12 
Topic=(("self-help group*")) OR Title=(("self-help group*")) 
Databases=SSCI Timespan=All years 
115 
13 
Topic=((recover* SAME group*)) OR Title=((recover* SAME 
group*)) Databases=SSCI Timespan=All years  
1,284 
14 
Topic=((Minnesota SAME (model* or program* or 
treatment*or Rehab* or cure* or therap* or detox* or recover* 
or intervent* or method*))) OR Title=((Minnesota SAME 
(model* or program* or treatment*or Rehab* or cure* or 
therap* or detox* or recover* or intervent* or method*))) 
Databases=SSCI Timespan=All years 
311 
15 
Topic=(TSF) OR Title=(TSF) Databases=SSCI Timespan=All 
years 
19 
16 
#15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 
Databases=SSCI Timespan=All years 
13,251 
17 
Topic=((amphetamine-related SAME disorder*)) OR 
Title=((amphetamine-related SAME disorder*)) 
Databases=SSCI Timespan=All years 
1 
18 
Topic=((Cocaine-Related SAME Disorder*)) OR 
Title=((Cocaine-Related SAME Disorder*)) Databases=SSCI 
Timespan=All years 
5 
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19 
Topic=(Marijuana SAME Abuse) OR Title=(Marijuana SAME 
Abuse) Databases=SSCI Timespan=All years 
284 
20 
Topic=(opioid-related SAME disorder*) OR Title=(opioid-
related SAME disorder*) Databases=SSCI Timespan=All years 
25 
21 
Topic=((substance SAME abuse) AND Intravenous) OR 
Title=((substance SAME abuse) AND Intravenous) 
Databases=SSCI Timespan=All years 
28 
22 
Topic=((substance SAME withdrawal SAME syndrome)) OR 
Title=((substance SAME withdrawal SAME syndrome)) 
Databases=SSCI Timespan=All years 
30 
23 
Topic=(heroin SAME dependen*) OR Title=(heroin SAME 
dependen*) Databases=SSCI Timespan=All years 
334 
24 
#23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 
Databases=SSCI Timespan=All years 
672 
25 
Topic=(opium) OR Title=(opium) Databases=SSCI 
Timespan=All years 
49 
26 
Topic=(heroin) OR Title=(heroin) Databases=SSCI 
Timespan=All years 
686 
27 
Topic=(cannabi*) OR Title=(cannabi*) Databases=SSCI 
Timespan=All years 
1,15 
28 
Topic=(marijuana SAME smoking) OR Title=(marijuana SAME 
smoking) Databases=SSCI Timespan=All years 
224 
29 
Topic=(cocain*) OR Title=(cocain*) Databases=SSCI 
Timespan=All years 
1,095 
30 
Topic=(methamphetamine*) OR Title=(methamphetamine*) 
Databases=SSCI Timespan=All years 
387 
31 
Topic=(amphetamine*) OR Title=(amphetamine*) 
Databases=SSCI Timespan=All years 
369 
32 
Topic=(designer SAME drug*) OR Title=(designer SAME 
drug*) Databases=SSCI Timespan=All years 
31 
33 
Topic=(drug*) OR Title=(drug*) Databases=SSCI Timespan=All 
years 
13,241 
34 
Topic=(substance*) OR Title=(substance*) Databases=SSCI 
Timespan=All years 
7,827 
35 
Topic=(stimulan*) OR Title=(stimulan*) Databases=SSCI 
Timespan=All years 
524 
36 
Topic=(narcotic*) OR Title=(narcotic*) Databases=SSCI 
Timespan=All years 
132 
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37 
Topic=(crack) OR Title=(crack) Databases=SSCI Timespan=All 
years 
307 
38 
Topic=(ecstasy) OR Title=(ecstasy) Databases=SSCI 
Timespan=All years 
147 
39 
Topic=(fantasy) OR Title=(fantasy) Databases=SSCI 
Timespan=All years 
449 
40 
Topic=(marijuana OR hashish) OR Title=(marijuana OR 
hashish) Databases=SSCI Timespan=All years 
877 
41 
#40 OR #39 OR #38 OR #37 OR #36 OR #35 OR #34 OR #33 
OR #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR #26 OR 
#25 Databases=SSCI Timespan=All years 
19,44 
42 
Topic=((substance* or drug* or stimulan* or Narcotic*) SAME 
(abus* or use* or misus* or addict* or depend*)) OR 
Title=((substance* or drug* or stimulan* or Narcotic*) SAME 
(abus* or use* or misus* or addict* or depend*)) 
Databases=SSCI Timespan=All years 
14,016 
43 #16 OR #7 Databases=SSCI Timespan=All years 13,256 
44 #43 AND #42 Databases=SSCI Timespan=All years 782 
45 #43 AND #41 Databases=SSCI Timespan=All years 930 
46 #43 AND #24 Databases=SSCI Timespan=All years 27 
47 #46 OR #45 OR #44 Databases=SSCI Timespan=All years 930 
48 
Topic=(opiate*) AND Title=(opiate*) Databases=SSCI 
Timespan=All years 
1,758 
49 #48 AND #43 Databases=SSCI Timespan=All years 5 
50 #49 OR #47 Databases=SSCI Timespan=All years 930 
 
SocIndex  
Searched December 2010.  
Update September 2011, July 2013, August 2015 and final update September 2016.  
 
Search 
number 
Term Totals 
s1 TI ( narcotics anonymous or Cocaine Anonymous or Crystal 
Meth Anonymous or Pills Anonymous or Marijuana 
Anonymous or Heroin Anonymous ) or AB ( narcotics 
anonymous or Cocaine Anonymous or Crystal Meth 
122 
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Anonymous or Pills Anonymous or Marijuana Anonymous or 
Heroin Anonymous )  
s2 TI Self-Help N1 group* or AB Self-Help N1 group*  824 
s3 TI Support* n1 group* or AB Support* n1 group*  3194 
s4 TI ( 12-step* or 12 n1 step* ) or AB ( 12-step* or 12 n1 step* )  646 
s5 TI ( twelve-step* or twelve n1 step* ) or AB ( twelve-step* or 
twelve n1 step* )  
646 
s6 DE "SELF-help groups" OR DE "SELF-help groups for 
substance abusers"  
1154 
s7 TI (Recover* n1 group*) and AB (Recover* n1 group*)  1 
s8 TI Minnesota n3 model* or AB Minnesota n3 model*  66 
s9 TI Minnesota n3 program* or AB Minnesota n3 program*  232 
s10 TI Minnesota n3 treatment* or AB Minnesota n3 treatment*  48 
s11 TI Minnesota n3 rehab* or AB Minnesota n3 rehab*  11 
s12 TI Minnesota n3 cure* or AB Minnesota n3 cure*  0 
s13 TI Minnesota n3 therap* or AB Minnesota n3 therap*  14 
s14 TI Minnesota n3 detox* or AB Minnesota n3 detox*  0 
s15 TI Minnesota n3 recover* or AB Minnesota n3 recover* 2 
s16 TI Minnesota n3 intervent* or AB Minnesota n3 intervent* 7 
s17 TI Minnesota n3 method* or AB Minnesota n3 method*  30 
s18 S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17  366 
s19 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S18  5354 
s20 TI Drug* or AB Drug*  67211 
s21 TI Substance* or AB Substance*  23945 
s22 TI Stimulan* or AB Stimulan*  1091 
s23 TI Narcotic* or AB Narcotic*  4104 
s24 TI ( Opium or Heroin or Crack or Cocaine* or 
Methamphetamine* or Amphetamin*or Ecstasy or Fantasy or 
Cannabis or Marijuana or Hashish ) or AB ( Opium or Heroin 
or Crack or Cocaine* or Methamphetamine* or 
Amphetamin*or Ecstasy or Fantasy or Cannabis or Marijuana 
or Hashish )  
18378 
s25 TI Designer n1 drug* or AB Designer n1 drug*  88 
s26 S20 or S21 or S22 or S23 or S24 or S25  92592 
s27 TI substance* n3 abus* or AB substance* n3 abus*  13074 
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s28 TI substance* n3 us* or AB substance* n3 us*  7400 
s29 TI substance* n3 addict* or AB substance* n3 addict*  447 
s30 TI substance* n3 depend* or AB substance* n3 depend* 932 
s31 TI substance* n3 misus* or AB substance* n3 misus*  711 
s32 S27 or S28 or S29 or S30 or S31  19148 
s33 TI drug* n3 abus* or AB drug* n3 abus*  14035 
s34 TI drug* n3 us* or AB drug* n3 us*  21927 
s35 TI drug* n3 misus* or AB drug* n3 misus*  939 
s36 TI drug* n3 addict* or AB drug* n3 addict*  3856 
s37 TI drug* n3 depend* or AB drug* n3 depend*  2412 
s38 S33 or S34 or S35 or S36 or S37  35750 
s39 TI stimulan* n3 abus* or AB stimulan* n3 abus*  96 
s40 TI stimulan* n3 us* or AB stimulan* n3 us*  258 
s41 TI stimulan* n3 misus* or AB stimulan* n3 misus*  8 
s42 TI stimulan* n3 addict* or AB stimulan* n3 addict*  25 
s43 TI stimulan* n3 depend* or AB stimulan* n3 depend* 35 
s44 S39 or S40 or S41 or S42 or S43  365 
s45 TI Narcotic* n3 abus* or AB Narcotic* n3 abus*  296 
s46 TI Narcotic* n3 us* or AB Narcotic* n3 us*  441 
s47 TI Narcotic* n3 misus* or AB Narcotic* n3 misus*  9 
s48 TI Narcotic* n3 addict* or AB Narcotic* n3 addict*  584 
s49 TI Narcotic* n3 depend* or AB Narcotic* n3 depend*  37 
s50 S45 or S46 or S47 or S48 or S49  1232 
s51 S32 or S38 or S44 or S50  50035 
s52 TI TSF or AB tsf  27 
s53 (S19 or S52)  5356 
s54 S26 and S53  933 
s55 S51 and S53  710 
s56 (S54 or S55) 933 
S57  (S54 or S55) - Date of Publication:20150901-20160901 64 
 
Dissertation Abstracts 
Searched December 2010.  
Update September 2011, July 2013, August 2015 and final update September 2016.  
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Search Terms Total 
S4 (((narcotics anonymous) OR (Cocaine Anonymous) OR (Crystal Meth Anonymous) 
OR (Crystal Meth Anonymous) OR (Pills Anonymous) OR (Marijuana Anonymous) 
OR (Heroin Anonymous)) OR (Self-Help NEAR/1 group) OR (Support NEAR/1 
group) OR (twelve-step*) OR (12-step*) OR (Recover NEAR/1 group) OR TSF OR 
(Minnesota AND (model* OR program* OR treatment*or Rehab* OR cure* OR 
therap* OR detox* OR recover* OR intervent* OR method*))) AND ((su(Heroin) 
OR su(Marijuana) OR su(cannabis) OR su(cocaine) OR su(Methamphetamine) OR 
su(Amphetamine) OR drug* OR Substance* OR Stimulan* OR Narcotic* OR Opium 
OR Heroin OR Crack OR Cocaine* OR Ecstasy OR Fantasy OR (designer NEAR/1 
drug*)) OR ((substance* OR drug* OR stimulan* OR Narcotic*) AND (substance* 
OR drug* OR stimulan* OR Narcotic*) AND (abus* OR us* OR misus* OR addict* 
OR depend*)) - Limited to 2015-current 
49 
S3 
(su(Heroin) OR su(Marijuana) OR su(cannabis) OR su(cocaine) OR 
su(Methamphetamine) OR su(Amphetamine) OR drug* OR Substance* OR 
Stimulan* OR Narcotic* OR Opium OR Heroin OR Crack OR Cocaine* OR Ecstasy 
OR Fantasy OR (designer NEAR/1 drug*)) OR ((substance* OR drug* OR stimulan* 
OR Narcotic*) AND (abus* OR us* OR misus* OR addict* OR depend*)) 
10.499 
S2 
((narcotics anonymous) OR (Cocaine Anonymous) OR (Crystal Meth Anonymous) 
OR (Crystal Meth Anonymous) OR (Pills Anonymous) OR (Marijuana Anonymous) 
OR (Heroin Anonymous)) OR (Self-Help NEAR/1 group) OR (Support NEAR/1 
group) OR (twelve-step*) OR (12-step*) OR (Recover NEAR/1 group) OR TSF OR 
(Minnesota AND (model* OR program* OR treatment*or Rehab* OR cure* OR 
therap* OR detox* OR recover* OR intervent* OR method*)) 
145 
S1 
((substance* OR drug* OR stimulan* OR Narcotic*) AND (abus* OR us* OR misus* 
OR addict* OR depend*))Limits applied 
2033 
 
Sociological Abstracts 
Searched December 2010.  
Update September 2011, July 2013, August 2015 and final update September 2016.  
 
Search Terms Total 
S4 (("narcotics anonymous" OR "Cocaine Anonymous" OR "Crystal Meth Anonymous" 
OR "Pills Anonymous" OR "Marijuana Anonymous" OR "Heroin Anonymous") OR 
(Self-Help NEAR/1 group) OR (Support NEAR/1 group) OR ((12-step*) OR (twelve-
step*)) OR (Recover NEAR/1 group) OR "TSF" OR ((Minnesota) AND (model* OR 
program* OR treatment*or Rehab* OR cure* OR therap* OR detox* OR recover* OR 
intervent* OR method*))) AND ((su(heroin) OR su((marijuana OR cannabis)) OR 
su((cocaine OR Methamphetamine)) OR su(Amphetamine)) OR ((drug*) OR 
((substance*) OR (stimulan*)) OR ((narcotic*) OR (opium)) OR ((heroin*) OR 
(crack*)) OR ((cocaine*) OR (ecstasy*)) OR ((fantas*) OR (designer NEAR/1 drug*))) 
OR ((substance* OR drug* OR stimulan* OR Narcotic*) AND (abus* OR us* OR 
misus* OR addict* OR depend*))) Limited to 2015 - current. 
7 
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S3 (su(heroin) OR su((marijuana OR cannabis)) OR su((cocaine OR Methamphetamine)) 
OR su(Amphetamine)) OR ((drug*) OR ((substance*) OR (stimulan*)) OR ((narcotic*) 
OR (opium)) OR ((heroin*) OR (crack*)) OR ((cocaine*) OR (ecstasy*)) OR ((fantas*) 
OR (designer NEAR/1 drug*))) OR ((substance* OR drug* OR stimulan* OR 
Narcotic*) AND (abus* OR us* OR misus* OR addict* OR depend*)) 
577 
S2 ("narcotics anonymous" OR "Cocaine Anonymous" OR "Crystal Meth Anonymous" OR 
"Pills Anonymous" OR "Marijuana Anonymous" OR "Heroin Anonymous") OR (Self-
Help NEAR/1 group) OR (Support NEAR/1 group) OR ((12-step*) OR (twelve-step*)) 
OR (Recover NEAR/1 group) OR "TSF" OR ((Minnesota) AND (model* OR program* 
OR treatment*or Rehab* OR cure* OR therap* OR detox* OR recover* OR intervent* 
OR method*)) 
52 
S1 ((substance* OR drug* OR stimulan* OR Narcotic*) AND (abus* OR us* OR misus* 
OR addict* OR depend*))  
294 
 
SveMed+  
Searched December 2010.  
Update September 2011 and July 2013 and final update September 2016.  
Search Terms Total 
1 narcotics anonymous 60 
2 Cocaine Anonymous 1 
3 Crystal Meth Anonymous 0 
4 Pills Anonymous 4 
5 Marijuana Anonymous 1 
6 Heroin Anonymous 3 
7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 68 
8 Self-Help group* 179 
9 Support* group* 253 
10 twelve-step* 0 
11 12-step* 0 
12 12-step 16 
13 Self-Help Groups 187 
14 recovery group 27 
15 minnesota model 4 
16 minnesota program 0 
17 minnesota treatment 11 
18 minnesota rehab 0 
19 minnesota cure 0 
20 minnesota therapy 9 
21 minnesota detox 0 
22 minnesota recover 0 
23 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR 
#20 OR #21 OR #22 407 
24 Amphetamine-Related Disorders 42 
25 Cocaine-Related Disorders 29 
26 Marijuana Abuse 59 
27 Opioid-Related Disorders 402 
28 Substance Abuse, Intravenous 127 
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29 Substance Withdrawal Syndrome 155 
30 Heroin Dependence 104 
31 #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 737 
53 
#32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 
OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 2552 
54 substance abus* 604 
55 substance us* 222 
56 substance addict* 198 
57 drug us* 841 
58 drug usage 8 
59 drug abus* 266 
60 drug addict* 177 
61 drug depend* 108 
62 #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 1715 
63 #7 OR #23 475 
64 #31 AND #63 13 
65 #62 AND #63 14 
66 #63 OR #64 OR #65 475 
67     #63 OR #64 OR #65 – Limited to 2015-2016.        3 
The original searches for this review where conducted in cooperation between the authors and the 
Swedish Ministry of Health and Social Affairs.  
Due to cease of cooperation, the search strategies for the following databases could not be 
identified and documented in the appendix:  
• ASSIA – Searched until July 2013 
• DiVA – Searched until July 2013 
• Artikelsök – Searched until July 2013.  
 
Grey literature search strategy 
 
The search strategy for the grey literature search was based on the search string for the electronic 
database search. Due to the limited search capacity on the grey literature information resources, 
web pages and search engines, a shortened search string was used. The search strategy on grey 
literature resources, trial registers and repositories was based on a simple “two-term” search. 
Searches were performed by searching for “12-step*” OR “twelve-step*” in search fields on web 
pages. If possible, combining “12-step*” OR “twelve-step*” with “drug* OR “drug abuse*” was used. 
On Google Scholar, advanced search was used. “12-step*” where searched in the field All of the 
words. “Drug abuse” where searched in the field Any of the words. Searches were performed as 
title and full-text searches.  
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9.2  CHARACTERISTICS OF INCLUDED STUDIES  
All studies analyse outcomes at the individual level. In all 10 included studies participants were 
individually assigned to either 12-step or the comparison condition. However some studies 
delivered one or more of the interventions in groups: 
• Three studies reported delivering 12-step intervention individually (Carroll et al., 1998; 
Carroll et al., 2012; Schottenfeld et al., 2011). However in Carroll et al. (2012) 12-step was 
delivered in addition to a treatment as usual intervention that was group based (although 
participants could request individual therapy). Seven studies delivered the intervention 
either purely in group sessions, or a combination of individual and group session (Bisset, 
2002; Gossop et al., 2007; Higgins et al., 1991; Maude-Griffin et al., 1998; McKay et al., 
1997; Petry et al., 2010; Wells et al., 1994) 
• Two studies reported delivering the comparison(s) individually (Carroll et al., 1998; 
Schottenfeld et al., 2011). In seven studies one or more of the comparisons contained a 
group element in delivery (Bisset et al., 2002; Carroll et al., 2012; Gossop et al., 2007; 
Maude-Griffin et al., 1998; McKay et al., 1997; Petry 2010; Wells et al., 1994). One study did 
not report whether the intervention was delivered individually or in groups (Higgins et al., 
1991). 
• Two studies delivered the 12-step intervention and the relevant comparisons individually 
(Carroll et al., 1998; Schottenfeld et al., 2011)  
 
Below we present additional details of included studies. 
Bisset, 2002 
Methods Randomised controlled trial 
Participants 124 men and women from the US with an average age of 43 years old. All 
participants used two kinds of drugs and methadone when entering the 
trial.  
Intervention Acceptance and Commitment Therapy & Intensive Twelve Step 
facilitation (ITSF). Both interventions were delivered individually and in 
groups. 
 
Duration of interventions: 16 weeks 
Outcomes and time 
points that are 
considered in this 
review 
Drug use, criminal behaviour, psychiatric symptoms, social function and 
employment status. All outcomes measured 8 weeks post treatment and 
6 months post treatment.  
Retention. 
Notes  
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Carroll et al., 1998 
Methods Randomised controlled trial 
Participants 122 men and women with average age of 31 years old from the US were 
randomised. All participants had a current cocaine dependence.  
Intervention Disulfiram, Cognitive Behavioural Training & Twelve Step Facilitation. 
All interventions delivered individually. 
 
Duration of interventions: 12 weeks 
Outcomes and time 
points that are 
considered in this 
review 
Drug use during treatment, at the end of treatment, 1 month FU, 6 
month FU, and 12 month FU. 
Retention. 
ASI subcomponent scores: post, 6 month FU, 12 month FU. 
Notes Drug use (“Days of cocaine use per month”): post, 6 month FU, 12 month 
FU, by author correspondence. 
ASI subcomponent scores: post, 6 month FU, 12 month FU by author 
correspondence. 
Carroll et al., 2012 
Methods Randomised controlled trial 
Participants 112 men and women from the US were included in the study. The average 
age was 38.8 overall. Participants were methadone maintenance 
patients. 
Intervention Disulfiram, Twelve Step Facilitation and Treatment as usual combined in 
different ways. Twelve step facilitation (TSF) was delivered individually. 
Treatment as usual delivered either in a group setting (default) or 
individually (participant’s choice)9.  
 
Duration of intervention: 12 weeks 
Outcomes and time 
points that are 
considered in this 
review 
Drug use during treatment, end of treatment (post), 6 month FU, 12 
months FU. 
Retention. 
 
Notes Drug use: during, post, 6 month FU, 12 month FU, by author 
correspondence. 
 
 
                                                        
9 Source: author correspondence 7th October, 2014. 
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Gossop et al., 2007 
Methods Quasi-experimental study 
Participants 
124 men and women from the UK with an over-representation of men. 
The average age of the participants was 29.7 years old. All participants 
had a drug dependence disorder. 
Intervention 
Narcotics Anonymous and Alcoholics Anonymous programs. 
“Intervention” delivered in self-help group. Comparison is no group 
attendance.  
 
The programs’ duration differs between 2-52 weeks 
Outcomes and time 
points that are 
considered in this 
review 
Drug use at 1 year, 2, years and 4-5 years follow-up post intake of 
treatment. 
Notes  
Higgins et al., 1991 
Methods Quasi-experimental study 
Participants 
25 American men and women initiated treatment. All participants had a 
cocaine dependence. The mean age in the two groups was 30.5 and 29 
years for the 12-step group and BT group respectively. 
Intervention 
Behavioural Therapy and Twelve Step Facilitation (TSF). TSF delivered 
in both individual and in group sessions. Behavioural Therapy delivery 
not reported. 
 
Duration of the programs: 12 weeks 
Outcomes and time 
points that are 
considered in this 
review 
Drug use during treatment.  
Notes 
Drug use. Author did not respond to our enquiries. Numerical data 
extracted by graphical methods. 
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Maude-Griffin et al., 1998 
Methods Randomised controlled trial 
Participants 
126 men and 2 women from the US with current cocaine abuse 
participated in the trial. Age not reported, but mean length of history of 
cocaine use in the sample was 19 years.  
Intervention 
Cognitive-Behavioural Coping Skills Training (CBT) and Twelve Step 
Facilitation (TSF). Both interventions delivered in individual and group 
sessions. 
 
Duration of the programs: 12 weeks 
Outcomes and time 
points that are 
considered in this 
review 
Drug use. Time points available: during, post, 14 weeks FU. 
Retention. 
Notes 
Corresponding author replied that data had been discarded. Numerical 
data extracted based on aggregate follow-up rates, assuming follow-up 
rate independent of treatment. 
McKay et al., 1997 
Methods Randomised controlled trial 
Participants 
98 (132 in McKay 1999) men with cocaine dependence. The average age 
of the participants was 40 years old.  
Intervention 
Relapse Prevention and 12-step standard group counselling. 12-step 
delivered in groups. Relapse Prevention delivered in both individual and 
group sessions. 
 
The intervention duration for RP is unclear while the 12-step program 
varied in length with a maximum of 23 months counselling.  
Outcomes and time 
points that are 
considered in this 
review 
Drug use during treatment: 1-6 months (during), follow-up 7-12 months 
(post), 13-18 months (6 months FU), and 24 months after beginning of 
treatment (12 months FU).  
Retention. 
Psychiatric symptoms, employment status and family functioning at 
baseline, 1-6 month(during treatment) and at follow-up after 7-12 month 
(post), 13-18 month (6 months FU) and 24 month after treatment start 
(12 months FU).  
Notes 
Author did not respond to our enquiries. Number of observation 
assumed based on overall follow-up rates (assumed independent of 
measure and treatment). 
 107     The Campbell Collaboration | www.campbellcollaboration.org 
Petry et al., 2010 
Methods Randomised controlled trial 
Participants 
170 HIV positive men and women with a cocaine or opioid abuse or 
dependence were randomised in the study. The mean age of the sample 
was 43.1 years and 42.6 for the 12-step group and the CM group 
respectively. The study was conducted in the US. 
Intervention 
Contingency Management and Twelve Step Facilitation (TSF). Both 
interventions delivered in groups. 
 
Duration of the programs: 24 weeks.  
Outcomes and time 
points that are 
considered in this 
review 
Drug use. During treatment and at 6 months follow-up. 
Retention.  
Notes 
Author did not respond to our enquiries. 
Drug use. Measurements taken during, post, 3 month FU, 6 months FU. 
Schottenfeld et al., 2011 
Methods Randomised controlled trial 
Participants 
145 women from the US with a mean age of 31.1 years were randomised 
in the study. All the included women had a cocaine dependence and were 
either pregnant or had custody of a young child.  
Intervention 
Community reinforcement approach, Contingency management, Non-
contingent- yoked voucher control and Twelve Step Facilitation (TSF). 
Individual delivery. 
 
Duration of the programs: 24 weeks 
Outcomes and time 
points that are 
considered in this 
review 
Drug use during treatment (week 1-24)  
Retention. 
Notes 
Author did not respond to our enquiries. 
Drug use. During (extracted from Fig. 3, p52), post (could not extract), 3 
months FU (extracted but not used in synthesis), 6 months (could not 
extract) 
Retention. Extracted from Fig. 1, p50. 
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Wells et al., 1994 
Methods Quasi randomised controlled trial 
Participants 
110 men and women from the US with substance dependence. The 
median age of the sample was 28 years.  
Intervention 
Relapse Prevention and Twelve Step Facilitation (TSF). Both 
interventions delivered in groups. 
 
Duration of the programs: 24 weeks  
Outcomes and time 
points that are 
considered in this 
review 
Drug use at treatment end (post) and 6 months FU. 
Retention.  
Notes  
 
9.3  CHARACTERISTICS OF EXCLUDED STUDIES  
Aase , Jason, Ferrari, Li, & Scott, (2014) 
 
Reason for Exclusion Participants mainly alcohol abuse.  
 
Bergman, Hoeppner, Nelson, Slaymaker, & Kelly, 2015 
 
Reason for Exclusion 
Participants. 75% cannabis users and 75% alcohol. Not reported 
separately. 
 
Bogenschutz, Rice, Tonigan, Vogel, Nowinski, Hume, & Arenella, 2014 
 
Reason for Exclusion Participants were alcohol dependents. 
 
Bowen, Witkiewitz, Clifasefi, Grow, Chawla, Hsu, ... , & Larimer, 2014 
 
Reason for Exclusion Participants. 10-15% had dependence on alcohol only. 
 
Brooks & Penn, 2003 
 
Reason for Exclusion 
Participants. 45% of study participants have alcohol dependence disorder 
only. No subgroup analysis available. 
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Brennan, 1998 
 
Reason for Exclusion 
Participants. 52% of the participants in the treatment group and 72% of 
the participants in the control group had alcohol dependence disorder 
only. No subgroup analysis available. 
 
Brown, Seraganian, Tremblay, & Annis, 2002 a+b 
 
Reason for Exclusion 28.6% of the participants were alcohol dependents.  
 
Chi, Weisner, Grella, Hser, Moore, & Mertens, 2014 
 
Reason for Exclusion 15% alcohol dependents.  
 
Donovan, Daley, Brigham, Hodgkins, Perl, Garrett, ... , & Kelly, 2013 
 
Reason for Exclusion No relevant comparison. Both interventions contain 12-step components.  
 
Doyle, & Donovan, 2014 
 
Reason for Exclusion No relevant comparison. Both interventions contain 12-step components.  
 
Fiorentine, 1999 
 
Reason for Exclusion At least 59 % are drug users; some participants alcohol only dependents.  
 
Henggeler, Pickrel, & Brondino, 1999; Henggeler, Clingempeel, Brondino, & Pickrel, 2002 
 
Reason for Exclusion 
At least 68% of the participants used drugs. A majority of the 
participants abused or were dependent on alcohol.   
 
Lydecker, Tate, Cummins, McQuaid, Granholm, & Brown, 2010 
 
Reason for Exclusion 66% of the participants were only using alcohol. 
 
Majer, Jason, Aase, Droege, & Ferrari, 2013 
 
Reason for Exclusion Participants. Not clear all participants were primarily drug users. 
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Manning, Best, Faulkner, Titherington, Morinan, Keaney, ... , & Strang, 2012 
 
Reason for Exclusion Participants. 57% alcohol as primary drug of use. 
 
McKay, Lynch K G, Shepard, Ratichek, Morrison, Koppenhaver, & Pettinati, 2004 
 
Reason for Exclusion 74.6% were cocaine dependents, the rest were only addicted to alcohol.  
 
McKay, Lynch, Shepard, & Pettinati, 2005 
Reason for Exclusion 
Participants were either alcohol or drug addicted, outcome not specified 
for each addiction. 
 
McKay, Lynch, Shepard, Morgenstern, Forman, & Pettinati, 2005 
 
Reason for Exclusion Participants with alcohol and/or cocaine dependence 
 
McKay, Pettinati, Morrison, Feeley, Mulvaney, & Gallop, 2002 
 
Reason for Exclusion 
Participants were either alcohol or drug addicted, outcome not specified 
for each addiction. 
 
Morgan-Lopez, Saavedra, Hien, Campbell, Wu, & Ruglass, 2013 
 
Reason for Exclusion 
Participants had either drug or alcohol dependence. Not reported 
separately. 
 
Rosenblum, Matusow, Fong, Vogel, Uttaro, Moore, & Magura, 2014 
 
Reason for Exclusion Unclear whether all participants were drug dependent. 
 
Wells, Donovan, Daley, Doyle, Brigham, Garrett, ... , & Walker, 2014 
 
Reason for Exclusion No relevant comparison. Both interventions contain 12-step components. 
 
Worley, Tate, & Brown, 2012; Worley, Tate, McQuaid, Granholm, & Brown, 2013.  
 
Reason for Exclusion 
Participants were either diagnosed with alcohol, stimulant or marijuana 
dependence 
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9.4  ASSESSMENT OF RISK OF BIAS IN INCLUDED STUDIES  
 
9.4.1 Risk of bias table 
 
Item Judgementa Description (quote from paper, 
or describe key information) 
1. Sequence generation   
2. Allocation concealment   
3. Confoundingb,c      
4. Blinding?b            
5. Incomplete outcome data 
addressed?b 
  
6. Free of selective reporting?b   
7. Free of other bias?   
8. A priori protocol?d   
9. A priori analysis plan?e   
 
a Some items on low/high risk/unclear scale (double-line border), some on 5 point 
scale/unclear (single line border), some on yes/no/unclear scale (dashed border). For all 
items, record “unclear” if inadequate reporting prevents a judgement being made. 
b For each outcome in the study.  
c This item is only used for QESs. It is based on list of confounders considered important at the 
outset and defined in the protocol for the review (assessment against worksheet).  
d Did the researchers write a protocol defining the study population, intervention and 
comparator, primary and other outcomes, data collection methods, etc. in advance of starting 
the study? 
e Did the researchers have an analysis plan defining the primary and other outcomes, statistical 
methods, subgroup analyses, etc. in advance of starting the study? 
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9.4.2 Risk of bias tool 
9.4.2.1 Studies for which RoB tool is intended 
The risk of bias model is developed by Prof. Barnaby Reeves in association with the Cochrane Non-
Randomised Studies Methods Group.10 This model, an extension of the Cochrane Collaboration’s 
risk of bias tool, covers both risk of bias in randomised controlled trials (RCTs and QRCTs), but 
also risk of bias in non-randomised studies (QES).  
The point of departure for the risk of bias model is the Cochrane Handbook for Systematic Reviews 
of interventions (Higgins & Green, 2008). The existing Cochrane risk of bias tool needs elaboration 
when assessing non-randomised studies because, for non-randomised studies, particular attention 
should be paid to selection bias / risk of confounding. Additional item on confounding is used only 
for non-randomised studies (QESs) and is not used for randomised controlled trials (RCTs and 
QRCTs). 
9.4.2.2 Assessment of risk of bias 
Issues when using modified RoB tool to assess included non-randomised studies: 
• Use existing principle: score judgement and provide information (preferably direct quote) to 
support judgement 
• QESs. 
• 5-point scale for some items (distinguish “unclear” from intermediate risk of bias). 
• Keep in mind the general philosophy – assessment is not about whether researchers could 
have done better but about risk of bias; the assessment tool must be used in a standard way 
whatever the difficulty / circumstances of investigating the research question of interest 
and whatever the study design used. 
• Anchors: “1/No/low risk” of bias should correspond to a high quality RCT. “5/high risk” of 
bias should correspond to a risk of bias that means the findings should not be considered 
(too risky, too much bias, more likely to mislead than inform) 
 
1. Sequence generation 
• Low/high/unclear RoB item 
• Always high RoB (not random) for a non-randomised study 
• Might argue that this item redundant for QES since always high – but important to include in 
RoB table (‘level playing field’ argument) 
 
2. Allocation concealment 
• Low/high/unclear RoB item 
• Potentially low RoB for a non-randomised study, e.g. quasi-randomised (so high RoB to 
sequence generation) but concealed (reviewer judges that the people making decisions 
about including participants didn’t know how allocation was being done, e.g. odd/even date 
of birth/hospital number) 
                                                        
10 This risk of bias model was introduced by Prof. Reeves at a workshop on risk of bias in non-randomized studies at SFI 
Campbell, February 2011. The model is a further development of work carried out in the Cochrane Non-Randomised 
Studies Method Group (NRSMG). 
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3. RoB from confounding (additional item for QES; assess for each outcome) 
• Assumes a pre-specified list of potential confounders defined in the protocol 
• Low(1) / 2 / 3 / 4 / high(5) / unclear RoB item 
• Judgement needs to factor in: 
o proportion of confounders (from pre-specified list) that were considered 
o whether most important confounders (from pre-specified list) were considered 
o resolution/precision with which confounders were measured 
o extent of imbalance between groups at baseline 
o care with which adjustment was done (typically a judgement about the statistical 
modeling carried out by authors) 
• Low RoB requires that all important confounders are balanced at baseline (not primarily/not 
only a statistical judgement) OR measured ‘well’ and ‘carefully’ controlled for in the 
analysis. 
 
Assess against pre-specified worksheet. Reviewers will make a RoB judgement about each factor 
first and then ‘eyeball’ these for the judgement RoB table. 
 
4. RoB from lack of blinding (assess for each outcome, as per existing RoB tool) 
• Low(1) / 2 / 3 / 4 / high(5) / unclear RoB item 
• Judgement needs to factor in: 
o nature of outcome (subjective / objective; source of information) 
o who was / was not blinded and the risk that those who were not blinded could introduce 
performance or detection bias 
o see Ch.8 
 
5. RoB from incomplete outcome data (assess for each outcome, as per existing RoB tool) 
• Low(1) / 2 / 3 / 4 / high(5) / unclear RoB item 
• Judgement needs to factor in: 
o reasons for missing data 
o whether amount of missing data balanced across groups, with similar reasons 
o see Ch.8 
 
6. RoB from selective reporting (assess for each outcome, NB different to existing Ch.8 
recommendation) 
• Low(1) / 2 / 3 / 4 / high(5) /unclear RoB item 
• Judgement needs to factor in: 
o existing RoB guidance on selective outcome reporting 
o see Ch.8 
o also, extent to which analyses (and potentially other choices) could have been 
manipulated to bias the findings reported, e.g. choice of method of model fitting, 
potential confounders considered / included   
o look for evidence that there was a protocol in advance of doing any analysis / obtaining 
the data (difficult unless explicitly reported); QES very different from RCTs. RCTs must 
have a protocol in advance of starting to recruit (for REC/IRB/other regulatory 
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approval); QES need not (especially older studies) 
o Hence, separate yes/no items asking reviewers whether they think the researchers had a 
pre-specified protocol and analysis plan. 
 
 
Confounding worksheet 
Assessment of how researchers dealt with confounding  
Method for identifying relevant confounders described by researchers:             yes 
                                                                              no                                                               
If yes, describe the method used: 
 
 
Relevant confounders described:                                                yes 
                                                                              no 
List confounders described on next page 
 
Method used for controlling for confounding 
At design stage (e.g. matching, regression discontinuity, instrument variable):  
………………………………………………..    
………………………………………………..  
………………………………………………..       
 
At analysis stage (e.g. stratification, multivariate regression, difference-indifference):   
………………………………………………..    
………………………………………………..  
………………………………………………..       
 
 
Describe confounders controlled for below 
 
 
Confounders described by researchers 
Tick (yes[0]/no[1] judgement) if confounder considered by the researchers [Cons’d?] 
Score (1[good precision] to 5[poor precision]) precision with which confounder measured 
Score (1[balanced] to 5[major imbalance]) imbalance between groups 
Score (1[very careful] to 5[not at all careful]) care with which adjustment for confounder was carried out 
 
Confounder Considered Precision Imbalance Adjustment 
Gender     
Age     
Socio-economic status     
Mental problems     
History of drug misuse     
Unobservables11  Irrelevant   
Other:     
Other:     
                                                        
11 See user guide for unobservables 
 115     The Campbell Collaboration | www.campbellcollaboration.org 
9.4.3 User guide for unobservables 
Selection bias is understood as systematic baseline differences between groups and can therefore 
compromise comparability between groups. Baseline differences can be observable (e.g. age and 
gender) and unobservable (to the researcher; e.g. motivation and ‘ability’). There is no single non-
randomised study design that always solves the selection problem. Different designs solve the 
selection problem under different assumptions and require different types of data. Especially how 
different designs deal with selection on unobservables varies. The “right” method depends on the 
model generating participation, i.e. assumptions about the nature of the process by which 
participants are selected into a program. 
As there is no universal correct way to construct counterfactuals we will assess the extent to which 
the identifying assumptions (the assumption that makes it possible to identify the counterfactual) 
are explained and discussed (preferably the authors should make an effort to justify their choice of 
method). We will look for evidence that authors using e.g. (this is NOT a complete list): 
Natural experiments: 
Discuss whether they face a truly random allocation of participants and that there is no change of 
behaviour in anticipation of e.g. policy rules. 
 
Instrument variable (IV): 
Explain and discuss the assumption that the instrument variable does not affect outcomes other 
than through their effect on participation. 
 
Matching (including propensity scores): 
Explain and discuss the assumption that there is no selection on unobservables, only selection on 
observables. 
 
(Multivariate) Regression: 
Explain and discuss the assumption that there is no selection on unobservables, only selection on 
observables. Further discuss the extent to which they compare comparable people. 
 
Regression discontinuity (RD): 
Explain and discuss the assumption that there is a (strict!) RD treatment rule. It must not be 
changeable by the agent in an effort to obtain or avoid treatment. Continuity in the expected 
impact at the discontinuity is required. 
 
Difference-in-difference (Treatment-control-before-after): 
Explain and discuss the assumption that outcomes of participants and nonparticipants evolve over 
time in the same way. 
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9.5  RISK OF BIAS 
Judgement score ranging from 1-4, where 1 indicates low risk of bias and 4 indicates high risk of bias. The judgement 5 
indicates unacceptable high risk of bias, and the study will be excluded from the numeric analysis because of it.  
 
Bisset 2002: 
 
Entry  Judgement Description 
Adequate sequence 
generation? 
 
Unclear 
Quote: “Subjects were randomly assigned to 
a condition. The following variables were 
monitored in assigning subjects to 
conditions: Methadone dose, psychiatric 
severity, substance use severity, and 
methadone clinic. Subjects were then 
randomly assigned to one of the two 
therapists in each treatment condition of the 
study" 
Note: The description of the randomisation 
varies substantially between the two study 
reports. No information on how 
randomisation was carried out is reported. 
Allocation concealment? 
 
Unclear 
Not reported who did allocation or which 
precautions were taken to avoid that 
allocation. 
Blinding? 
Primary 
outcome 
3 
Assessors blind to treatment. Therapists and 
participants were not. 
Secondary 
outcomes 
4 
Retention 2 
Incomplete outcome data 
addressed? 
Primary 
outcome 
2 
Missing some intake, post intake and follow-
up data. 
 
Secondary 
outcomes 
3 
Retention 1 
Selective reporting? All outcomes 1 Data reported in table 1. 
Other bias? 
 
3 
Interaction among individuals randomised to 
the same group therapy is expected. 
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Effective sample size is smaller than 
reported, due to participants individually 
randomised to group therapy. 
Followed a priori protocol?  Unclear No registered protocol 
Followed a priori analysis plan?  Unclear No published protocol 
 
Carroll et al., 1998: 
 
Entry  Judgement Description 
Adequate sequence generation?  Unclear 
Subjects were randomised. No 
further details given.  
Allocation concealment?  Unclear 
Not clear whether subjects, 
therapist, or analysists could 
manipulate assignment.  
Blinding? 
Primary 
outcomes 
2 
Neither participants nor therapists 
were blinded to the treatment 
delivered. It is not reported who 
measured the outcome. Retention 3 
Incomplete outcome data addressed? 
Primary 
outcome 
Unclear 
Unclear whether measurements 
were taken until dropout or 
continued after dropout. Since 
mean number retained varies by 
condition (p718, 1998), bias is 
unclear. 60-70 subjects per time 
point followed up. Completers more 
likely to respond.  
Secondary 
outcomes 
Unclear 
Retention Unclear 
Selective reporting? 
Primary 
outcome 
2 Administer the ASI at baseline. 
Data retrieved via author 
correspondence. Secondary 
outcomes 
1 
Retention 2 Not reported by treatment 
Other bias?  1  
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Followed a priori protocol?  Unclear Not reported 
Followed a priori analysis plan?  Unclear Not reported 
 
Carroll et al., 2012: 
 
Entry  Judgement Description 
Adequate sequence generation?  Low risk 
Computer urn algorithm from 
project MATCH. 
Allocation concealment?  Low risk 
Each new draw is a biased coin 
based on assignment of previous 
patient.  
Blinding? 
Primary 
outcome 
3 
Subjects blind to 
Disulfiram/Placebo comparison, 
probably not blind to tau+tsf/tau. 
Personnel non-blind to tau+tsf/tau 
comparison, unclear whether blind 
to Dis/Pla comparison. 
Retention 3 
Incomplete outcome data addressed? 
Primary 
outcome 
2 Complete self-report outcome data 
available for 98% during treatment 
and 93% at 12 months follow-up Retention 1 
Selective reporting? 
Primary 
outcome 
1  
Retention 2 
Details are not reported for 
estimates which are statistically 
insignificant 
Other bias?  4 
TAU is group based intervention, 
and 3. order bias due to urn 
procedure. 
Followed a priori protocol?  Yes clinicaltrials.gov id NCT00350870 
Followed a priori analysis plan?  Unclear Not stated 
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Gossop et al., 2007: 
Entry  Judgement Description 
Adequate sequence generation?  High risk 
The study is not a randomised 
study  
Allocation concealment?  High risk High risk of selection bias 
Confounding  5 
Balance not displayed, cannot 
judge distributional overlap. Sites 
are different based on descriptive 
piece, but not controlled for. 
Control for pre-intake NA/AA 
attendance and dependence 
severity. Over time hardly any 
change in the number subjects 
attending NA/AA. Pre exposure is 
strongly correlated with post take 
up (p.121), which suggest that 
identification of the effect of 
attendance comes primarily from 
those individual who attended and 
subsequently dropped out.  
Blinding? 
Primary 
outcomes 
4 Not blind 
Incomplete outcome data addressed? 
Primary 
outcome 
3 
Eligible sample of 255. Analysis 
sample is 142 subjects who had 
data for all years. Attrition analysis 
suggests 113 subjects have similar 
pre-intake characteristics to the 
analysis sample. 
Selective reporting? 
Primary 
outcome 
1 No sign of selective reporting 
Other bias?  3 
Treatment is 12-step attendance, a 
group based intervention. Risk of 
bias since participants may interact 
during treatment (should be cluster 
corrected on group identifier). 
Followed a priori protocol?  Unclear 
Referenced as a prospective cohort 
study. No approved protocol. 
Followed a priori analysis plan?  Unclear Not reported 
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Higgins et al., 1991: 
 
Entry  Judgement Description 
Adequate sequence generation?  High risk 
Non-random sequence generation. 
13 consecutive to Behavioural 
Therapy, next 15 to 12-step 
Allocation concealment?  High risk 
The fact that recruitment to BT 
stops after 13 (not pre-specified) 
suggests that allocation was not 
concealed to either staff or analyst. 
Blinding? 
Primary 
outcome 
4 
 
Not blinded. Since Behavioural 
therapy is linked to incentive pay, it 
needs to be clarified who decided 
what. Appears that staff played a 
role in linking performance to pay.  
Retention: same concerns as for 
drug use, but smaller risk of bias 
due to the nature of the outcome. 
Retention 3 
Incomplete outcome data addressed? 
Primary 
outcome 
3 
Treat missing UAs as positive 
screen for drug use. However they 
only make payment based on 
cocaine screen. Appears to be drug 
substitution in the BT treatment. 
Appears to be differential retention 
between behavioural and 12-step 
is a concern. 85% completed vs 
42% Missing data level not 
reported. 
Retention 1 
Selective reporting? 
Primary 
outcome 
2 Missing data level not reported 
Other bias?  3 12-step is group based.  
Followed a priori protocol?  Unclear Not stated 
Followed a priori analysis plan?  Unclear Not stated  
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Maude-griffin et al., 1998: 
 
Entry  Judgement Description 
Adequate sequence generation?  Unclear 
There are no details on the 
randomisation process.  
Allocation concealment?  Unclear No details given  
Blinding? 
Primary 
outcome 
Unclear 
It is not stated who did the 
assessment. Therapists not 
blinded, and were rotated and 
delivered therefore both types of 
treatments. Subjects not blind.  
Retention Unclear 
Incomplete outcome data addressed? 
Primary 
outcome 
2 89% completed 4 week, 86% 8 
week, 92% 12 week, 84% 26 
weeks. No differential attrition.  Retention 1 
Selective reporting? 
Primary 
outcome 
1 Retention is not reported by 
treatment condition 
Retention 2 
Other bias?  3 
The participants received group 
based intervention. Not cluster 
corrected on group identifier. 
 
Followed a priori protocol?  Unclear Not reported 
Followed a priori analysis plan?  Unclear Not reported 
 
McKay et al., 1997: 
 
Entry  Judgement Description 
Adequate sequence generation?  Low risk 
Participants randomised by urn 
randomisation  
 
Allocation concealment? 
 Unclear Insufficient details given  
Blinding? 
Primary 
outcome 
4 
Neither participants nor clinicians 
are blinded to treatment. Baseline 
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Secondary 
outcomes 
3 
and follow-up assessors had had 
been informed of treatment 
condition. 
 
ASI interview used to secondary 
outcomes were non blinded 
Retention 3 
Incomplete outcome data addressed? 
Primary 
outcome 
2 
Follow-up rate not specified 
separately by outcome. 100% 
baseline, 98% 6 months, 92% 24 
months. Urine toxicology results 
were obtained from 93 patients 
(95%) at 3 months and 91 patients 
(93%) at 6 months. 
Retention 1 
Selective reporting? All outcomes 1 
Retention is not reported by 
treatment condition 
Other bias?  4 
Both treatments contain group 
session element, which is not 
corrected for.  
Followed a priori protocol?  Unclear Not reported. 
Followed a priori analysis plan?  Unclear 
Not stated. ASI measures only done 
post treatment, and at baseline, so 
likely not in original protocol. 
 
Petry et al., 2010: 
 
Entry  Judgement Description 
Adequate sequence generation?  Low risk 
Quote: “Randomly assigned to of 
two treatments and scheduled to 
attend first group session within a 
1-week period. Used a 
computerised urn procedure that 
balanced treatment groups on 
race, baseline urine analysis, and 
HIV medication". 
Appears to be a minimisation 
algorithm. 
Allocation concealment?  Low risk 
Computer algorithm likely a 
minimisation algorithm. 
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Blinding? 
Primary 
outcome 
4 
Outcome collected by research 
assistant, who were not was 
blinded. 
 
According to retention, nothing is 
stated but likely taken by therapists 
who were not blind to treatment. 
Retention 3 
Incomplete outcome data addressed? 
Primary 
outcome 
4 Primary: Large discrepancy 
between figure 1 and p. 92.  
Retention 1 
Selective reporting? 
Primary 
outcome 
3 
Outcomes not reported for 6 
months post follow-up and 9 
months follow-up of screens. 
 
Do not report numbers of 
participants according to retentions 
rate. 
Retention 1 
Other bias?  4 
Not corrected for group based 
intervention. Screens were 
collected weekly, since cocaine 
metabolises quickly there is the 
possibility to game the screens. 
4 year recruitment period, 
possibility of time trends in 
treatment, and or participant 
characteristics.  
Followed a priori protocol?  Unclear 
Participants signed consent forms, 
but it is not stated whether protocol 
was approved in advance 
Followed a priori analysis plan?  Unclear Unclear 
 
Schottenfeld et al., 2011: 
 
Entry  Judgement Description 
Adequate sequence generation?  Low risk Urn randomisation was utilised. 
Allocation concealment?  Low risk 
Computer algorithm likely a 
minimisation algorithm. Not stated 
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whether allocation was done by 
third part. 
Blinding? 
Primary 
outcome 
4 
Participants were not blinded to the 
treatment, neither were the 
therapists. 
According to retention, double non-
blind. In particular risk that 
therapists favouring a treatment 
may work differentially harder at 
retaining patients. 
Retention 3 
Incomplete outcome data addressed? 
Primary 
outcome 
3 
Assessment completion rates were 
86% (n=125) for the midpoint of 
treatment (3-month), 72% (n=105) 
for the end of treatment (6-month), 
and 66% (n=96) for one of the 
post-treament follow-up 
assessments. 49% (n=71) at 
month 9 and 48% (n=69) at month 
12.  
Retention 1 
Selective reporting? All outcomes 1 
Reports on all 3 measures related 
to cocaine use. 
Other bias?  2 
Women assigned to 12-step 
reported significantly more days of 
use than those assigned to CRA. 
Suggesting randomisation did not 
fully work on an important 
(confounding) variable.  
Urn randomisation leads to risk of 
3rd order bias. Makes it likely that 
those assigning treatment could 
predict with some precision the 
following allocation (biased urn).  
Followed a priori protocol?  Yes 
Protocol approved by Yale Medical 
School's Human Investigation 
Committee. Trial registered at 
Clinicaltrials.gov as NCT00914381 
Followed a priori analysis plan?  Unclear 
Not reported. Reviewer checked 
protocol, but it contains no analysis 
plan.  
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Wells et al., 1994: 
 
Entry  Judgement Description 
Adequate sequence generation?  High risk 
Alternation, and in addition 48 
assigned to RP and 62 to TS. 
Authors note this is done because 
TS had higher attrition. 
Allocation concealment?  High risk 
Since alternation was the allocation 
method it is likely that both 
subjects and researchers could 
predict the next assignment.  
Blinding? 
Primary 
outcome 
4 
 
Participants and therapists non-
blind to treatment. Not reported 
who conducted interviews. 
Risk of differential effect from 
therapist non-blinding on retention. 
Retention 3 
Incomplete outcome data addressed? 
Primary 
outcome 
3 
17 subjects lost to follow-up. 
Obtained complete data on cocaine 
use at 3 measurement points for 
92 subjects (42 Rel, 50 in TS). Only 
those 92 are used for analysis. 110 
assigned so one is missing. 
Attrition 6 from RP, and 12 from 
TS. 
Retention is not listed as outcome, 
but presented in results section as 
being contrary to expectation, and 
there only reported as mean 
number of sessions (number of 
observations not reported.  
Secondary 3 
Retention Unclear 
Selective reporting? 
Primary 
outcome 
2 
Only partial reporting on the 
complete abstinence outcome. 
Table 2 only reports on days of 
drug use. Urine screens not 
reported either (although listed as 
validation tool only).  
 
Retention Unclear 
Other bias?  4 
No therapist crossover increases 
risk of therapist effects driving 
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results. Both interventions are 
group based, but no correction 
made in analysis. Recruitment 
procedure itself appears to have a 
long temporal aspect increasing 
the risk that changes in the 
participant pool or treatment 
fidelity over time may confound 
results. 
Followed a priori protocol?  Unclear Not stated 
Followed a priori analysis plan?  Unclear Not stated  
 127     The Campbell Collaboration | www.campbellcollaboration.org 
10 Figures 
10.1  NARCOTICS ANONYMOUS 
 
The 12 Steps of Narcotics Anonymous (Narcotics Anonymous, 2008) 
• We admitted that we were powerless over our addiction, that our lives had become 
unmanageable. 
• We came to believe that a power greater than ourselves could restore us to sanity. 
• We made a decision to turn our will and our lives over to the care of God as we understand 
Him. 
• We made a searching and fearless moral inventory of ourselves. 
• We admitted to God, to ourselves, and to another human being the exact nature of our 
wrongs. 
• We were entirely ready to have God remove all these defects of character. 
• We humbly asked him to remove our shortcomings. 
• We made a list of all persons we had harmed, and became willing to make amends to them all. 
• We made direct amends to such people wherever possible, except when to do so would injure 
them or others. 
• We continued to take personal inventory when we were wrong and promptly admitted it. 
• We sought through prayer and meditation to improve our conscious contact with God as we 
understood Him, praying only for knowledge of His will for us and the power to carry that 
out. 
• Having had a spiritual awakening as the result of these steps, we tried to carry this message to 
addicts, and to practice these principles in all our affairs. 
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The 12 Traditions of Narcotics Anonymous (Narcotics Anonymous, 2008) 
• Our common welfare should come first; personal recovery depends on NA unity. 
• For our group purpose there is but one ultimate authority – a loving God as He may express 
Himself in our group conscience. Our leaders are but trusted servants; they do not govern. 
• The only requirement for membership is a desire to stop using. 
• Each group should be autonomous except in matters affecting other groups or NA as a whole. 
• Each group has but one primary purpose – to carry the message to the addict who still suffers. 
• An NA group ought never endorse, finance, or lend the NA name to any related facility or 
outside enterprise. Lest problems of money, property, or prestige divert us from our 
primary purpose. 
• Every NA group ought to be fully self-supporting, declining outside contributions. 
• Narcotics Anonymous should remain forever nonprofessional, but our service centres may 
employ special workers. 
• NA, as such, ought never be organised, but we may create service boards or committees 
directly responsible to those they serve. 
• Narcotics Anonymous has no opinion on outside issues: hence the NA name ought never be 
drawn into public controversy. 
• Our public relations policy is based on attraction rather than promotion; we need always 
maintain personal anonymity at the level of press, radio, and films. 
• Anonymity is the spiritual foundation of all our Traditions, ever reminding us to place 
principles before personalities. 
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10.2  FLOW OF STUDIES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Flowchart 
Databases 
  
Artikelsök, ASSIA, 
Bibliotek.dk, Bibsys, 
CINAHL, Cochrane 
Library, DIVA, 
Embase, Libris, 
Medline, PsycINFO, 
Science Citation 
Abstracts, Social 
Services Abstract, 
Social Science 
Citation, SocINDEX, 
Sociological 
Abstracts, SveMed+,  
Total       20,055 
21,765 
  
  
  
  
  
  
  
  
  
Grey literature 
 
Dissertations & Thesis, 
OpenGrey, Google Scholar, 
Google, Social Care Online, 
Subject specific sites (e.g., 
NIDA, EMCDDA, SAMHSA, 
NCJRS) 
 
  
  
  
Total 2,639       
2232639 
 
  
 21,974 potentially relevant records to be screened 
for retrieval. (Databases:17,416; Grey: 2,639; Hand 
search etc.: 1,919). 
428 Full text papers Including 9 grey were retrieved 
for 2. level screening. 
10 studies (13 reports) met the eligibility criteria and 
were included in the review 
4,349 excluded for being 
duplicates. 
415 excluded for not 
fulfilling second level 
questions. 
21,546 excluded for 
not fulfilling first level 
screening questions. 
Hand search 
1063  
  
Grants    15 
 
Snowball 
28 
 
Experts 
0 
 
 
 
Total          1,919 
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11 Data and analyses 
11.1  DESCRIPTION OF MEASURES 
Measure Description 
 
Primary Outcome: Drug use 
Bisset (2002) Measure(s): 
abstinence 
Instrument(s): 
urine analysis screen. Urine was screened for: “[…] polydrug use, 
including opiates, cocaine, benzodiazepines, barbiturates, 
amphetamines, marijuana, alcohol, and methadone" (Bisset, 2002, 
p.76); “relevant portions of ASI” (Hayes et al., 2004, p 673) 
Time Point(s): 
baseline, 8 weeks, post treatment (16 weeks), and FU (6mths post 
treatment). Urine Analysis collected twice per week at group and 
individual session 
Carroll et al. (1998) Measure(s): 
duration of periods of abstinence from cocaine, alcohol and both 
substances; frequency of cocaine use (number of days per week); 
quantity use (grams per week). 
Instrument(s): 
self-reports verified by UA. In cases of discrepancy the instrument 
indicating cocaine use was used. Follow-up: Days of use in past 28 
days based Substance Abuse Calendar. 
Time Point(s): 
Baseline, weekly during treat, post (12 weeks), and FU: 1, 3, 6, 12 
months post. 
Carroll et al. (2012) Measure(s): 
% days of cocaine use/number of days per week cocaine use; % 
cocaine-positive urine samples. 
Instrument(s): 
Self-report (Substance Abuse Calendar); urine toxicology screen 
Time Point(s): 
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Self-report: Baseline, weekly during treatment, treatment end (12 
weeks), every 3 months post treatment (up to 1 year); urine: 3 times 
weekly during treatment, and at each FU. 
Gossop et al. (2007) Measure(s): 
substance use for the 90 previous days 
Instrument(s): 
Structured interview 
Time Point(s): 
1, 2, and 4-5 years post intake to treatment 
Higgins et al. (1991) Measure(s): 
abstinence 
Instrument(s): 
Urine screen. Screened for metabolite of cocaine, and one other 
randomly selected specimen per week screened for other drugs of 
abuse 
Time Point(s): 
collected 4 times per week during treatment 
Maude-Griffin et al. 
(1998) 
Measure(s): 
4 consecutive weeks of abstinence during treatment verified via 
urine samples; point prevalence at each assessment. 
Instrument(s): 
urine samples collected once each week on a random schedule. To 
be coded as abstinent, the participant had to report no cocaine use 
during the prior 30 days and produce a cocaine-free urine sample. 
Any discrepancy coded as not abstinent. 
Time Point(s): 
baseline, weeks 4, 8, 12, and 26 
McKay et al. (1997, 1999) Measure(s): 
percent days of cocaine use. 
Instrument(s): 
Timeline Followback; ASI-drug; urine screens for validation. 
Time Point(s): 
3, 6, 12, 18, and 24 months post intake.  
Petry et al. (2010) Measure(s): 
longest consecutive number of weeks of negative samples 
submitted; proportion of negative samples submitted. 
Instrument(s): 
urine screens. 
Time Point(s): 
weekly during treatment screened for cocaine and opioids; 3, 6 
(post treatment), 9, 12 months 
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Schottenfeld et al. (2011) Measure(s): 
maximum consecutive weeks of documented cocaine abstinence; 
the proportion of negative urine tests; percent days using cocaine; 
FU: 30 days cocaine abstinence 
Instrument(s): 
weekly TLFB of drug use (Weekly Substance Use Inventory); ASI: 
drug composite score. 
Time Point(s): 
twice weekly during treatment; FU assessment: urine toxicology 
and ASI. FU at 3, 6, 9, and 12 months. (based on self-report + 
negative urine sample) 
Wells et al. (1994) Measure(s): 
number days of use in past 30 days (cocaine, alcohol, marijuana) 
Instrument(s): 
monthly random urine samples 
Time Point(s): 
baseline, 12 weeks (post treatment), 6 months after treatment end.  
Measure Description 
 
Secondary outcome: Retention 
Bisset (2002) ACT/12-step: attending at least 50% of the group and individual 
sessions (p675); MM: giving urine samples at least 8/16 weeks 
Carroll et al. (1998) Treatment completers 
Carroll et al. (2012) Treatment completers; days retained in treatment 
Gossop et al. (2007) Not relevant (only completers) 
Higgins et al. (1991) Treatment completers 
Maude-Griffin et al. 
(1998) 
Therapy session attendance 
McKay et al. (1997, 1999) number of continuing care sessions attended during treatment 
Petry et al. (2010) Number of sessions attended 
Schottenfeld et al. (2011) Retention in treatment 
Wells et al. (1994) Number of sessions attended 
 
 
Measure Description 
 
Secondary outcome: Criminal behaviour, psychiatric symptoms, social functioning, 
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employment status 
Bisset (2002) ASI-legal; Social Adjustment Scale, Beck Depression Index, 
Symptom Checklist-90-R, ASI-psychiatric; ASI-family; ASI-
employment 
Carroll et al. (1998) ASI-legal; ASI-psychiatric; ASI-family; ASI-employment 
McKay et al. (1997, 1999) ASI-psychiatric; ASI-family; ASI-employment 
 
11.2  OUTCOME MEASURE BY STUDY AND TIME OF MEASUREMENT  
Table 15: Type of outcome measure by study and time of measurement 
Study 
Outcome 
Primary: Drug use Secondary: Retention Secondary: Other  
Continuous Discrete Continuous Discrete Continuous Discrete 
Bisset 2002 - po, fu - po po, fu - 
Carroll 1998 du, po, fu du - po po, fu - 
Carroll 2012 du, po, fu - po po - - 
Higgins 1991 du du - po - - 
Maude-Griffin 
1998 
- du, po, fu - - - - 
McKay 1997 du, po, fu  - po - po, fu - 
Petry 2010 du fu po - - - 
Schottenfeld 
2011 
du fu - po - - 
Wells 1994 po, fu - po - - - 
Notes: Time of measurement: du = during, po = post, fu = follow-up. Effect size transformed for synthesis (from 
discrete to continuous or vice versa) in bold.  
 
11.3  STUDY EFFECT SIZES 
Effect sizes for each study is provided in the online appendix, see 
https://campbellcollaboration.org/library/12-step-programmes-illicit-drug-abuse-reduction.html. 
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11.4  FOREST PLOTS 
11.4.1 Comparison: 12-step vs psychosocial intervention 
11.4.1.1 Primary outcome: Drug use 
11.4.1.1.1 During treatment 
A positive effect size favours 12-step. 
11.4.1.1.2 Post treatment 
A positive effect size favours 12-step. 
11.4.1.1.3 Follow-up 
FU 6m 
 FU 12-18m 
 
A positive effect size favours 12-step. 
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11.4.1.2 Secondary outcomes 
11.4.1.2.1 Post treatment 
 
Criminal behaviour 
A positive effect size favours 12-step. 
 
Psychiatric symptoms 
A positive effect size favours 12-step. 
 
Social functioning 
A positive effect size favours 12-step. 
 
Employment 
A positive effect size favours 12-step. 
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Retention 
 
An effect size > 1 favours 12-step. 
11.4.1.2.2 Follow-up 
 
Criminal behaviour 
6m FU 
 
12m FU 
 
A positive effect size favours 12-step. 
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Psychiatric symptoms 
 
6m FU 
 
 
12m FU 
 
A positive effect size favours 12-step. 
 
Social functioning 
6m FU 
 
12m FU 
 
A positive effect size favours 12-step. 
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Employment 
6m FU 
 
12m FU 
 
 
A positive effect size favours 12-step. 
11.4.2 Comparison: 12-step + add-on vs psychosocial + add-on 
11.4.2.1 Primary outcome: Drug use 
11.4.2.1.1 During treatment 
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A positive effect size favours 12-step. 
11.4.2.1.2 Post treatment 
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A positive effect size favours 12-step. 
11.4.2.1.3 Follow-up 
 
FU 6m 
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FU 12m 
 
 
 
 
A positive effect size favours 12-step. 
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11.4.2.2 Secondary outcomes 
11.4.2.2.1 Post treatment 
 
Retention 
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An effect size > 1 favours 12-step. 
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11.5  SENSITIVITY 
11.5.1 Comparison: 12-step vs psychosocial intervention 
11.5.1.1 Primary outcome: drug use 
11.5.1.1.1 During treatment 
 
Figure 3: Sensitivity Analysis. 12 step vs other psychosocial intervention, during treatment. Outcome: 
drug use. Sensitivity of effect size to excluding studies with high risk of bias on item: sequence 
generation (high or unclear), incomplete data (score of 4), and other bias (score of 4) respectively.  
 
  
All studies
Excluded: Sequence generation score high or unclear
Excluded: Incomplete data score 4
Excluded: Other bias score 4
-1.5 -1 -.5 0 .5
SMD
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11.5.1.1.2 Post treatment 
 
Figure 4: Sensitivity Analysis. 12 step vs other psychosocial intervention, post treatment. Outcome: drug 
use. Sensitivity of effect size to excluding studies with high risk of bias on item: incomplete data (score 
of 4), and other bias (score of 4) respectively.  
 
  
All studies
Excluded: Incomplete data score 4
Excluded: Other bias score 4
-.6 -.4 -.2 0 .2
SMD
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11.5.1.1.3 Follow-up 
 
Figure 5: Sensitivity Analysis. 12 step vs other psychosocial intervention, post treatment. Outcome: drug 
use. Sensitivity of effect size to excluding studies with high risk of bias on item: incomplete data (score 
of 4), and other bias (score of 4) respectively.  
 
 
  
All studies
Excluded: Sequence generation score high or unclear
Excluded: Incomplete data score 4
Excluded: Other bias score 4
-.6 -.4 -.2 0 .2
SMD
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11.5.1.2 Secondary outcome: retention 
 
Figure 6: Sensitivity Analysis. 12 step vs other psychosocial intervention. Outcome: retention. 
Sensitivity of effect size to excluding studies with high risk of bias on item: sequence generation (high or 
unclear), and other bias (score of 4) respectively.  
 
 
11.6  FUNNEL PLOTS 
11.6.1 Comparison: 12-step vs psychosocial intervention 
11.6.1.1 Primary outcome: drug use 
11.6.1.1.1 During treatment 
All studies
Excluded: Sequence generation score high or unclear
Excluded: Other bias score 4
0 .5 1 1.5
OR
 148     The Campbell Collaboration | www.campbellcollaboration.org 
Figure 7: Funnel plot for the comparison of 12-step vs other psychosocial interventions. Outcome: drug 
use. Time point: during treatment. 
 
11.6.1.1.2 Post treatment 
 
Figure 8: Funnel plot for the comparison of 12-step vs other psychosocial interventions. Outcome: drug 
use. Time point: post treatment. 
 
11.6.1.1.3 Follow-up 
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Figure 9: Funnel plot for the comparison of 12-step vs other psychosocial interventions. Outcome: drug 
use. Time point: follow-up. 
 
11.6.1.2  Secondary outcome: retention 
11.6.1.2.1 Post treatment 
 
Figure 10: Funnel plot for the comparison of 12-step vs other psychosocial interventions. Outcome: 
retention. Time point: post treatment. 
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About this review
Illicit drug abuse is a globally recognised problem leading to high human, social and 
economic costs.  
The 12-step program, modelled on the approach of Alcoholics Anonymous and adopted by 
Narcotics Anonymous and others, aims for complete abstinence. The 12-step approach is used 
both by self-help groups and for professional treatment called Twelve Step Facilitation (TSF). 
The broad applicability and low cost of the 12-step approach may appeal to policy makers.
This review examines the effectiveness of 12-step programs in reducing the use of illicit drugs. 
Secondary outcomes considered are on criminal behaviour, prostitution, psychiatric symptoms, 
social functioning, employment status, homelessness, and treatment retention.
